<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2025"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2025"
  xmlns:ttrx="http://turntherapeutics.com/20251231"
  xmlns:us-gaap="http://fasb.org/us-gaap/2025"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="ttrx-20251231.xsd" xlink:type="simple"/>
    <context id="cref_921481251">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:RightsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-03-23</startDate>
            <endDate>2026-03-23</endDate>
        </period>
    </context>
    <context id="cref_722814996">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ttrx:TrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-03-23</startDate>
            <endDate>2026-03-23</endDate>
        </period>
    </context>
    <context id="cref_1280488936">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-03-23</startDate>
            <endDate>2026-03-23</endDate>
        </period>
    </context>
    <context id="cref_1770926710">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ttrx:DiscretionaryTrancheThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-23</instant>
        </period>
    </context>
    <context id="cref_1479140274">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ttrx:DiscretionaryTrancheThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-03-23</startDate>
            <endDate>2026-03-23</endDate>
        </period>
    </context>
    <context id="cref_2003872429">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ttrx:AvenueVentureOpportunitiesFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-03-23</startDate>
            <endDate>2026-03-23</endDate>
        </period>
    </context>
    <context id="cref_1587420057">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ttrx:SecondAnniversaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-03-23</startDate>
            <endDate>2026-03-23</endDate>
        </period>
    </context>
    <context id="cref_599627115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ttrx:FirstAnniversaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-03-23</startDate>
            <endDate>2026-03-23</endDate>
        </period>
    </context>
    <context id="cref_222881735">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ttrx:AvenueVentureOpportunitiesFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-23</instant>
        </period>
    </context>
    <context id="cref_16953884">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-23</instant>
        </period>
    </context>
    <context id="cref_1149805041">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ttrx:DiscretionaryTrancheThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ttrx:AvenueVentureOpportunitiesFundMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-23</instant>
        </period>
    </context>
    <context id="cref_1452955949">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ttrx:EquityFinancingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ttrx:AgreementAxis">ttrx:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-23</instant>
        </period>
    </context>
    <context id="cref_100235816">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ttrx:TrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ttrx:AgreementAxis">ttrx:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-23</instant>
        </period>
    </context>
    <context id="cref_614510382">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ttrx:TrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ttrx:AgreementAxis">ttrx:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-24</instant>
        </period>
    </context>
    <context id="cref_248263701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ttrx:AgreementAxis">ttrx:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-24</instant>
        </period>
    </context>
    <context id="cref_883848846">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="cref_86219827">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ttrx:DavisPolkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="cref_680374124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ttrx:DavisPolkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="cref_1258711090">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="cref_1550899278">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ttrx:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="cref_132432864">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ttrx:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="cref_67270298">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ttrx:TwoThousandTwentyFiveOmnibusIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="cref_860008128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ttrx:AmendedAndRestated2018StockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="cref_1952831379">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ttrx:AmendedAndRestated2018StockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="cref_1736530910">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_1473726351">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ttrx:FlexProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="cref_1368018852">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ttrx:FlexProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="cref_1872303994">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ttrx:MiMedxAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="cref_422807255">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ttrx:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="cref_550689438">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="cref_1345747743">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_109726865">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="cref_1482179895">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="cref_1952870394">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="cref_1095715565">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_1600168694">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="cref_2046516106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="cref_343391046">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="cref_1455255571">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="cref_1676632137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="cref_89276483">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
        </entity>
        <period>
            <startDate>2023-12-31</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="cref_1073580153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ttrx:TwoThousandTwentyFiveOmnibusIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_1952615956">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ttrx:TwoThousandTwentyFiveOmnibusIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="cref_191593545">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ttrx:TwoThousandTwentyFourStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_241059500">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ttrx:TwoThousandTwentyFourStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="cref_809785702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ttrx:TwoThousandEighteenStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_2096142304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ttrx:TwoThousandEighteenStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="cref_887761315">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
        </entity>
        <period>
            <instant>2025-12-15</instant>
        </period>
    </context>
    <context id="cref_1079578947">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
        </entity>
        <period>
            <instant>2025-10-31</instant>
        </period>
    </context>
    <context id="cref_463525103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
        </entity>
        <period>
            <startDate>2025-10-31</startDate>
            <endDate>2025-10-31</endDate>
        </period>
    </context>
    <context id="cref_1756333194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="cref_1880216289">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="cref_1532961810">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ttrx:SharePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2028-01-01</startDate>
            <endDate>2028-12-31</endDate>
        </period>
    </context>
    <context id="cref_1659816710">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ttrx:SharePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2027-01-01</startDate>
            <endDate>2027-12-31</endDate>
        </period>
    </context>
    <context id="cref_1107119832">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ttrx:SharePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-12-31</endDate>
        </period>
    </context>
    <context id="cref_1317970188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="cref_810996763">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2028-01-01</startDate>
            <endDate>2028-12-31</endDate>
        </period>
    </context>
    <context id="cref_132470439">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2027-01-01</startDate>
            <endDate>2027-12-31</endDate>
        </period>
    </context>
    <context id="cref_1173190570">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-12-31</endDate>
        </period>
    </context>
    <context id="cref_1386699006">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-04-30</endDate>
        </period>
    </context>
    <context id="cref_274473387">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-04-30</endDate>
        </period>
    </context>
    <context id="cref_473866816">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-04-30</endDate>
        </period>
    </context>
    <context id="cref_1813648080">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
        </entity>
        <period>
            <startDate>2024-12-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="cref_1940919373">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="cref_1493865715">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="cref_1348601230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ttrx:SharePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="cref_2075620970">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ttrx:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="cref_1420194174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ttrx:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_768225102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ttrx:RSU2025OmnibusIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_1804545600">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ttrx:TwoThousandEighteenTwentyFourTwentyFiveOmnibusIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="cref_1898829802">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ttrx:TwoThousandEighteenTwentyFourTwentyFiveOmnibusIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_1088714907">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ttrx:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_972788662">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ttrx:WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ttrx:SharePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_1722875840">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ttrx:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="cref_552847412">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ttrx:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="cref_39095262">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ttrx:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="cref_858939083">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:InvestmentAdvisoryManagementAndAdministrativeServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-31</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="cref_1420823530">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
        </entity>
        <period>
            <startDate>2025-10-23</startDate>
            <endDate>2025-10-23</endDate>
        </period>
    </context>
    <context id="cref_667980030">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
        </entity>
        <period>
            <instant>2025-10-23</instant>
        </period>
    </context>
    <context id="cref_1703771666">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ttrx:ThousandTwentyFiveRegulationDOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-23</startDate>
            <endDate>2025-10-23</endDate>
        </period>
    </context>
    <context id="cref_1948620180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ttrx:ThousandTwentyFiveRegulationDOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-06-27</startDate>
            <endDate>2025-06-27</endDate>
        </period>
    </context>
    <context id="cref_1542701830">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ttrx:ThousandTwentyFiveRegulationDOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="cref_1777302032">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ttrx:ThousandTwentyFiveRegulationDOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-31</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="cref_1838285380">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ttrx:ThousandTwentyFiveRegulationAOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-31</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="cref_726349098">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ttrx:ThousandTwentyFiveRegulationAOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="cref_1999913520">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ttrx:TwoThousandTwentyFourCrowdfundingOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="cref_1612569306">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ttrx:TwoThousandTwentyFourCrowdfundingOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="cref_272530156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ttrx:TwoThousandTwentyFourCrowdfundingOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-31</instant>
        </period>
    </context>
    <context id="cref_1254118259">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:IndefinitelivedIntangibleAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="cref_2089094047">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:IndefinitelivedIntangibleAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_924705981">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:FiniteLivedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="cref_1973613927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:FiniteLivedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_56268728">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:FiniteLivedIntangibleAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="cref_1380797291">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:FiniteLivedIntangibleAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_325524734">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">ttrx:BlackScholesOptionValuationModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_1984457882">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">ttrx:BlackScholesOptionValuationModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_290393463">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">ttrx:BlackScholesOptionValuationModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_375937522">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">ttrx:BlackScholesOptionValuationModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_1950547996">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_1672670786">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">ttrx:MonteCarloSimulationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_1802705679">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_1815012910">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">ttrx:MonteCarloSimulationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_959056149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_1255060193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">ttrx:MonteCarloSimulationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_692088655">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_79394648">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">ttrx:MonteCarloSimulationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_1119474399">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_774196967">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="cref_323803066">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="cref_1669429594">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="cref_1203589937">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_1912481805">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="cref_2091224969">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_1398699727">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">ttrx:AccountsPayableAndAccruedExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">ttrx:VendorTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="cref_1776903312">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">ttrx:AccountsPayableAndAccruedExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">ttrx:VendorOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="cref_1542616136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">ttrx:VendorTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="cref_451938818">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">ttrx:VendorOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="cref_338945579">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">ttrx:AccountsPayableAndAccruedExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">ttrx:VendorTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="cref_1159790254">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">ttrx:AccountsPayableAndAccruedExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">ttrx:VendorOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="cref_157123121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">ttrx:VendorOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_145712525">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">ttrx:AsRevisedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="cref_1074816519">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">ttrx:ImpactOfStockSplitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="cref_609458734">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="cref_2088675772">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
        </entity>
        <period>
            <startDate>2025-09-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="cref_593034427">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
        </entity>
        <period>
            <startDate>2025-09-01</startDate>
            <endDate>2025-09-11</endDate>
        </period>
    </context>
    <context id="cref_830575058">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_1495557967">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_128292186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_153310236">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_1778799606">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="cref_1480925456">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="cref_2125858781">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="cref_605097494">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="cref_566794310">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="cref_698189977">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="cref_1261566747">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="cref_1866611515">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="cref_876232622">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="cref_1159091871">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="cref_919024790">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="cref_1760188914">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="cref_2051066427">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="cref_679163987">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="cref_868190972">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
        </entity>
        <period>
            <instant>2026-03-30</instant>
        </period>
    </context>
    <context id="cref_489304616">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="cref_1399650699">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_1487892989">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="cref_235481319">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="cref_1822897190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ttrx:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="cref_909308480">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ttrx:TwoThousandTwentyFiveOmnibusIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="cref_1711586801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="cref_1011030614">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="cref_1462856618">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="cref_2030495464">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ttrx:RSU2025OmnibusIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="cref_2103163862">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ttrx:AmendedAndRestated2018StockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_1648087271">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ttrx:AmendedAndRestated2018StockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="cref_2099920207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ttrx:TwoThousandTwentyFiveOmnibusIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="cref_900855687">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="cref_1161587692">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">ttrx:MonteCarloSimulationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_904101031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_1920536609">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">ttrx:BlackScholesOptionValuationModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <unit id="uref_921481251">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="uref_1280488936">
        <measure>pure</measure>
    </unit>
    <unit id="uref_1683791803">
        <measure>shares</measure>
    </unit>
    <unit id="uref_923572658">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="cref_1736530910"
      id="fc_1921957413"
      unitRef="uref_1683791803"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesIssued
      contextRef="cref_550689438"
      id="fc_693613376"
      unitRef="uref_1683791803"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="cref_550689438"
      id="fc_458262351"
      unitRef="uref_1683791803"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="cref_1258711090"
      id="fc_1905163605"
      unitRef="uref_923572658"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="cref_2046516106"
      id="fc_1828132396"
      unitRef="uref_1280488936"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="cref_1600168694"
      id="fc_1068764795"
      unitRef="uref_1280488936"
      xsi:nil="true"/>
    <ttrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsEstimatedForfeitureRatesForOptionsGranted
      contextRef="cref_2046516106"
      id="fc_797993294"
      unitRef="uref_1280488936"
      xsi:nil="true"/>
    <ttrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsEstimatedForfeitureRatesForOptionsGranted
      contextRef="cref_1600168694"
      id="fc_1132659108"
      unitRef="uref_1280488936"
      xsi:nil="true"/>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="cref_883848846"
      id="fc_1071933758"
      unitRef="uref_921481251"
      xsi:nil="true"/>
    <us-gaap:StockIssued1
      contextRef="cref_1258711090"
      id="fc_1494680058"
      unitRef="uref_921481251"
      xsi:nil="true"/>
    <us-gaap:NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationWarrantsIssued1
      contextRef="cref_1258711090"
      id="fc_1782002740"
      unitRef="uref_1683791803"
      xsi:nil="true"/>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="cref_1399650699"
      id="fc_1399650699"
      unitRef="uref_921481251"
      xsi:nil="true"/>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="cref_1119474399"
      id="fc_128341880"
      unitRef="uref_921481251"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="cref_1203589937"
      id="fc_775147019"
      unitRef="uref_921481251"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="cref_1399650699"
      id="fc_1361040787"
      unitRef="uref_921481251"
      xsi:nil="true"/>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="cref_1487892989"
      id="fc_1487892989"
      unitRef="uref_921481251"
      xsi:nil="true"/>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="cref_235481319"
      id="fc_235481319"
      unitRef="uref_921481251"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="cref_1669429594"
      id="fc_1413630943"
      unitRef="uref_921481251"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="cref_1487892989"
      id="fc_389922116"
      unitRef="uref_921481251"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="cref_235481319"
      id="fc_1749934688"
      unitRef="uref_921481251"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="cref_550689438"
      id="fc_1474617115"
      unitRef="uref_921481251"
      xsi:nil="true"/>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="cref_2089094047"
      id="fc_1448152013"
      unitRef="uref_921481251"
      xsi:nil="true"/>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="cref_1254118259"
      id="fc_1685252194"
      unitRef="uref_921481251"
      xsi:nil="true"/>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
      contextRef="cref_235481319"
      id="fc_1956622950"
      unitRef="uref_921481251"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate contextRef="cref_1822897190" id="fc_1822897190">2029-07-29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="cref_1736530910"
      id="fc_1677803623"
      unitRef="uref_921481251"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate contextRef="cref_883848846" id="fc_89359823">2029-10-08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="cref_1258711090"
      id="fc_123774085"
      unitRef="uref_921481251"
      xsi:nil="true"/>
    <ttrx:GainFromChangeInFairValueOfForwardContractLiability
      contextRef="cref_1813648080"
      id="fc_1172866984"
      unitRef="uref_921481251"
      xsi:nil="true"/>
    <ttrx:GainFromChangeInFairValueOfForwardContractLiability
      contextRef="cref_1258711090"
      id="fc_308541683"
      unitRef="uref_921481251"
      xsi:nil="true"/>
    <ttrx:SettlementOfForwardContractLiabilityForSaleOfSharesToGEMPursuantToInitialDrawDownNotice
      contextRef="cref_1258711090"
      id="fc_1455398139"
      unitRef="uref_921481251"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="cref_605097494"
      id="fc_1417521674"
      unitRef="uref_921481251"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="cref_1778799606"
      id="fc_2063708645"
      unitRef="uref_921481251"
      xsi:nil="true"/>
    <ttrx:StockIssuedDuringPeriodValueIssuanceOfCommonStockUnderRegulationANetOfIssuanceCosts
      contextRef="cref_605097494"
      id="fc_1400031731"
      unitRef="uref_921481251"
      xsi:nil="true"/>
    <ttrx:StockIssuedDuringPeriodValueIssuanceOfCommonStockUnderRegulationANetOfIssuanceCosts
      contextRef="cref_1778799606"
      id="fc_2057842780"
      unitRef="uref_921481251"
      xsi:nil="true"/>
    <ttrx:StockIssuedDuringPeriodValueIssuanceOfCommonStockUnderRegulationDNetOfIssuanceCosts
      contextRef="cref_605097494"
      id="fc_1095083675"
      unitRef="uref_921481251"
      xsi:nil="true"/>
    <ttrx:StockIssuedDuringPeriodValueIssuanceOfCommonStockUnderRegulationDNetOfIssuanceCosts
      contextRef="cref_1778799606"
      id="fc_1546069628"
      unitRef="uref_921481251"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="cref_605097494"
      id="fc_63181087"
      unitRef="uref_921481251"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="cref_1778799606"
      id="fc_627609894"
      unitRef="uref_921481251"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="cref_605097494"
      id="fc_1797955779"
      unitRef="uref_921481251"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="cref_1778799606"
      id="fc_1910759716"
      unitRef="uref_921481251"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="cref_2125858781"
      id="fc_362564499"
      unitRef="uref_921481251"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="cref_605097494"
      id="fc_662219778"
      unitRef="uref_921481251"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="cref_1778799606"
      id="fc_2073996508"
      unitRef="uref_921481251"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="cref_2125858781"
      id="fc_1134039189"
      unitRef="uref_921481251"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="cref_1480925456"
      id="fc_156743776"
      unitRef="uref_921481251"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="cref_605097494"
      id="fc_1868238860"
      unitRef="uref_921481251"
      xsi:nil="true"/>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="cref_909308480"
      id="fc_909308480"
      unitRef="uref_1683791803"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="cref_1711586801"
      id="fc_1711586801"
      unitRef="uref_921481251"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="cref_1011030614"
      id="fc_1011030614"
      unitRef="uref_921481251"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="cref_1866611515"
      id="fc_795442395"
      unitRef="uref_921481251"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="cref_1159091871"
      id="fc_997512259"
      unitRef="uref_921481251"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="cref_1011030614"
      id="fc_477917217"
      unitRef="uref_921481251"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="cref_1866611515"
      id="fc_664661225"
      unitRef="uref_921481251"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="cref_1159091871"
      id="fc_1567774098"
      unitRef="uref_921481251"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="cref_876232622"
      id="fc_1806586653"
      unitRef="uref_921481251"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="cref_1011030614"
      id="fc_140464120"
      unitRef="uref_921481251"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="cref_1462856618"
      id="fc_1462856618"
      unitRef="uref_921481251"
      xsi:nil="true"/>
    <ttrx:CommonStockIssuedInExchangeForServices
      contextRef="cref_1258711090"
      id="fc_352305785"
      unitRef="uref_921481251"
      xsi:nil="true"/>
    <us-gaap:SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration contextRef="cref_883848846" id="fc_1205013097">http://fasb.org/srt/2025#ChiefExecutiveOfficerMember</us-gaap:SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration>
    <ttrx:ContractWithCustomerLiabilityAdditions
      contextRef="cref_883848846"
      id="fc_857573411"
      unitRef="uref_921481251"
      xsi:nil="true"/>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="cref_883848846"
      id="fc_1530781833"
      unitRef="uref_921481251"
      xsi:nil="true"/>
    <us-gaap:DeferredCosts
      contextRef="cref_550689438"
      id="fc_2064971879"
      unitRef="uref_921481251"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="cref_550689438"
      id="fc_1756716107"
      unitRef="uref_921481251"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityNoteSubscriptionsReceivable
      contextRef="cref_550689438"
      id="fc_292483807"
      unitRef="uref_921481251"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="cref_1736530910"
      id="fc_1150662578"
      unitRef="uref_921481251"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="cref_1736530910"
      id="fc_1647638685"
      unitRef="uref_921481251"
      xsi:nil="true"/>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="cref_1258711090"
      id="fc_888393720"
      unitRef="uref_921481251"
      xsi:nil="true"/>
    <us-gaap:WriteOffOfDeferredDebtIssuanceCost
      contextRef="cref_1258711090"
      id="fc_1197158994"
      unitRef="uref_921481251"
      xsi:nil="true"/>
    <ttrx:StockIssuedDuringPeriodValueIssuanceOfCommonStockForDrawDownNotice
      contextRef="cref_1778799606"
      id="fc_694902424"
      unitRef="uref_921481251"
      xsi:nil="true"/>
    <ttrx:StockIssuedDuringPeriodValueCommonStockForDeferredOfferingCost
      contextRef="cref_605097494"
      id="fc_528726493"
      unitRef="uref_921481251"
      xsi:nil="true"/>
    <ttrx:StockIssuedDuringPeriodValueCommonStockForDeferredOfferingCost
      contextRef="cref_1778799606"
      id="fc_120157971"
      unitRef="uref_921481251"
      xsi:nil="true"/>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="cref_1258711090"
      id="fc_1646595620"
      unitRef="uref_921481251"
      xsi:nil="true"/>
    <us-gaap:WriteOffOfDeferredDebtIssuanceCost
      contextRef="cref_1258711090"
      id="fc_1316248252"
      unitRef="uref_921481251"
      xsi:nil="true"/>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="cref_550689438"
      id="fc_2109637448"
      unitRef="uref_921481251"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="cref_883848846"
      id="fc_1991277332"
      unitRef="uref_923572658"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="cref_1258711090"
      id="fc_1757654135"
      unitRef="uref_1683791803"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="cref_883848846"
      id="fc_1687452012"
      unitRef="uref_1683791803"
      xsi:nil="true"/>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="cref_2030495464"
      id="fc_2030495464"
      unitRef="uref_1683791803"
      xsi:nil="true"/>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="cref_2103163862"
      id="fc_2103163862"
      unitRef="uref_1683791803"
      xsi:nil="true"/>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="cref_1648087271"
      id="fc_1648087271"
      unitRef="uref_1683791803"
      xsi:nil="true"/>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="cref_2099920207"
      id="fc_2099920207"
      unitRef="uref_1683791803"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="cref_900855687"
      id="fc_900855687"
      unitRef="uref_1683791803"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="cref_900855687"
      id="fc_925291853"
      unitRef="uref_923572658"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="cref_109726865"
      id="fc_831707518"
      unitRef="uref_1683791803"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="cref_109726865"
      id="fc_390540446"
      unitRef="uref_923572658"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="cref_109726865"
      id="fc_115080714"
      unitRef="uref_1683791803"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="cref_109726865"
      id="fc_1703437644"
      unitRef="uref_923572658"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="cref_109726865"
      id="fc_134391249"
      unitRef="uref_1683791803"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="cref_109726865"
      id="fc_2140821549"
      unitRef="uref_923572658"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="cref_1952870394"
      id="fc_462562138"
      unitRef="uref_1683791803"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="cref_1952870394"
      id="fc_616701571"
      unitRef="uref_923572658"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="cref_1482179895"
      id="fc_1008009244"
      unitRef="uref_1683791803"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="cref_1482179895"
      id="fc_1916845139"
      unitRef="uref_923572658"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="cref_1482179895"
      id="fc_1201657668"
      unitRef="uref_1683791803"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="cref_1482179895"
      id="fc_1979471054"
      unitRef="uref_923572658"
      xsi:nil="true"/>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="cref_883848846"
      id="fc_2018375862"
      unitRef="uref_921481251"
      xsi:nil="true"/>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="cref_1258711090"
      id="fc_1363859510"
      unitRef="uref_921481251"
      xsi:nil="true"/>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="cref_883848846"
      id="fc_376116076"
      unitRef="uref_921481251"
      xsi:nil="true"/>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="cref_1258711090"
      id="fc_1587337319"
      unitRef="uref_921481251"
      xsi:nil="true"/>
    <us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit
      contextRef="cref_883848846"
      id="fc_74677262"
      unitRef="uref_921481251"
      xsi:nil="true"/>
    <us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit
      contextRef="cref_1258711090"
      id="fc_969593374"
      unitRef="uref_921481251"
      xsi:nil="true"/>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="cref_883848846"
      id="fc_554446855"
      unitRef="uref_921481251"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="cref_883848846"
      id="fc_1329091867"
      unitRef="uref_921481251"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="cref_1258711090"
      id="fc_858113959"
      unitRef="uref_921481251"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="cref_1736530910"
      id="fc_1371966609"
      unitRef="uref_921481251"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="cref_550689438"
      id="fc_1737986731"
      unitRef="uref_921481251"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="cref_1482179895"
      id="fc_1254595273"
      unitRef="uref_1683791803"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="cref_109726865"
      id="fc_1555861181"
      unitRef="uref_1683791803"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesIssued
      contextRef="cref_1736530910"
      id="fc_1731589186"
      unitRef="uref_1683791803"
      xsi:nil="true"/>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="cref_1161587692"
      id="fc_1161587692"
      unitRef="uref_1280488936"
      xsi:nil="true"/>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="cref_904101031"
      id="fc_904101031"
      unitRef="uref_1280488936"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="cref_1920536609"
      id="fc_1920536609"
      unitRef="uref_1280488936"
      xsi:nil="true"/>
    <dei:AmendmentFlag contextRef="cref_883848846" id="ixv-10643">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="cref_883848846" id="ixv-10644">0002023016</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalPeriodFocus contextRef="cref_883848846" id="ixv-10645">FY</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentType contextRef="cref_883848846" id="ixv-11871">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="cref_883848846" id="ixv-11872">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="cref_883848846" id="ixv-11873">2025-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="cref_883848846" id="ixv-11874">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="cref_883848846" id="ixv-11875">2025</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="cref_883848846" id="ixv-11876">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="cref_883848846" id="ixv-11877">001-42875</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="cref_883848846" id="ixv-11878">Turn Therapeutics Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="cref_883848846" id="ixv-11879">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="cref_883848846" id="ixv-11880">32-0456090</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="cref_883848846" id="ixv-11881">250         N.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="cref_883848846" id="ixv-11882">Westlake Blvd</dei:EntityAddressAddressLine2>
    <dei:EntityAddressAddressLine3 contextRef="cref_883848846" id="ixv-11883">STE         210</dei:EntityAddressAddressLine3>
    <dei:EntityAddressCityOrTown contextRef="cref_883848846" id="ixv-11884">Westlake         Village</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="cref_883848846" id="ixv-11885">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="cref_883848846" id="ixv-11886">91362</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="cref_883848846" id="ixv-11887">(818)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="cref_883848846" id="ixv-11888">564-4011</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="cref_883848846" id="ixv-11889">Common         Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="cref_883848846" id="ixv-11890">TTRX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="cref_883848846" id="ixv-11891">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="cref_883848846" id="ixv-11892">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="cref_883848846" id="ixv-11893">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="cref_883848846" id="ixv-11894">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="cref_883848846" id="ixv-11895">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="cref_883848846" id="ixv-11896">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="cref_883848846" id="ixv-11897">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="cref_883848846" id="ixv-11898">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="cref_883848846" id="ixv-11899">false</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag contextRef="cref_883848846" id="ixv-11900">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="cref_883848846" id="ixv-11901">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="cref_883848846" id="ixv-11902">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="cref_489304616"
      decimals="0"
      id="ixv-11903"
      unitRef="uref_921481251">0</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="cref_868190972"
      decimals="0"
      id="ixv-11904"
      unitRef="uref_1683791803">29788040</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock contextRef="cref_883848846" id="ixv-11905">None</dei:DocumentsIncorporatedByReferenceTextBlock>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock contextRef="cref_883848846" id="ixv-3151">

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt; In the normal course of
business, we may collect and store certain sensitive company information, including proprietary and confidential business information.
We maintain various protections designed to safeguard against cyberattacks. We consider these cybersecurity risk management efforts as
part of our broader risk management framework. This
integration
helps ensure that cybersecurity considerations are a fundamental part of our decision-making processes. Our management team works with
our audit committee and board of directors (the &#x201c;Board&#x201d;) to evaluate and address cybersecurity risks in alignment with our
business objectives and operational needs. &lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt; To date, we have&#160;not
engaged&#160;independent
third parties to assess the risks associated with our information technology resources and information assets. In the future, we may engage
third parties to analyze data on the interactions of users of our information technology resources, including our employees, and evaluate
the performance of our cybersecurity systems and processes. &lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;i&gt;&lt;/i&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt; We utilize various third-party
software applications in the functioning of our core business. We consider the cybersecurity practices of our&#160;third-party&#160;service
providers, as appropriate, before engaging them in order to help protect us from any related vulnerabilities. Our assessment of risks
associated with the use of third-party providers is part of our overall risk management framework. &lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;We face risk from cybersecurity
threats that could have a material adverse effect on our business, financial condition, results of operations, cash flows or reputation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt; To
date, we have not
experienced any previous cybersecurity incidents that have materially affected or are reasonably likely to&#160;materially affect&#160;our
business strategy, results of operations, or financial condition. &lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;Our Board is aware of the
critical nature of managing risks associated with cybersecurity threats, and recognizes the significance of these threats to our operational
integrity and stockholder confidence.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The
audit committee is central to the Board&#x2019;s&#160;oversight&#160;of cybersecurity risks and bears the primary responsibility for this
domain as part of its broader responsibility for risk assessment and management. The audit committee is responsible for
escalating significant cybersecurity matters and strategic risk management decisions to the Board, granting the Board comprehensive oversight
and the ability to provide guidance on critical cybersecurity issues. We intend for the audit committee to review the Company&#x2019;s
cybersecurity posture and the effectiveness of its risk management strategies annually and brief the full Board with respect to the Company&#x2019;s
cybersecurity posture and potential risks on a regular basis, with a minimum frequency of once per year.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;We do not currently have
an employee who has significant and demonstrated professional IT management experience and possesses the requisite education, skills and
experience needed to develop and execute our cybersecurity strategies. Presently, our senior management is responsible for monitoring
our cybersecurity risks and maintaining an ongoing dialogue with the audit committee regarding emerging or potential cybersecurity risks
as needed. The relationship between senior management and the audit committee regarding current and emerging cybersecurity concerns helps
to integrate cybersecurity consideration into the Company&#x2019;s broader strategic objectives.&lt;/p&gt;</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock contextRef="cref_883848846" id="ixv-11906">This
integration
helps ensure that cybersecurity considerations are a fundamental part of our decision-making processes. Our management team works with
our audit committee and board of directors (the &#x201c;Board&#x201d;) to evaluate and address cybersecurity risks in alignment with our
business objectives and operational needs.</cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedFlag contextRef="cref_883848846" id="ixv-11907">true</cyd:CybersecurityRiskManagementProcessesIntegratedFlag>
    <cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag contextRef="cref_883848846" id="ixv-11908">false</cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag>
    <cyd:CybersecurityRiskManagementThirdPartyEngagedFlag contextRef="cref_883848846" id="ixv-11909">true</cyd:CybersecurityRiskManagementThirdPartyEngagedFlag>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock contextRef="cref_883848846" id="ixv-11910">To
date, we have not
experienced any previous cybersecurity incidents that have materially affected or are reasonably likely to&#160;materially affect&#160;our
business strategy, results of operations, or financial condition.</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag contextRef="cref_883848846" id="ixv-11911">false</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag>
    <cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock contextRef="cref_883848846" id="ixv-11912">The
audit committee is central to the Board&#x2019;s&#160;oversight&#160;of cybersecurity risks and bears the primary responsibility for this
domain as part of its broader responsibility for risk assessment and management.</cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="cref_679163987" id="ixv-11913">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="cref_679163987" id="ixv-11914">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="cref_679163987" id="ixv-11915">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="cref_679163987" id="ixv-11916">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:InsiderTrdPoliciesProcAdoptedFlag contextRef="cref_883848846" id="ixv-11917">true</ecd:InsiderTrdPoliciesProcAdoptedFlag>
    <dei:AuditorOpinionTextBlock contextRef="cref_883848846" id="ixv-5737">

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Opinion on the consolidated financial
statements&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We have audited the accompanying consolidated balance
sheets of Turn Therapeutics, Inc. (formerly, &#x201c;Global Health Solutions Inc.&#x201d;) (the &#x201c;Company&#x201d;) as of December 31,
2025 and 2024, and the related consolidated statements of operations, changes in stockholders&#x2019; equity (deficit), and cash flows
for each of the two years ended December 31, 2025 and 2024, and the related notes (collectively referred to as the &#x201c;consolidated
financial statements&#x201d;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial
position of the Company as of December 31, 2025 and 2024, and the results of its operations and its cash flows for each of the two years
ended December 31, 2025 and 2024, in conformity with principles generally accepted in the United States of America.&lt;/p&gt;</dei:AuditorOpinionTextBlock>
    <dei:AuditorName contextRef="cref_883848846" id="ixv-11918">WithumSmith+Brown, PC</dei:AuditorName>
    <dei:AuditorLocation contextRef="cref_883848846" id="ixv-11919">Whippany, New Jersey</dei:AuditorLocation>
    <dei:AuditorFirmId contextRef="cref_883848846" id="ixv-11920">100</dei:AuditorFirmId>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="cref_1736530910"
      decimals="0"
      id="ixv-11921"
      unitRef="uref_921481251">5076144</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="cref_550689438"
      decimals="0"
      id="ixv-11922"
      unitRef="uref_921481251">872599</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="cref_1736530910"
      decimals="0"
      id="ixv-11923"
      unitRef="uref_921481251">120300</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="cref_550689438"
      decimals="0"
      id="ixv-11924"
      unitRef="uref_921481251">225325</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="cref_1736530910"
      decimals="0"
      id="ixv-11925"
      unitRef="uref_921481251">5196444</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="cref_550689438"
      decimals="0"
      id="ixv-11926"
      unitRef="uref_921481251">1097924</us-gaap:AssetsCurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="cref_1736530910"
      decimals="0"
      id="ixv-11927"
      unitRef="uref_921481251">78620</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="cref_550689438"
      decimals="0"
      id="ixv-11928"
      unitRef="uref_921481251">120452</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="cref_1736530910"
      decimals="0"
      id="ixv-11929"
      unitRef="uref_921481251">922171</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="cref_550689438"
      decimals="0"
      id="ixv-11930"
      unitRef="uref_921481251">821931</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:DeferredCosts
      contextRef="cref_1736530910"
      decimals="0"
      id="ixv-11931"
      unitRef="uref_921481251">5956424</us-gaap:DeferredCosts>
    <us-gaap:SecurityDeposit
      contextRef="cref_1736530910"
      decimals="0"
      id="ixv-11932"
      unitRef="uref_921481251">8582</us-gaap:SecurityDeposit>
    <us-gaap:SecurityDeposit
      contextRef="cref_550689438"
      decimals="0"
      id="ixv-11933"
      unitRef="uref_921481251">8582</us-gaap:SecurityDeposit>
    <us-gaap:Assets
      contextRef="cref_1736530910"
      decimals="0"
      id="ixv-11934"
      unitRef="uref_921481251">12162241</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="cref_550689438"
      decimals="0"
      id="ixv-11935"
      unitRef="uref_921481251">2048889</us-gaap:Assets>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="cref_1736530910"
      decimals="0"
      id="ixv-11936"
      unitRef="uref_921481251">2928728</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="cref_550689438"
      decimals="0"
      id="ixv-11937"
      unitRef="uref_921481251">667272</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="cref_1736530910"
      decimals="0"
      id="ixv-11938"
      unitRef="uref_921481251">3028401</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="cref_1736530910"
      decimals="0"
      id="ixv-11939"
      unitRef="uref_921481251">46295</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="cref_550689438"
      decimals="0"
      id="ixv-11940"
      unitRef="uref_921481251">40660</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="cref_1736530910"
      decimals="0"
      id="ixv-11941"
      unitRef="uref_921481251">6003424</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="cref_550689438"
      decimals="0"
      id="ixv-11942"
      unitRef="uref_921481251">707932</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="cref_1736530910"
      decimals="0"
      id="ixv-11943"
      unitRef="uref_921481251">34081</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="cref_550689438"
      decimals="0"
      id="ixv-11944"
      unitRef="uref_921481251">80376</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="cref_1736530910"
      decimals="0"
      id="ixv-11945"
      unitRef="uref_921481251">1438013</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="cref_550689438"
      decimals="0"
      id="ixv-11946"
      unitRef="uref_921481251">1438013</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="cref_1736530910"
      decimals="0"
      id="ixv-11947"
      unitRef="uref_921481251">7475518</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="cref_550689438"
      decimals="0"
      id="ixv-11948"
      unitRef="uref_921481251">2226321</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="cref_1736530910"
      decimals="4"
      id="fc_2076402872"
      unitRef="uref_923572658">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="cref_550689438"
      decimals="4"
      id="fc_1888374326"
      unitRef="uref_923572658">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="cref_1736530910"
      decimals="-6"
      id="fc_1245061297"
      unitRef="uref_1683791803">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="cref_550689438"
      decimals="-6"
      id="fc_1428237468"
      unitRef="uref_1683791803">40000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="cref_1736530910"
      decimals="0"
      id="fc_149733321"
      unitRef="uref_1683791803">29445183</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="cref_550689438"
      decimals="0"
      id="fc_1618157086"
      unitRef="uref_1683791803">26845690</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="cref_1736530910"
      decimals="0"
      id="fc_802189528"
      unitRef="uref_921481251">2943</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="cref_550689438"
      decimals="0"
      id="fc_1196160309"
      unitRef="uref_921481251">2684</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="cref_1736530910"
      decimals="0"
      id="ixv-11957"
      unitRef="uref_921481251">28143873</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="cref_550689438"
      decimals="0"
      id="ixv-11958"
      unitRef="uref_921481251">19015897</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:StockholdersEquityNoteSubscriptionsReceivable
      contextRef="cref_1736530910"
      decimals="0"
      id="ixv-11959"
      unitRef="uref_921481251">1070000</us-gaap:StockholdersEquityNoteSubscriptionsReceivable>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="cref_1736530910"
      decimals="0"
      id="ixv-11960"
      unitRef="uref_921481251">-22390093</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="cref_550689438"
      decimals="0"
      id="ixv-11961"
      unitRef="uref_921481251">-19196013</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="cref_1736530910"
      decimals="0"
      id="ixv-11962"
      unitRef="uref_921481251">4686723</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="cref_550689438"
      decimals="0"
      id="ixv-11963"
      unitRef="uref_921481251">-177432</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="cref_1736530910"
      decimals="0"
      id="ixv-11964"
      unitRef="uref_921481251">12162241</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="cref_550689438"
      decimals="0"
      id="ixv-11965"
      unitRef="uref_921481251">2048889</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="cref_883848846"
      decimals="0"
      id="ixv-11967"
      unitRef="uref_921481251">5593078</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="cref_1258711090"
      decimals="0"
      id="ixv-11968"
      unitRef="uref_921481251">1551168</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="cref_883848846"
      decimals="0"
      id="ixv-11969"
      unitRef="uref_921481251">265570</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="cref_1258711090"
      decimals="0"
      id="ixv-11970"
      unitRef="uref_921481251">245956</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OperatingExpenses
      contextRef="cref_883848846"
      decimals="0"
      id="ixv-11971"
      unitRef="uref_921481251">5858648</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="cref_1258711090"
      decimals="0"
      id="ixv-11972"
      unitRef="uref_921481251">1797124</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="cref_883848846"
      decimals="0"
      id="ixv-11973"
      unitRef="uref_921481251">-5858648</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="cref_1258711090"
      decimals="0"
      id="ixv-11974"
      unitRef="uref_921481251">-1797124</us-gaap:OperatingIncomeLoss>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="cref_883848846"
      decimals="0"
      id="ixv-11975"
      unitRef="uref_921481251">2574971</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <ttrx:GainFromChangeInFairValueOfForwardContractLiability
      contextRef="cref_883848846"
      decimals="0"
      id="ixv-11976"
      unitRef="uref_921481251">-380442</ttrx:GainFromChangeInFairValueOfForwardContractLiability>
    <us-gaap:WriteOffOfDeferredDebtIssuanceCost
      contextRef="cref_883848846"
      decimals="0"
      id="ixv-11977"
      unitRef="uref_921481251">496948</us-gaap:WriteOffOfDeferredDebtIssuanceCost>
    <us-gaap:InvestmentIncomeInterest
      contextRef="cref_883848846"
      decimals="0"
      id="ixv-11978"
      unitRef="uref_921481251">29583</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="cref_1258711090"
      decimals="0"
      id="ixv-11979"
      unitRef="uref_921481251">28709</us-gaap:InvestmentIncomeInterest>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="cref_883848846"
      decimals="0"
      id="ixv-11980"
      unitRef="uref_921481251">176520</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="cref_883848846"
      decimals="0"
      id="ixv-11981"
      unitRef="uref_921481251">2664568</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="cref_1258711090"
      decimals="0"
      id="ixv-11982"
      unitRef="uref_921481251">28709</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="cref_883848846"
      decimals="0"
      id="ixv-11983"
      unitRef="uref_921481251">-3194080</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="cref_1258711090"
      decimals="0"
      id="ixv-11984"
      unitRef="uref_921481251">-1768415</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="cref_883848846"
      decimals="2"
      id="ixv-11985"
      unitRef="uref_923572658">-0.12</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="cref_883848846"
      decimals="2"
      id="ixv-11986"
      unitRef="uref_923572658">-0.12</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="cref_1258711090"
      decimals="2"
      id="ixv-11987"
      unitRef="uref_923572658">-0.07</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="cref_1258711090"
      decimals="2"
      id="ixv-11988"
      unitRef="uref_923572658">-0.07</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="cref_883848846"
      decimals="0"
      id="ixv-11989"
      unitRef="uref_1683791803">27716045</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="cref_883848846"
      decimals="0"
      id="ixv-11990"
      unitRef="uref_1683791803">27716045</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="cref_1258711090"
      decimals="0"
      id="ixv-11991"
      unitRef="uref_1683791803">26643432</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="cref_1258711090"
      decimals="0"
      id="ixv-11992"
      unitRef="uref_1683791803">26643432</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="cref_2051066427"
      decimals="0"
      id="fc_1776654961"
      unitRef="uref_1683791803">26494482</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="cref_2051066427"
      decimals="0"
      id="fc_2051066427"
      unitRef="uref_921481251">2649</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="cref_1760188914"
      decimals="0"
      id="ixv-11995"
      unitRef="uref_921481251">17510717</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="cref_919024790"
      decimals="0"
      id="ixv-11996"
      unitRef="uref_921481251">-17427598</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="cref_1676632137"
      decimals="0"
      id="ixv-11997"
      unitRef="uref_921481251">85768</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="cref_1159091871"
      decimals="0"
      id="fc_234313724"
      unitRef="uref_1683791803">351208</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="cref_1159091871"
      decimals="0"
      id="fc_1159091871"
      unitRef="uref_921481251">35</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="cref_876232622"
      decimals="0"
      id="ixv-12000"
      unitRef="uref_921481251">1152347</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="cref_1258711090"
      decimals="0"
      id="ixv-12001"
      unitRef="uref_921481251">1152382</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="cref_876232622"
      decimals="0"
      id="ixv-12002"
      unitRef="uref_921481251">352833</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="cref_1258711090"
      decimals="0"
      id="ixv-12003"
      unitRef="uref_921481251">352833</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:NetIncomeLoss
      contextRef="cref_1866611515"
      decimals="0"
      id="ixv-12004"
      unitRef="uref_921481251">-1768415</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="cref_1258711090"
      decimals="0"
      id="ixv-12005"
      unitRef="uref_921481251">-1768415</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="cref_1261566747"
      decimals="0"
      id="fc_1839485908"
      unitRef="uref_1683791803">26845690</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="cref_1261566747"
      decimals="0"
      id="fc_1261566747"
      unitRef="uref_921481251">2684</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="cref_698189977"
      decimals="0"
      id="ixv-12008"
      unitRef="uref_921481251">19015897</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="cref_566794310"
      decimals="0"
      id="ixv-12009"
      unitRef="uref_921481251">-19196013</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="cref_550689438"
      decimals="0"
      id="ixv-12010"
      unitRef="uref_921481251">-177432</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="cref_2125858781"
      decimals="0"
      id="fc_630707599"
      unitRef="uref_1683791803">215972</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="cref_2125858781"
      decimals="0"
      id="fc_1883966516"
      unitRef="uref_921481251">22</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="cref_1480925456"
      decimals="0"
      id="ixv-12013"
      unitRef="uref_921481251">777781</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="cref_883848846"
      decimals="0"
      id="ixv-12014"
      unitRef="uref_921481251">777803</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <ttrx:StockIssuedDuringPeriodSharesIssuanceOfCommonStockUnderRegulationANetOfIssuanceCostsShares
      contextRef="cref_2125858781"
      decimals="0"
      id="fc_1727071466"
      unitRef="uref_1683791803">83610</ttrx:StockIssuedDuringPeriodSharesIssuanceOfCommonStockUnderRegulationANetOfIssuanceCostsShares>
    <ttrx:StockIssuedDuringPeriodValueIssuanceOfCommonStockUnderRegulationANetOfIssuanceCosts
      contextRef="cref_2125858781"
      decimals="0"
      id="fc_1664853907"
      unitRef="uref_921481251">8</ttrx:StockIssuedDuringPeriodValueIssuanceOfCommonStockUnderRegulationANetOfIssuanceCosts>
    <ttrx:StockIssuedDuringPeriodValueIssuanceOfCommonStockUnderRegulationANetOfIssuanceCosts
      contextRef="cref_1480925456"
      decimals="0"
      id="ixv-12017"
      unitRef="uref_921481251">280484</ttrx:StockIssuedDuringPeriodValueIssuanceOfCommonStockUnderRegulationANetOfIssuanceCosts>
    <ttrx:StockIssuedDuringPeriodValueIssuanceOfCommonStockUnderRegulationANetOfIssuanceCosts
      contextRef="cref_883848846"
      decimals="0"
      id="ixv-12018"
      unitRef="uref_921481251">280492</ttrx:StockIssuedDuringPeriodValueIssuanceOfCommonStockUnderRegulationANetOfIssuanceCosts>
    <ttrx:StockIssuedDuringPeriodSharesIssuanceOfCommonStockUnderRegulationDNetOfIssuanceCosts
      contextRef="cref_2125858781"
      decimals="0"
      id="fc_850771456"
      unitRef="uref_1683791803">800720</ttrx:StockIssuedDuringPeriodSharesIssuanceOfCommonStockUnderRegulationDNetOfIssuanceCosts>
    <ttrx:StockIssuedDuringPeriodValueIssuanceOfCommonStockUnderRegulationDNetOfIssuanceCosts
      contextRef="cref_2125858781"
      decimals="0"
      id="fc_141944097"
      unitRef="uref_921481251">80</ttrx:StockIssuedDuringPeriodValueIssuanceOfCommonStockUnderRegulationDNetOfIssuanceCosts>
    <ttrx:StockIssuedDuringPeriodValueIssuanceOfCommonStockUnderRegulationDNetOfIssuanceCosts
      contextRef="cref_1480925456"
      decimals="0"
      id="ixv-12021"
      unitRef="uref_921481251">2860819</ttrx:StockIssuedDuringPeriodValueIssuanceOfCommonStockUnderRegulationDNetOfIssuanceCosts>
    <ttrx:StockIssuedDuringPeriodValueIssuanceOfCommonStockUnderRegulationDNetOfIssuanceCosts
      contextRef="cref_883848846"
      decimals="0"
      id="ixv-12022"
      unitRef="uref_921481251">2860899</ttrx:StockIssuedDuringPeriodValueIssuanceOfCommonStockUnderRegulationDNetOfIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="cref_2125858781"
      decimals="0"
      id="fc_949861460"
      unitRef="uref_1683791803">54466</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="cref_2125858781"
      decimals="0"
      id="fc_1235019873"
      unitRef="uref_921481251">5</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="cref_1480925456"
      decimals="0"
      id="ixv-12025"
      unitRef="uref_921481251">249995</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="cref_883848846"
      decimals="0"
      id="ixv-12026"
      unitRef="uref_921481251">250000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="cref_2125858781"
      decimals="0"
      id="fc_1975586323"
      unitRef="uref_1683791803">47620</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="cref_2125858781"
      decimals="0"
      id="fc_358054683"
      unitRef="uref_921481251">4</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="cref_1480925456"
      decimals="0"
      id="ixv-12029"
      unitRef="uref_921481251">234</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="cref_883848846"
      decimals="0"
      id="ixv-12030"
      unitRef="uref_921481251">238</us-gaap:StockIssuedDuringPeriodValueOther>
    <ttrx:StockIssuedDuringPeriodSharesIssuanceOfCommonStockForDrawDownNotice
      contextRef="cref_2125858781"
      decimals="0"
      id="fc_1914277625"
      unitRef="uref_1683791803">1235200</ttrx:StockIssuedDuringPeriodSharesIssuanceOfCommonStockForDrawDownNotice>
    <ttrx:StockIssuedDuringPeriodValueIssuanceOfCommonStockForDrawDownNotice
      contextRef="cref_2125858781"
      decimals="0"
      id="fc_1608902388"
      unitRef="uref_921481251">124</ttrx:StockIssuedDuringPeriodValueIssuanceOfCommonStockForDrawDownNotice>
    <ttrx:StockIssuedDuringPeriodValueIssuanceOfCommonStockForDrawDownNotice
      contextRef="cref_1480925456"
      decimals="0"
      id="ixv-12033"
      unitRef="uref_921481251">3689434</ttrx:StockIssuedDuringPeriodValueIssuanceOfCommonStockForDrawDownNotice>
    <ttrx:StockIssuedDuringPeriodValueIssuanceOfCommonStockForDrawDownNotice
      contextRef="cref_605097494"
      decimals="0"
      id="ixv-12034"
      unitRef="uref_921481251">-1070000</ttrx:StockIssuedDuringPeriodValueIssuanceOfCommonStockForDrawDownNotice>
    <ttrx:StockIssuedDuringPeriodValueIssuanceOfCommonStockForDrawDownNotice
      contextRef="cref_883848846"
      decimals="0"
      id="ixv-12035"
      unitRef="uref_921481251">2619558</ttrx:StockIssuedDuringPeriodValueIssuanceOfCommonStockForDrawDownNotice>
    <ttrx:StockIssuedDuringPeriodSharesCommonStockForDeferredOfferingCost
      contextRef="cref_2125858781"
      decimals="0"
      id="fc_326726658"
      unitRef="uref_1683791803">161905</ttrx:StockIssuedDuringPeriodSharesCommonStockForDeferredOfferingCost>
    <ttrx:StockIssuedDuringPeriodValueCommonStockForDeferredOfferingCost
      contextRef="cref_2125858781"
      decimals="0"
      id="fc_2125858781"
      unitRef="uref_921481251">16</ttrx:StockIssuedDuringPeriodValueCommonStockForDeferredOfferingCost>
    <ttrx:StockIssuedDuringPeriodValueCommonStockForDeferredOfferingCost
      contextRef="cref_1480925456"
      decimals="0"
      id="ixv-12038"
      unitRef="uref_921481251">849984</ttrx:StockIssuedDuringPeriodValueCommonStockForDeferredOfferingCost>
    <ttrx:StockIssuedDuringPeriodValueCommonStockForDeferredOfferingCost
      contextRef="cref_883848846"
      decimals="0"
      id="ixv-12039"
      unitRef="uref_921481251">850000</ttrx:StockIssuedDuringPeriodValueCommonStockForDeferredOfferingCost>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="cref_1480925456"
      decimals="0"
      id="ixv-12040"
      unitRef="uref_921481251">419245</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="cref_883848846"
      decimals="0"
      id="ixv-12041"
      unitRef="uref_921481251">419245</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:NetIncomeLoss
      contextRef="cref_1778799606"
      decimals="0"
      id="ixv-12042"
      unitRef="uref_921481251">-3194080</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="cref_883848846"
      decimals="0"
      id="ixv-12043"
      unitRef="uref_921481251">-3194080</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="cref_153310236"
      decimals="0"
      id="fc_1558260796"
      unitRef="uref_1683791803">29445183</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="cref_153310236"
      decimals="0"
      id="fc_153310236"
      unitRef="uref_921481251">2943</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="cref_128292186"
      decimals="0"
      id="ixv-12046"
      unitRef="uref_921481251">28143873</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="cref_1495557967"
      decimals="0"
      id="ixv-12047"
      unitRef="uref_921481251">-1070000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="cref_830575058"
      decimals="0"
      id="ixv-12048"
      unitRef="uref_921481251">-22390093</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="cref_1736530910"
      decimals="0"
      id="ixv-12049"
      unitRef="uref_921481251">4686723</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="cref_883848846"
      decimals="0"
      id="ixv-12050"
      unitRef="uref_921481251">-3194080</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="cref_1258711090"
      decimals="0"
      id="ixv-12051"
      unitRef="uref_921481251">-1768415</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="cref_883848846"
      decimals="0"
      id="ixv-12052"
      unitRef="uref_921481251">52746</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="cref_1258711090"
      decimals="0"
      id="ixv-12053"
      unitRef="uref_921481251">47483</us-gaap:DepreciationAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="cref_883848846"
      decimals="0"
      id="ixv-12054"
      unitRef="uref_921481251">419245</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="cref_1258711090"
      decimals="0"
      id="ixv-12055"
      unitRef="uref_921481251">352833</us-gaap:ShareBasedCompensation>
    <ttrx:NoncashOperatingLeaseExpense
      contextRef="cref_883848846"
      decimals="0"
      id="ixv-12056"
      unitRef="uref_921481251">1172</ttrx:NoncashOperatingLeaseExpense>
    <ttrx:NoncashOperatingLeaseExpense
      contextRef="cref_1258711090"
      decimals="0"
      id="ixv-12057"
      unitRef="uref_921481251">8650</ttrx:NoncashOperatingLeaseExpense>
    <ttrx:CommonStockIssuedInExchangeForServices
      contextRef="cref_883848846"
      decimals="0"
      id="ixv-12058"
      unitRef="uref_921481251">250000</ttrx:CommonStockIssuedInExchangeForServices>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="cref_883848846"
      decimals="0"
      id="ixv-12059"
      unitRef="uref_921481251">2574971</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <ttrx:GainFromChangeInFairValueOfForwardContractLiability
      contextRef="cref_883848846"
      decimals="0"
      id="ixv-12060"
      unitRef="uref_921481251">-380442</ttrx:GainFromChangeInFairValueOfForwardContractLiability>
    <us-gaap:WriteOffOfDeferredDebtIssuanceCost
      contextRef="cref_883848846"
      decimals="0"
      id="ixv-12061"
      unitRef="uref_921481251">496948</us-gaap:WriteOffOfDeferredDebtIssuanceCost>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="cref_883848846"
      decimals="0"
      id="ixv-12062"
      unitRef="uref_921481251">-105025</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="cref_1258711090"
      decimals="0"
      id="ixv-12063"
      unitRef="uref_921481251">204505</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="cref_883848846"
      decimals="0"
      id="ixv-12064"
      unitRef="uref_921481251">2261456</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="cref_1258711090"
      decimals="0"
      id="ixv-12065"
      unitRef="uref_921481251">202649</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="cref_883848846"
      decimals="0"
      id="ixv-12066"
      unitRef="uref_921481251">-2562901</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="cref_1258711090"
      decimals="0"
      id="ixv-12067"
      unitRef="uref_921481251">-1361305</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="cref_883848846"
      decimals="0"
      id="ixv-12068"
      unitRef="uref_921481251">152986</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="cref_1258711090"
      decimals="0"
      id="ixv-12069"
      unitRef="uref_921481251">99475</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="cref_883848846"
      decimals="0"
      id="ixv-12070"
      unitRef="uref_921481251">-152986</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="cref_1258711090"
      decimals="0"
      id="ixv-12071"
      unitRef="uref_921481251">-99475</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="cref_883848846"
      decimals="0"
      id="ixv-12072"
      unitRef="uref_921481251">6919432</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="cref_1258711090"
      decimals="0"
      id="ixv-12073"
      unitRef="uref_921481251">1152382</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="cref_883848846"
      decimals="0"
      id="ixv-12074"
      unitRef="uref_921481251">6919432</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="cref_1258711090"
      decimals="0"
      id="ixv-12075"
      unitRef="uref_921481251">1152382</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectDisposalGroupIncludingDiscontinuedOperations
      contextRef="cref_883848846"
      decimals="0"
      id="ixv-12076"
      unitRef="uref_921481251">4203545</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectDisposalGroupIncludingDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectDisposalGroupIncludingDiscontinuedOperations
      contextRef="cref_1258711090"
      decimals="0"
      id="ixv-12077"
      unitRef="uref_921481251">-308398</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectDisposalGroupIncludingDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="cref_550689438"
      decimals="0"
      id="ixv-12078"
      unitRef="uref_921481251">872599</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="cref_1676632137"
      decimals="0"
      id="ixv-12079"
      unitRef="uref_921481251">1180997</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="cref_1736530910"
      decimals="0"
      id="ixv-12080"
      unitRef="uref_921481251">5076144</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="cref_550689438"
      decimals="0"
      id="ixv-12081"
      unitRef="uref_921481251">872599</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="cref_1258711090"
      decimals="0"
      id="ixv-12082"
      unitRef="uref_921481251">133615</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:StockIssued1
      contextRef="cref_883848846"
      decimals="0"
      id="ixv-12083"
      unitRef="uref_921481251">850000</us-gaap:StockIssued1>
    <ttrx:SettlementOfForwardContractLiabilityForSaleOfSharesToGEMPursuantToInitialDrawDownNotice
      contextRef="cref_883848846"
      decimals="0"
      id="ixv-12084"
      unitRef="uref_921481251">380442</ttrx:SettlementOfForwardContractLiabilityForSaleOfSharesToGEMPursuantToInitialDrawDownNotice>
    <us-gaap:NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationWarrantsIssued1
      contextRef="cref_883848846"
      decimals="0"
      id="ixv-12085"
      unitRef="uref_1683791803">5603372</us-gaap:NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationWarrantsIssued1>
    <us-gaap:NatureOfOperations contextRef="cref_883848846" id="ixv-7203">

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;
  &lt;tbody&gt;
  &lt;tr style="vertical-align: top; text-align: justify"&gt;
    &lt;td style="width: 0in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;1.&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;ORGANIZATION AND DESCRIPTION OF BUSINESS&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We were formed in Delaware in January 2015 as
Global Health Solutions, LLC. In October 2018, we converted into a Delaware corporation under the name Global Health Solutions, Inc.,
and in September 2025, we changed our corporate name to Turn Therapeutics Inc. (hereinafter referred to as the &#x201c;Company&#x201d;,
&#x201c;we&#x201d;, &#x201c;us&#x201d; or &#x201c;our&#x201d;). Our corporate headquarters are located in Westlake Village, California.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We are a clinical-stage biotechnology and medical
device development company built around our proprietary platform technology called PermaFusion&lt;sup&gt;&#xae;&lt;/sup&gt; designed to enhance drug
performance. Our primary drug development programs focus on dermatological diseases, including moderate to severe eczema and onychomycosis.
We also have a portfolio of Food and Drug Administration (&#x201c;FDA&#x201d;) cleared medical devices. We are also developing an intranasal
vaccine with sufficient thermostability for rapid deployment for pandemic response.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&lt;span style="text-decoration:underline"&gt;Direct
Listing&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On October 8, 2025, we completed direct listing
of our common stock on Nasdaq (the &#x201c;Direct Listing&#x201d;) under the ticker symbol TTRX.&lt;/p&gt;</us-gaap:NatureOfOperations>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="cref_883848846" id="ixv-7224">

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;
  &lt;tbody&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;2.&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;BASIS OF PRESENTATION, PRINCIPLES OF CONSOLIDATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The accompanying consolidated financial statements
have been prepared in accordance with accounting principles generally accepted in the United States (&#x201c;GAAP&#x201d;), and reflect
the operations of the Company and our wholly owned subsidiary. Any reference in these notes to applicable guidance is meant to refer to
GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Updates (&#x201c;ASU&#x201d;) promulgated
by the Financial Accounting Standards Board (&#x201c;FASB&#x201d;). All material intercompany accounts and transactions have been eliminated
in consolidation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&lt;span style="text-decoration:underline"&gt;2-for-1
Forward Stock Split&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt; On September 11, 2025, our board of directors
(&#x201c;Board&#x201d;) approved a 2-for-1 forward
stock split (the &#x201c;Stock Split&#x201d;) of our common stock upon the effectiveness of our registration statement on
Form S-1 filed with the Securities and Exchange Commission (&#x201c;SEC&#x201d;) and our Amended and Restated Certificate of Incorporation
filed with the State of Delaware. &lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt; On September 30, 2025, our registration statement
on Form S-1 was declared effective by the SEC and our Amended and Restated Certificate of Incorporation was filed with the State of Delaware
giving effect to a 2-for-1 forward split
of our common stock. &lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Unless otherwise indicated, all authorized, issued,
and outstanding stock and per share amounts contained herein have been adjusted to reflect the effect of the Stock Split for all prior
periods presented. Proportionate adjustments were made to exercise prices and the number of shares issuable under our equity incentive
plans and outstanding warrants.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The impacts of the Stock Split were applied retroactively
for all periods presented in accordance with applicable guidance and therefore, amounts may differ from those previously reported.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The following table illustrates changes in equity,
as previously reported prior to, and as adjusted subsequent to, the impact of the Stock Split retroactively adjusted for the periods previously
presented:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tbody&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December 31, 2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;As Previously Reported&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Impact of Stock Split&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;As Revised&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%"&gt;Common stock - shares&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;13,422,845&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;13,422,845&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;26,845,690&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Common stock - amount&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;1,342&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;1,342&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;2,684&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Additional paid-in capital&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;19,017,239&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(1,342&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;19,015,897&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/tbody&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&lt;span style="text-decoration:underline"&gt;Liquidity
and Going Concern&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt; As of December 31, 2025, we had approximately
$5.1
million of cash and cash equivalents and working capital of approximately $2.2
million (excluding the derivative liability). We have a relatively limited operating history, and the revenue and income potential of
our business and market are unproven. We have experienced net losses and negative cash flows from operations since inception and, as of
December 31, 2025, we had an accumulated deficit of $22.4
million. During the year ended December 31, 2025, we incurred a net loss of $3.2
million and had cash out flows from operations of $2.6
million. We will continue to incur costs and expenses related to our ongoing operations until we successfully commercialize, develop,
obtain regulatory approval for and gain market acceptance of products and product candidates and achieve revenues adequate to support
our operations. &lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;From inception through December&#160;31, 2025,
we have funded our operations primarily with proceeds from the sale of common stock, including through exempt offerings under Regulation
Crowdfunding, Regulation A+ and Regulation D, draw-down from our Share Purchase Agreement (Note 7) as well as through proceeds from license
and collaboration agreements. Based on our current operating plan, we estimate that our cash and cash equivalents as of December&#160;31,
2025 will be sufficient to fund our operating expenses and capital expenditure requirements into the third quarter of 2026. We have based
this estimate on assumptions that may prove to be wrong, and could deplete our capital resources sooner than we currently expect. Our
capital resources may not be sufficient to fund operations through at least the next 12&#160;months from the date that these audited consolidated
financial statements as of December&#160;31, 2025 are issued based on our expected cash needs, which raises substantial doubt about our
ability to continue as a going concern.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As we continue to pursue our business plan, we
expect to finance our operations through potential public or private equity offerings, including future draw-downs under our Share Purchase
Agreement (Note 7), proceeds from executed debt financing (Note 15), and additional debt financings or other capital sources, including
current or potential future collaborations, licenses and other similar arrangements. However, there can be no assurance that any additional
financing or strategic arrangements will be available to us on acceptable terms, if at all. If events or circumstances occur such that
we are not able to obtain additional funding, it may be necessary to significantly reduce our scope of operations to reduce the current
rate of spending through actions such as reductions in staff and the need to delay, limit, reduce or terminate product development or
future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and
market ourselves, which could have a material adverse effect on our business, results of operations or financial condition.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The accompanying consolidated financial statements
have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary
course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded
asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&lt;span style="text-decoration:underline"&gt;Summary
of Significant Accounting Policies&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The preparation of consolidated financial statements
in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities,
the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and
expenses during the reporting period. Significant estimates include, but are not limited to, those relating to stock-based compensation,
revenue recognition, research and development expenses, fair value estimates of warrants and other derivative liabilities, and determination
of right-of-use assets under lease transactions and related lease obligations. Although these estimates are based on our knowledge of
current events and actions we may undertake in the future, actual results may materially differ from these estimates and assumptions.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Concentration
of Credit Risk &lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt; Financial instruments which potentially subject
us to significant concentration of credit risk consist of cash and cash equivalents. We maintain deposits in federally insured financial
institutions in excess of federally insured limits. We have not experienced any losses in such accounts, and management believes that
we are not exposed to significant credit risk due to the nature of the instruments held in the depository institutions. As of December
31, 2025 and 2024, cash and cash equivalents exceeded Federal Deposit Insurance Corporation insured limits by $4.5
million and $0.3
million, respectively. &lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt; The majority of our accounts payable and accrued
expenses are concentrated with one vendor having balance of approximately $1.5
million which represents approximately 51%
of our accounts payable and accrued expenses as of December 31, 2025. The amount owed to two majorly concentrated vendors as of December
31, 2024 was approximately $0.3
million and $0.1
million which represent approximately 65%
of our accounts payable and accrued expenses. &lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Cash and Cash
Equivalents&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Cash and cash equivalents are considered to be
highly liquid investments with maturities of three months or less at the date of purchase. Cash equivalents primarily represent funds
invested in readily available money market accounts. As of December 31, 2025 and 2024, we had cash and cash equivalent balances deposited
at multiple major financial institutions.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Intangible
Assets&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt; We capitalize costs associated with obtaining
patents and trademarks. Intangible assets are amortized over the estimated useful life of 20
years and trademark costs are indefinitely lived. &lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Impairment
of Long-Lived Assets&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We evaluate our long-lived assets, which consist
of property and equipment and identifiable intangibles, for impairment at least annually, or whenever events or changes in circumstances
indicate that the carrying amount of such assets may not be recoverable. Recoverability of assets to be held and used is measured by a
comparison of the carrying amount of an asset to the future undiscounted net cash flows expected to be generated by the asset or eventual
disposal. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying
amount of the asset exceeds the fair value of the asset. To date, we have not recorded any impairment losses on long-lived assets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Research and
Development Expenses&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Research and development expenses are composed
of both internal and external costs. Internal costs include salaries and employment-related expenses of scientific personnel and direct
project costs. External research and development expenses consist primarily of costs associated with clinical and non-clinical development
programs and are charged to expenses as incurred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We also record accruals for estimated ongoing
clinical trial costs. Clinical trial costs primarily represent costs incurred by contract research organizations and clinical trial sites.
We analyze the progress of the clinical trial, including levels of subject enrollment, invoices received and contracted costs when evaluating
the adequacy of accrued liabilities. In accruing for these services, we estimate the time period over which services will be performed
and the level of effort to be expended in each period. These estimates are based on communications with the third-party service providers
and our estimates of accrued expenses based on information available at each balance sheet date. If the actual timing of the performance
of services or the level of effort varies from the estimate, we will adjust the accrual accordingly.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Revenue Recognition&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Under ASC 606, we recognize revenue when our customer
obtains control of promised goods or services, in an amount that reflects the consideration that we expect to receive in exchange for
those goods or services. To determine revenue recognition for arrangements that we determine are within the scope of ASC 606, we perform
the following five steps: (i) identify the contract with a customer; (ii) identify the performance obligations in the contract; (iii)
determine the transaction price, including variable consideration, if any; (iv) allocate the transaction price to the performance obligations
in the contract; and (v) recognize revenue when (or as) we satisfy a performance obligation. We only apply the five-step model to contracts
when it is probable that we will collect the consideration to which we are entitled in exchange for the goods or services we transfer
to a customer.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;At contract inception, once the contract is determined
to be within the scope of ASC 606, we assess whether the goods or services promised within each contract are distinct and, therefore,
represent a separate performance obligation. Goods and services that are determined not to be distinct are combined with other promised
goods and services until a distinct combined performance obligation is identified. We then allocate the transaction price (that is, the
amount of consideration we expect to be entitled to from a customer in exchange for the promised goods or services) to each performance
obligation and recognize the associated revenue when (or as) each performance obligation is satisfied. Our estimate of the transaction
price for each contract includes all variable consideration to which we expect to be entitled, subject to the constraint on variable consideration.
Variable consideration is not constrained if the potential reversal of cumulative revenue recognized at the contract level is not significant.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;License
Rights&lt;/span&gt;&lt;/i&gt; &#x2014; If the license to our intellectual property (IP) is determined to be distinct from the other promises or performance
obligations identified in the arrangement, which generally include research and development services, we recognize revenue from non-refundable,
upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from
the license. In assessing whether a license is distinct from the other promises, we consider relevant facts and circumstances of each
arrangement, including the research and development capabilities of the collaboration partner and the availability of the associated expertise
in the general marketplace. In addition, we consider whether the collaboration partner can benefit from the license for its intended purpose
without the receipt of the remaining promises, whether the value of the license is dependent on the unsatisfied promises, whether there
are other vendors that could provide the remaining promises and whether it is separately identifiable from the remaining promises.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;For licenses that are combined with other promises,
we utilize judgment to assess the nature of the combined performance obligation and whether the license is the predominant promise within
the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time
and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;If the license is the predominant promise, and
it is determined that the license represents functional IP, revenue is recognized at the point in time when control of the license is
transferred. If it is determined that the license does not represent functional IP, revenue is recognized over time using an appropriate
method of measuring progress.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Milestone
Payments&lt;/span&gt;&lt;/i&gt; &#x2014; At the inception of an arrangement that includes development milestone payments, we evaluate whether the milestones
are considered likely to be achieved and estimate the amount to be included in the transaction price using the most likely amount method.
If it is probable that a significant reversal of cumulative revenue recognized would not occur, the associated milestone value is included
in the transaction price. Milestone payments that are not within our control, such as regulatory approvals, are not considered probable
to be achieved until those approvals are received. We evaluate factors such as the scientific, clinical, regulatory, commercial and other
risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved in
determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period,
we re-evaluate the probability of achievement of all milestones subject to constraint and, if necessary, adjust its estimate of the overall
transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period
of adjustment.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Royalties&lt;/span&gt;&lt;/i&gt;
&#x2014; For arrangements that include sales-based royalties, including milestone payments based on a level of sales, where the license
is deemed to be the predominant item to which the royalties relate, we recognize revenue at the later of (i) when the related sales occur
or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).
To date, we have not recognized any royalty revenue resulting from licensing agreements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Amounts due to us for satisfying the revenue recognition
criteria or that are contractually due based upon the terms of the collaboration agreements are recorded as accounts receivable on the
consolidated balance sheets. Amounts received prior to satisfying the revenue recognition criteria are recorded as deferred revenue. Amounts
expected to be recognized as revenue within the one year following the balance sheet date are classified as current deferred revenue.
Amounts not expected to be recognized as revenue within the one year following the balance sheet date are classified as deferred revenue,
net of current portion.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Income Taxes&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We are taxed as a &#x201c;Corporation&#x201d; for
both federal and state income tax purposes. We account for income taxes using the asset and liability approach promulgated by ASC 740&lt;i&gt;,&lt;/i&gt;&#160;&lt;i&gt;Income
Taxes&lt;/i&gt;, for financial reporting purposes. Deferred tax assets and liabilities are recognized for the future tax consequences attributable
to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and
operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply
to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax
assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Valuation allowances
are established, when necessary, to reduce the deferred tax assets to an amount expected to be realized.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We are required to evaluate the tax positions
taken in the course of preparing tax returns to determine whether tax positions will more likely than not be substantiated by the tax
authorities. Tax benefits of positions not deemed to meet the more-likely-than-not threshold are recorded as a tax expense. The amount
recognized is subject to estimate and judgement with respect to the likely outcome of each uncertain tax position. The amount that is
ultimately sustained for an individual or all uncertain tax position(s) could differ from the amount that is initially recognized. We
recognize interest and/or penalties related to tax matter as income tax expense.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-variant: small-caps"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Leases&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;At the inception of a contractual agreement, we
determine whether the contract is or contains a lease, by assessing whether there is an identified asset and whether the contract conveys
the right to control the use of the identified asset in exchange for consideration over a period of time. If both criteria are met, we
record the associated lease liability and corresponding right-of-use asset upon commencement of the lease using the implicit rate or a
discount rate based on a credit-adjusted secured borrowing rate commensurate with the term of the lease. When determining the lease term,
we include options to extend or terminate the lease when it is reasonably certain, at inception, that we will exercise that option. Additionally,
we evaluate leases at their inception to determine if they are to be accounted for as an operating lease or a finance lease.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Operating lease assets represent our right to
use an underlying asset for the lease term (Right-of-use assets) and operating lease liabilities represent our obligation to make lease
payments arising from the lease. The lease payments used to determine our operating lease assets may include lease incentives, stated
rent increases and escalation clauses, when determinable, and are recognized in determining our Right-of-use assets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt; Operating lease liabilities with a term greater
than one year and their corresponding right-of-use assets are recognized on the balance sheets at the commencement date of the lease based
on the present value of lease payments over the expected lease term. We exclude short-term leases, if any, having initial terms of 12
months or less at lease commencement as an accounting policy election. Variable lease payments are amounts owed by us to a lessor that
are not fixed, such as reimbursement for common area maintenance costs for our office lease; and are expensed when incurred. Operating
right-of-use assets are reflected in right-of-use asset in the accompanying consolidated balance sheets. Operating lease liabilities are
reflected in operating lease liability, current and non-current in the accompanying consolidated balance sheets. &lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Financing leases are treated similarly to operating
leases except that the asset subject to the lease is included in the appropriate fixed asset category, rather than recorded as a Right-of-use
asset, and depreciated over its estimated useful life, or lease term, if shorter.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Stock-Based
Compensation&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We account for stock-based compensation for both
employees and non-employees in accordance with ASC 718, &lt;i&gt;Compensation &#x2013; Stock Compensation&lt;/i&gt;. Under the fair value recognition
provisions of ASC 718, stock-based compensation cost is measured at the grant date based on the fair value of the award and is recognized
as expense ratably over the requisite service period, which is generally the option vesting period.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Segment Reporting&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Operating segments are identified as components
of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker
(&#x201c;CODM&#x201d;) in making decisions regarding resource allocation and assessing performance. We manage our operations as a single
reportable segment for the purposes of assessing performance and making operating decisions.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Warrants&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt; We evaluate the appropriate balance sheet classification
of warrants we issue as either equity or as a derivative liability. In accordance with ASC 815-40,&#160;&lt;i&gt;Derivatives and Hedging-Contracts
in the Entity&lt;/i&gt;&#x2019;&lt;i&gt;s Own Equity&lt;/i&gt;, we classify a warrant as equity if it is &#x201c;indexed to the Company&#x2019;s equity&#x201d;
and meets several specific conditions for equity classification. As of December 31, 2025&lt;i&gt;&#160;&lt;/i&gt;and 2024, 0
and 87,744
outstanding warrants, respectively, were classified as equity. &lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt; A warrant is not considered &#x201c;indexed to
the Company&#x2019;s equity,&#x201d; in general, when it contains certain types of exercise contingencies or potential adjustments to its
exercise price. If a warrant is not indexed to the Company&#x2019;s equity or it has net cash settlement provisions that result in the
warrants being accounted for under ASC 480,&#160;&lt;i&gt;Distinguishing Liabilities from Equity,&lt;/i&gt;&#160;or ASC 815-40, it is classified as
a derivative liability which is carried on the consolidated balance sheets at fair value with any changes in its fair value recognized
immediately in the consolidated statements of operations. As of December 31, 2025&lt;i&gt;&#160;&lt;/i&gt;and 2024, 1,192,207
and &lt;span style="-sec-ix-hidden:fc_2109637448"&gt;no&lt;/span&gt; outstanding warrants, respectively, were classified as liabilities. &lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Derivatives&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Derivative financial instruments, including the
liability instrument, are recorded at fair value on the consolidated balance sheets. Liabilities classified as derivatives are remeasured
at their fair value at each reporting date, with decreases or increases in the fair value recognized as other gain or loss, respectively,
within the consolidated statements of operations. Equity classified derivatives are not remeasured at each reporting date. If a liability
classified derivative becomes eligible for reclassification to an equity classified derivative, any gains or losses recognized up to the
point of reclassification are not reversed.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Fair Value
of Financial Instruments&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Financial assets and liabilities recorded at fair
value on a recurring basis in the balance sheets are categorized based upon the level of judgment associated with the inputs used to measure
their fair values. Fair value is defined as the price we would receive to sell an investment in a timely transaction or pay to transfer
a liability in a timely transaction with an independent buyer in the principal market, or in the absence of a principal market, the most
advantageous market for the investment or liability. A framework is used for measuring fair value utilizing a three-tier hierarchy or
levels that prioritizes the inputs to valuation techniques used to measure fair value.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;These levels, in order of the highest to lowest
priority, are described below:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Level&#160;1&lt;/i&gt;&lt;/span&gt;&#x2014;
Unadjusted quoted prices in active markets that are accessible at the measurement date for identical assets or liabilities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Level&#160;2&lt;/i&gt;&lt;/span&gt;&#x2014;
Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are
observable, either directly or indirectly, for substantially the full term of the asset or liability.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Level&#160;3&lt;/i&gt;&lt;/span&gt;&#x2014;
Prices or valuation techniques that require inputs that are both significant to the fair value measurement and are unobservable (i.e.,
supported by little or no market activity).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Comprehensive
Loss&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We have no components of other comprehensive loss
other than net loss, and accordingly, our comprehensive loss is equivalent to our net loss for the periods presented.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Net Loss Per
Share&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We calculate basic and diluted net loss per share
attributable to common stockholders in conformity with the two-class method required for participating securities. Warrants issued in
2017 and outstanding as of December 31, 2024 were considered outstanding shares in the basic earnings per share calculation for the year
ended December 31, 2024 given their nominal exercise price. The net loss attributable to common stockholders is not allocated to the warrant
holders as the holders of warrants do not have a contractual obligation to share in losses. Basic net loss per share is calculated by
dividing the net loss by the weighted-average number of common shares outstanding for the period. Diluted net loss per share is computed
by dividing the net loss by the weighted-average number of shares of common stock and common stock equivalents outstanding for the period.
Common stock equivalents are only included when their effect is dilutive.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Our potentially dilutive securities, including
outstanding stock options under our equity incentive plans and warrants with exercise prices that are not nominal, have been excluded
from the computation of diluted net loss per share as their inclusion would be anti-dilutive. For all periods presented, there is no difference
in the number of shares used to calculate basic and diluted shares outstanding due to our net loss position.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Related Parties&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Transactions between related parties are considered
to be related party transactions even though they may not be given accounting recognition. ASC 850,&lt;i&gt;&#160;Related Party Disclosures&lt;/i&gt;&#160;(ASC
850), requires that transactions with related parties that would make a difference in decision-making shall be disclosed so that users
of the financial statements can evaluate their significance.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Emerging Growth
Company Status&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We qualify as an emerging growth company (&#x201c;EGC&#x201d;)
as defined in the Jumpstart Our Business Startups Act of 2012, as amended (the &#x201c;JOBS Act&#x201d;), and may take advantage of certain
exemptions from various reporting requirements that are applicable to other public companies that are not an EGC. We may take advantage
of these exemptions until we are no longer an EGC under Section 107 of the JOBS Act, and we have elected to use the extended transition
period for complying with new or revised accounting standards. As a result of this election, our consolidated financial statements may
not be comparable to companies that comply with public company FASB standards&#x2019; effective dates.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Recently Adopted
Accounting Principles&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In December 2023, the FASB issued ASU No. 2023-09,&#160;&lt;i&gt;Income
Taxes (Topic 740): Improvements to Income Tax Disclosures.&lt;/i&gt;&#160;ASU 2023-09 requires disaggregated information about a reporting entity&#x2019;s
effective tax rate reconciliation as well as information on income taxes paid. ASU 2023-09 is effective for public entities with annual
periods beginning after December 15, 2024, and should be applied on a retrospective basis to all periods presented. We adopted the guidance
in the fiscal year beginning January 1, 2025, and the adoption had no material impact on our consolidated financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Issued Accounting
Pronouncements Not Yet Adopted&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In November 2024, the FASB issued ASU No. 2024-03,
&lt;i&gt;Income Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense Disaggregation Disclosures&lt;/i&gt; (Subtopic 220-40). The ASU improves
the disclosures about a public business entity&#x2019;s expenses and provides more detailed information about the types of expenses in
commonly presented expense captions. The amendments require that at each interim and annual reporting period an entity will, among other
things, disclose amounts of purchases of inventory, employee compensation, depreciation and amortization included in each relevant expense
caption (such as cost of sales, SG&amp;amp;A and research and development). The ASU is effective for fiscal years beginning after December
15, 2026, and interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. We are currently evaluating
this ASU to determine its impact on our disclosures.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Although there were several other new accounting
pronouncements issued or proposed by the FASB, we do not believe any of those accounting pronouncements have had or will have a material
impact on our financial position or operating results.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:StockholdersEquityNoteStockSplit contextRef="cref_593034427" id="ixv-12086">2-for-1 forward
stock split</us-gaap:StockholdersEquityNoteStockSplit>
    <us-gaap:StockholdersEquityNoteStockSplit contextRef="cref_2088675772" id="ixv-12087">2-for-1 forward split</us-gaap:StockholdersEquityNoteStockSplit>
    <us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock contextRef="cref_883848846" id="ixv-7264">

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The following table illustrates changes in equity,
as previously reported prior to, and as adjusted subsequent to, the impact of the Stock Split retroactively adjusted for the periods previously
presented:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tbody&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December 31, 2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;As Previously Reported&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Impact of Stock Split&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;As Revised&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%"&gt;Common stock - shares&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;13,422,845&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;13,422,845&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;26,845,690&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Common stock - amount&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;1,342&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;1,342&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;2,684&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Additional paid-in capital&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;19,017,239&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(1,342&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;19,015,897&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/tbody&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock>
    <us-gaap:CommonStockSharesIssued
      contextRef="cref_609458734"
      decimals="0"
      id="ixv-12088"
      unitRef="uref_1683791803">13422845</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="cref_1074816519"
      decimals="0"
      id="ixv-12089"
      unitRef="uref_1683791803">13422845</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="cref_145712525"
      decimals="0"
      id="ixv-12090"
      unitRef="uref_1683791803">26845690</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="cref_609458734"
      decimals="0"
      id="ixv-12091"
      unitRef="uref_921481251">1342</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="cref_1074816519"
      decimals="0"
      id="ixv-12092"
      unitRef="uref_921481251">1342</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="cref_145712525"
      decimals="0"
      id="ixv-12093"
      unitRef="uref_921481251">2684</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="cref_609458734"
      decimals="0"
      id="ixv-12094"
      unitRef="uref_921481251">19017239</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="cref_1074816519"
      decimals="0"
      id="ixv-12095"
      unitRef="uref_921481251">-1342</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="cref_145712525"
      decimals="0"
      id="ixv-12096"
      unitRef="uref_921481251">19015897</us-gaap:AdditionalPaidInCapital>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="cref_1736530910"
      decimals="-5"
      id="ixv-12097"
      unitRef="uref_921481251">5100000</us-gaap:CashEquivalentsAtCarryingValue>
    <ttrx:WorkingCapital
      contextRef="cref_1736530910"
      decimals="-5"
      id="ixv-12098"
      unitRef="uref_921481251">2200000</ttrx:WorkingCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="cref_1736530910"
      decimals="-5"
      id="ixv-12099"
      unitRef="uref_921481251">-22400000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:NetIncomeLoss
      contextRef="cref_883848846"
      decimals="-5"
      id="ixv-12100"
      unitRef="uref_921481251">-3200000</us-gaap:NetIncomeLoss>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="cref_883848846"
      decimals="-5"
      id="ixv-12101"
      unitRef="uref_921481251">-2600000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:UseOfEstimates contextRef="cref_883848846" id="ixv-7364">

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The preparation of consolidated financial statements
in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities,
the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and
expenses during the reporting period. Significant estimates include, but are not limited to, those relating to stock-based compensation,
revenue recognition, research and development expenses, fair value estimates of warrants and other derivative liabilities, and determination
of right-of-use assets under lease transactions and related lease obligations. Although these estimates are based on our knowledge of
current events and actions we may undertake in the future, actual results may materially differ from these estimates and assumptions.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="cref_883848846" id="ixv-7371">

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Concentration
of Credit Risk &lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt; Financial instruments which potentially subject
us to significant concentration of credit risk consist of cash and cash equivalents. We maintain deposits in federally insured financial
institutions in excess of federally insured limits. We have not experienced any losses in such accounts, and management believes that
we are not exposed to significant credit risk due to the nature of the instruments held in the depository institutions. As of December
31, 2025 and 2024, cash and cash equivalents exceeded Federal Deposit Insurance Corporation insured limits by $4.5
million and $0.3
million, respectively. &lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt; The majority of our accounts payable and accrued
expenses are concentrated with one vendor having balance of approximately $1.5
million which represents approximately 51%
of our accounts payable and accrued expenses as of December 31, 2025. The amount owed to two majorly concentrated vendors as of December
31, 2024 was approximately $0.3
million and $0.1
million which represent approximately 65%
of our accounts payable and accrued expenses. &lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashFDICInsuredAmount
      contextRef="cref_1736530910"
      decimals="-5"
      id="ixv-12102"
      unitRef="uref_921481251">4500000</us-gaap:CashFDICInsuredAmount>
    <us-gaap:CashFDICInsuredAmount
      contextRef="cref_550689438"
      decimals="-5"
      id="ixv-12103"
      unitRef="uref_921481251">300000</us-gaap:CashFDICInsuredAmount>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="cref_157123121"
      decimals="-5"
      id="ixv-12104"
      unitRef="uref_921481251">1500000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="cref_1159790254"
      decimals="2"
      id="ixv-12105"
      unitRef="uref_1280488936">0.51</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="cref_338945579"
      decimals="2"
      id="ixv-12106"
      unitRef="uref_1280488936">0.51</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="cref_451938818"
      decimals="-5"
      id="ixv-12107"
      unitRef="uref_921481251">300000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="cref_1542616136"
      decimals="-5"
      id="ixv-12108"
      unitRef="uref_921481251">100000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="cref_1776903312"
      decimals="2"
      id="ixv-12109"
      unitRef="uref_1280488936">0.65</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="cref_1398699727"
      decimals="2"
      id="ixv-12110"
      unitRef="uref_1280488936">0.65</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="cref_883848846" id="ixv-7382">

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Cash and Cash
Equivalents&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Cash and cash equivalents are considered to be
highly liquid investments with maturities of three months or less at the date of purchase. Cash equivalents primarily represent funds
invested in readily available money market accounts. As of December 31, 2025 and 2024, we had cash and cash equivalent balances deposited
at multiple major financial institutions.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="cref_883848846" id="ixv-7391">

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Intangible
Assets&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt; We capitalize costs associated with obtaining
patents and trademarks. Intangible assets are amortized over the estimated useful life of 20
years and trademark costs are indefinitely lived. &lt;/p&gt;</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="cref_1736530910" id="ixv-12111">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="cref_883848846" id="ixv-7400">

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Impairment
of Long-Lived Assets&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We evaluate our long-lived assets, which consist
of property and equipment and identifiable intangibles, for impairment at least annually, or whenever events or changes in circumstances
indicate that the carrying amount of such assets may not be recoverable. Recoverability of assets to be held and used is measured by a
comparison of the carrying amount of an asset to the future undiscounted net cash flows expected to be generated by the asset or eventual
disposal. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying
amount of the asset exceeds the fair value of the asset. To date, we have not recorded any impairment losses on long-lived assets.&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="cref_883848846" id="ixv-7426">

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Research and
Development Expenses&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Research and development expenses are composed
of both internal and external costs. Internal costs include salaries and employment-related expenses of scientific personnel and direct
project costs. External research and development expenses consist primarily of costs associated with clinical and non-clinical development
programs and are charged to expenses as incurred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We also record accruals for estimated ongoing
clinical trial costs. Clinical trial costs primarily represent costs incurred by contract research organizations and clinical trial sites.
We analyze the progress of the clinical trial, including levels of subject enrollment, invoices received and contracted costs when evaluating
the adequacy of accrued liabilities. In accruing for these services, we estimate the time period over which services will be performed
and the level of effort to be expended in each period. These estimates are based on communications with the third-party service providers
and our estimates of accrued expenses based on information available at each balance sheet date. If the actual timing of the performance
of services or the level of effort varies from the estimate, we will adjust the accrual accordingly.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="cref_883848846" id="ixv-7437">

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Revenue Recognition&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Under ASC 606, we recognize revenue when our customer
obtains control of promised goods or services, in an amount that reflects the consideration that we expect to receive in exchange for
those goods or services. To determine revenue recognition for arrangements that we determine are within the scope of ASC 606, we perform
the following five steps: (i) identify the contract with a customer; (ii) identify the performance obligations in the contract; (iii)
determine the transaction price, including variable consideration, if any; (iv) allocate the transaction price to the performance obligations
in the contract; and (v) recognize revenue when (or as) we satisfy a performance obligation. We only apply the five-step model to contracts
when it is probable that we will collect the consideration to which we are entitled in exchange for the goods or services we transfer
to a customer.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;At contract inception, once the contract is determined
to be within the scope of ASC 606, we assess whether the goods or services promised within each contract are distinct and, therefore,
represent a separate performance obligation. Goods and services that are determined not to be distinct are combined with other promised
goods and services until a distinct combined performance obligation is identified. We then allocate the transaction price (that is, the
amount of consideration we expect to be entitled to from a customer in exchange for the promised goods or services) to each performance
obligation and recognize the associated revenue when (or as) each performance obligation is satisfied. Our estimate of the transaction
price for each contract includes all variable consideration to which we expect to be entitled, subject to the constraint on variable consideration.
Variable consideration is not constrained if the potential reversal of cumulative revenue recognized at the contract level is not significant.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;License
Rights&lt;/span&gt;&lt;/i&gt; &#x2014; If the license to our intellectual property (IP) is determined to be distinct from the other promises or performance
obligations identified in the arrangement, which generally include research and development services, we recognize revenue from non-refundable,
upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from
the license. In assessing whether a license is distinct from the other promises, we consider relevant facts and circumstances of each
arrangement, including the research and development capabilities of the collaboration partner and the availability of the associated expertise
in the general marketplace. In addition, we consider whether the collaboration partner can benefit from the license for its intended purpose
without the receipt of the remaining promises, whether the value of the license is dependent on the unsatisfied promises, whether there
are other vendors that could provide the remaining promises and whether it is separately identifiable from the remaining promises.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;For licenses that are combined with other promises,
we utilize judgment to assess the nature of the combined performance obligation and whether the license is the predominant promise within
the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time
and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;If the license is the predominant promise, and
it is determined that the license represents functional IP, revenue is recognized at the point in time when control of the license is
transferred. If it is determined that the license does not represent functional IP, revenue is recognized over time using an appropriate
method of measuring progress.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Milestone
Payments&lt;/span&gt;&lt;/i&gt; &#x2014; At the inception of an arrangement that includes development milestone payments, we evaluate whether the milestones
are considered likely to be achieved and estimate the amount to be included in the transaction price using the most likely amount method.
If it is probable that a significant reversal of cumulative revenue recognized would not occur, the associated milestone value is included
in the transaction price. Milestone payments that are not within our control, such as regulatory approvals, are not considered probable
to be achieved until those approvals are received. We evaluate factors such as the scientific, clinical, regulatory, commercial and other
risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved in
determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period,
we re-evaluate the probability of achievement of all milestones subject to constraint and, if necessary, adjust its estimate of the overall
transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period
of adjustment.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Royalties&lt;/span&gt;&lt;/i&gt;
&#x2014; For arrangements that include sales-based royalties, including milestone payments based on a level of sales, where the license
is deemed to be the predominant item to which the royalties relate, we recognize revenue at the later of (i) when the related sales occur
or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).
To date, we have not recognized any royalty revenue resulting from licensing agreements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Amounts due to us for satisfying the revenue recognition
criteria or that are contractually due based upon the terms of the collaboration agreements are recorded as accounts receivable on the
consolidated balance sheets. Amounts received prior to satisfying the revenue recognition criteria are recorded as deferred revenue. Amounts
expected to be recognized as revenue within the one year following the balance sheet date are classified as current deferred revenue.
Amounts not expected to be recognized as revenue within the one year following the balance sheet date are classified as deferred revenue,
net of current portion.&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="cref_883848846" id="ixv-7486">

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Income Taxes&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We are taxed as a &#x201c;Corporation&#x201d; for
both federal and state income tax purposes. We account for income taxes using the asset and liability approach promulgated by ASC 740&lt;i&gt;,&lt;/i&gt;&#160;&lt;i&gt;Income
Taxes&lt;/i&gt;, for financial reporting purposes. Deferred tax assets and liabilities are recognized for the future tax consequences attributable
to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and
operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply
to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax
assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Valuation allowances
are established, when necessary, to reduce the deferred tax assets to an amount expected to be realized.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We are required to evaluate the tax positions
taken in the course of preparing tax returns to determine whether tax positions will more likely than not be substantiated by the tax
authorities. Tax benefits of positions not deemed to meet the more-likely-than-not threshold are recorded as a tax expense. The amount
recognized is subject to estimate and judgement with respect to the likely outcome of each uncertain tax position. The amount that is
ultimately sustained for an individual or all uncertain tax position(s) could differ from the amount that is initially recognized. We
recognize interest and/or penalties related to tax matter as income tax expense.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="cref_883848846" id="ixv-7515">

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Leases&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;At the inception of a contractual agreement, we
determine whether the contract is or contains a lease, by assessing whether there is an identified asset and whether the contract conveys
the right to control the use of the identified asset in exchange for consideration over a period of time. If both criteria are met, we
record the associated lease liability and corresponding right-of-use asset upon commencement of the lease using the implicit rate or a
discount rate based on a credit-adjusted secured borrowing rate commensurate with the term of the lease. When determining the lease term,
we include options to extend or terminate the lease when it is reasonably certain, at inception, that we will exercise that option. Additionally,
we evaluate leases at their inception to determine if they are to be accounted for as an operating lease or a finance lease.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Operating lease assets represent our right to
use an underlying asset for the lease term (Right-of-use assets) and operating lease liabilities represent our obligation to make lease
payments arising from the lease. The lease payments used to determine our operating lease assets may include lease incentives, stated
rent increases and escalation clauses, when determinable, and are recognized in determining our Right-of-use assets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt; Operating lease liabilities with a term greater
than one year and their corresponding right-of-use assets are recognized on the balance sheets at the commencement date of the lease based
on the present value of lease payments over the expected lease term. We exclude short-term leases, if any, having initial terms of 12
months or less at lease commencement as an accounting policy election. Variable lease payments are amounts owed by us to a lessor that
are not fixed, such as reimbursement for common area maintenance costs for our office lease; and are expensed when incurred. Operating
right-of-use assets are reflected in right-of-use asset in the accompanying consolidated balance sheets. Operating lease liabilities are
reflected in operating lease liability, current and non-current in the accompanying consolidated balance sheets. &lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Financing leases are treated similarly to operating
leases except that the asset subject to the lease is included in the appropriate fixed asset category, rather than recorded as a Right-of-use
asset, and depreciated over its estimated useful life, or lease term, if shorter.&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="cref_1736530910" id="ixv-12112">P12M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="cref_883848846" id="ixv-7530">

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Stock-Based
Compensation&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We account for stock-based compensation for both
employees and non-employees in accordance with ASC 718, &lt;i&gt;Compensation &#x2013; Stock Compensation&lt;/i&gt;. Under the fair value recognition
provisions of ASC 718, stock-based compensation cost is measured at the grant date based on the fair value of the award and is recognized
as expense ratably over the requisite service period, which is generally the option vesting period.&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="cref_883848846" id="ixv-7542">

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Segment Reporting&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Operating segments are identified as components
of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker
(&#x201c;CODM&#x201d;) in making decisions regarding resource allocation and assessing performance. We manage our operations as a single
reportable segment for the purposes of assessing performance and making operating decisions.&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <ttrx:WarrantsPolicyTextBlock contextRef="cref_883848846" id="ixv-7551">

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Warrants&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt; We evaluate the appropriate balance sheet classification
of warrants we issue as either equity or as a derivative liability. In accordance with ASC 815-40,&#160;&lt;i&gt;Derivatives and Hedging-Contracts
in the Entity&lt;/i&gt;&#x2019;&lt;i&gt;s Own Equity&lt;/i&gt;, we classify a warrant as equity if it is &#x201c;indexed to the Company&#x2019;s equity&#x201d;
and meets several specific conditions for equity classification. As of December 31, 2025&lt;i&gt;&#160;&lt;/i&gt;and 2024, 0
and 87,744
outstanding warrants, respectively, were classified as equity. &lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt; A warrant is not considered &#x201c;indexed to
the Company&#x2019;s equity,&#x201d; in general, when it contains certain types of exercise contingencies or potential adjustments to its
exercise price. If a warrant is not indexed to the Company&#x2019;s equity or it has net cash settlement provisions that result in the
warrants being accounted for under ASC 480,&#160;&lt;i&gt;Distinguishing Liabilities from Equity,&lt;/i&gt;&#160;or ASC 815-40, it is classified as
a derivative liability which is carried on the consolidated balance sheets at fair value with any changes in its fair value recognized
immediately in the consolidated statements of operations. As of December 31, 2025&lt;i&gt;&#160;&lt;/i&gt;and 2024, 1,192,207
and &lt;span style="-sec-ix-hidden:fc_2109637448"&gt;no&lt;/span&gt; outstanding warrants, respectively, were classified as liabilities. &lt;/p&gt;</ttrx:WarrantsPolicyTextBlock>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="cref_2091224969"
      decimals="0"
      id="ixv-12113"
      unitRef="uref_921481251">0</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="cref_1912481805"
      decimals="0"
      id="ixv-12114"
      unitRef="uref_921481251">87744</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="cref_1736530910"
      decimals="0"
      id="ixv-12115"
      unitRef="uref_921481251">1192207</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:DerivativesPolicyTextBlock contextRef="cref_883848846" id="ixv-7583">

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Derivatives&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Derivative financial instruments, including the
liability instrument, are recorded at fair value on the consolidated balance sheets. Liabilities classified as derivatives are remeasured
at their fair value at each reporting date, with decreases or increases in the fair value recognized as other gain or loss, respectively,
within the consolidated statements of operations. Equity classified derivatives are not remeasured at each reporting date. If a liability
classified derivative becomes eligible for reclassification to an equity classified derivative, any gains or losses recognized up to the
point of reclassification are not reversed.&lt;/p&gt;</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="cref_883848846" id="ixv-7592">

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Fair Value
of Financial Instruments&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Financial assets and liabilities recorded at fair
value on a recurring basis in the balance sheets are categorized based upon the level of judgment associated with the inputs used to measure
their fair values. Fair value is defined as the price we would receive to sell an investment in a timely transaction or pay to transfer
a liability in a timely transaction with an independent buyer in the principal market, or in the absence of a principal market, the most
advantageous market for the investment or liability. A framework is used for measuring fair value utilizing a three-tier hierarchy or
levels that prioritizes the inputs to valuation techniques used to measure fair value.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;These levels, in order of the highest to lowest
priority, are described below:&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="cref_883848846" id="ixv-7621">

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Comprehensive
Loss&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We have no components of other comprehensive loss
other than net loss, and accordingly, our comprehensive loss is equivalent to our net loss for the periods presented.&lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="cref_883848846" id="ixv-7630">

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Net Loss Per
Share&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We calculate basic and diluted net loss per share
attributable to common stockholders in conformity with the two-class method required for participating securities. Warrants issued in
2017 and outstanding as of December 31, 2024 were considered outstanding shares in the basic earnings per share calculation for the year
ended December 31, 2024 given their nominal exercise price. The net loss attributable to common stockholders is not allocated to the warrant
holders as the holders of warrants do not have a contractual obligation to share in losses. Basic net loss per share is calculated by
dividing the net loss by the weighted-average number of common shares outstanding for the period. Diluted net loss per share is computed
by dividing the net loss by the weighted-average number of shares of common stock and common stock equivalents outstanding for the period.
Common stock equivalents are only included when their effect is dilutive.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Our potentially dilutive securities, including
outstanding stock options under our equity incentive plans and warrants with exercise prices that are not nominal, have been excluded
from the computation of diluted net loss per share as their inclusion would be anti-dilutive. For all periods presented, there is no difference
in the number of shares used to calculate basic and diluted shares outstanding due to our net loss position.&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <ttrx:RelatedPartiesPolicyTextBlock contextRef="cref_883848846" id="ixv-7658">

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Related Parties&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Transactions between related parties are considered
to be related party transactions even though they may not be given accounting recognition. ASC 850,&lt;i&gt;&#160;Related Party Disclosures&lt;/i&gt;&#160;(ASC
850), requires that transactions with related parties that would make a difference in decision-making shall be disclosed so that users
of the financial statements can evaluate their significance.&lt;/p&gt;</ttrx:RelatedPartiesPolicyTextBlock>
    <ttrx:EmergingGrowthCompanyStatusPolicyTextBlock contextRef="cref_883848846" id="ixv-7668">

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Emerging Growth
Company Status&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We qualify as an emerging growth company (&#x201c;EGC&#x201d;)
as defined in the Jumpstart Our Business Startups Act of 2012, as amended (the &#x201c;JOBS Act&#x201d;), and may take advantage of certain
exemptions from various reporting requirements that are applicable to other public companies that are not an EGC. We may take advantage
of these exemptions until we are no longer an EGC under Section 107 of the JOBS Act, and we have elected to use the extended transition
period for complying with new or revised accounting standards. As a result of this election, our consolidated financial statements may
not be comparable to companies that comply with public company FASB standards&#x2019; effective dates.&lt;/p&gt;</ttrx:EmergingGrowthCompanyStatusPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="cref_883848846" id="ixv-7677">

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Recently Adopted
Accounting Principles&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In December 2023, the FASB issued ASU No. 2023-09,&#160;&lt;i&gt;Income
Taxes (Topic 740): Improvements to Income Tax Disclosures.&lt;/i&gt;&#160;ASU 2023-09 requires disaggregated information about a reporting entity&#x2019;s
effective tax rate reconciliation as well as information on income taxes paid. ASU 2023-09 is effective for public entities with annual
periods beginning after December 15, 2024, and should be applied on a retrospective basis to all periods presented. We adopted the guidance
in the fiscal year beginning January 1, 2025, and the adoption had no material impact on our consolidated financial statements.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <ttrx:IssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock contextRef="cref_883848846" id="ixv-7687">

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Issued Accounting
Pronouncements Not Yet Adopted&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In November 2024, the FASB issued ASU No. 2024-03,
&lt;i&gt;Income Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense Disaggregation Disclosures&lt;/i&gt; (Subtopic 220-40). The ASU improves
the disclosures about a public business entity&#x2019;s expenses and provides more detailed information about the types of expenses in
commonly presented expense captions. The amendments require that at each interim and annual reporting period an entity will, among other
things, disclose amounts of purchases of inventory, employee compensation, depreciation and amortization included in each relevant expense
caption (such as cost of sales, SG&amp;amp;A and research and development). The ASU is effective for fiscal years beginning after December
15, 2026, and interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. We are currently evaluating
this ASU to determine its impact on our disclosures.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Although there were several other new accounting
pronouncements issued or proposed by the FASB, we do not believe any of those accounting pronouncements have had or will have a material
impact on our financial position or operating results.&lt;/p&gt;</ttrx:IssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="cref_883848846" id="ixv-7697">

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;
  &lt;tbody&gt;
  &lt;tr style="vertical-align: top; text-align: justify"&gt;
    &lt;td style="width: 0in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;3.&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;FAIR VALUE MEASUREMENTS&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-indent: 0in"&gt;&lt;span style="font-weight: normal; text-transform: none"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The carrying amounts reflected in the consolidated
balance sheets for prepaid expenses, accounts payable and accrued expenses and other liabilities are shown at their historical values
which approximate their fair values.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-indent: 0in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-indent: 0in"&gt;&lt;span style="font-weight: normal; text-transform: none"&gt;The
following tables presents the financial instruments carried at fair value on a recurring basis:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-transform: uppercase"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tbody&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;As at December 31, 2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Level 1&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Level 2&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Level 3&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Total&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;Assets&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; width: 52%; text-align: left; padding-bottom: 2.5pt"&gt;Cash equivalents&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;4,027,862&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1399650699"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_128341880"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;4,027,862&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-left: 5.4pt"&gt;Liabilities&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt"&gt;Derivative liability instrument&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_775147019"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1361040787"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,028,401&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,028,401&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/tbody&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tbody&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt; text-indent: 0pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;As at December 31, 2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt; text-indent: 0pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Level 1&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Level 2&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Level 3&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Total&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt; text-indent: 0pt"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt; font-weight: bold; text-indent: 0pt"&gt;Assets&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 0.125in; width: 52%; text-align: left; text-indent: 0pt"&gt;Cash equivalents&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;498,286&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1487892989"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_235481319"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;498,286&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt; text-indent: 0pt"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt; font-weight: bold; text-indent: 0pt"&gt;Liabilities&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 0.125in; text-align: left; text-indent: 0pt"&gt;Derivative liability instrument&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1413630943"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_389922116"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1749934688"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1474617115"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/tbody&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt; As of December 31, 2024, derivative liability
instrument includes contingent warrant liability and the contingent put option liability as a single unit of account under the Share Purchase
Agreement (Note 7). We measured derivative liability instrument to be immaterial as of December 31, 2024. The warrant liability and forward
contract liability were contingent upon a public listing of our common stock on a stock exchange event, and is classified within Level
3 of the value hierarchy because the liability was based upon a valuation model that used inputs and assumptions including potential outcomes,
interest rates, probabilities, and timing. We completed Direct Listing of our common stock on NASDAQ and bifurcated the liability instrument
into its separate warrant liability and put contract liability components. The fair value of the Warrant liability to be issued upon completion
of the public listing was $5.6
million, and this fair value decreased to $2.8
million at December 31, 2025. The fair value of the put contract liability was $0.2 million at December 31, 2025. &lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The following table summarizes the activity related
to Level 3 financial liabilities for the year ended December 31, 2025:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tbody&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Derivative Liability Instrument&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Fair value at December 31, 2024&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1956622950"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 88%; text-align: left; padding-left: 9pt"&gt;Addition to derivative liability for warrants under Share Purchase Agreement&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;5,603,372&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Increase in fair value of put contract derivative under Share Purchase Agreement&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;202,871&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"&gt;Decrease in fair value of warrant derivative liability&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(2,777,842&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Fair value at December 31, 2025&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,028,401&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/tbody&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Upon public listing and as of December 31, 2025,
the warrant liability value for the warrant issued to investor under the Share Purchase Agreement (Note 7) was determined using a Monte
Carlo simulation. Inputs used in the Monte Carlo simulation are as below:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tbody&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;As at &lt;br/&gt; October
        8,&lt;br/&gt; 2025&lt;/td&gt;
    &lt;td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;As at &lt;br/&gt; December
        31,&lt;br/&gt; 2025&lt;/td&gt;
    &lt;td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Risk-free interest rate&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;3.63&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;3.54&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Dividend yield&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1161587692"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_904101031"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Term (years)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;3.00&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;2.77&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Annual Volatility&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;87.1&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;94.4&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Closing stock price&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;7.00&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;3.94&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/tbody&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Put contract derivative liability as of public
listing date was not material. As of December 31, 2025, the put contract derivative liability was remeasured using a Black-Scholes option
valuation model, followed by a series of contractual adjustments. Inputs used in Black-Scholes model for valuation as of December 31,
2025 were as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tbody&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;
        &lt;p style="margin-top: 0; margin-bottom: 0"&gt;As at&lt;/p&gt;
        &lt;p style="margin-top: 0; margin-bottom: 0"&gt;December 31, &lt;br/&gt; 2025&lt;/p&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;Risk-free interest rate&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;3.61&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Dividend yield&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1920536609"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Term (years)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;2.77&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Annual Volatility&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;87.70&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Closing stock price&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;3.94&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/tbody&gt;
  &lt;/table&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="cref_883848846" id="ixv-7708">

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-indent: 0in"&gt;&lt;span style="font-weight: normal; text-transform: none"&gt;The
following tables presents the financial instruments carried at fair value on a recurring basis:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-transform: uppercase"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tbody&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;As at December 31, 2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Level 1&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Level 2&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Level 3&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Total&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;Assets&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; width: 52%; text-align: left; padding-bottom: 2.5pt"&gt;Cash equivalents&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;4,027,862&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1399650699"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_128341880"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;4,027,862&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-left: 5.4pt"&gt;Liabilities&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt"&gt;Derivative liability instrument&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_775147019"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1361040787"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,028,401&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,028,401&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/tbody&gt;
  &lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tbody&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt; text-indent: 0pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;As at December 31, 2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt; text-indent: 0pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Level 1&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Level 2&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Level 3&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Total&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt; text-indent: 0pt"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt; font-weight: bold; text-indent: 0pt"&gt;Assets&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 0.125in; width: 52%; text-align: left; text-indent: 0pt"&gt;Cash equivalents&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;498,286&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1487892989"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_235481319"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;498,286&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt; text-indent: 0pt"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt; font-weight: bold; text-indent: 0pt"&gt;Liabilities&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 0.125in; text-align: left; text-indent: 0pt"&gt;Derivative liability instrument&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1413630943"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_389922116"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1749934688"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1474617115"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/tbody&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="cref_1203589937"
      decimals="0"
      id="ixv-12116"
      unitRef="uref_921481251">4027862</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="cref_1736530910"
      decimals="0"
      id="ixv-12117"
      unitRef="uref_921481251">4027862</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="cref_1119474399"
      decimals="0"
      id="ixv-12118"
      unitRef="uref_921481251">3028401</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="cref_1736530910"
      decimals="0"
      id="ixv-12119"
      unitRef="uref_921481251">3028401</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="cref_1669429594"
      decimals="0"
      id="ixv-12120"
      unitRef="uref_921481251">498286</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="cref_550689438"
      decimals="0"
      id="ixv-12121"
      unitRef="uref_921481251">498286</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="cref_323803066"
      decimals="-5"
      id="ixv-12122"
      unitRef="uref_921481251">5600000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="cref_883848846"
      decimals="-5"
      id="ixv-12123"
      unitRef="uref_921481251">2800000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock contextRef="cref_883848846" id="ixv-7988">

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The following table summarizes the activity related
to Level 3 financial liabilities for the year ended December 31, 2025:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tbody&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Derivative Liability Instrument&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Fair value at December 31, 2024&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1956622950"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 88%; text-align: left; padding-left: 9pt"&gt;Addition to derivative liability for warrants under Share Purchase Agreement&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;5,603,372&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Increase in fair value of put contract derivative under Share Purchase Agreement&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;202,871&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"&gt;Decrease in fair value of warrant derivative liability&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(2,777,842&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Fair value at December 31, 2025&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,028,401&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/tbody&gt;
  &lt;/table&gt;</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock>
    <ttrx:AdditionToDerivativeLiabilityForWarrantsUnderSharePurchaseAgreement
      contextRef="cref_774196967"
      decimals="0"
      id="ixv-12124"
      unitRef="uref_921481251">5603372</ttrx:AdditionToDerivativeLiabilityForWarrantsUnderSharePurchaseAgreement>
    <ttrx:IncreaseInFairValueOfPutContractDerivativeUnderSharePurchaseAgreement
      contextRef="cref_774196967"
      decimals="0"
      id="ixv-12125"
      unitRef="uref_921481251">202871</ttrx:IncreaseInFairValueOfPutContractDerivativeUnderSharePurchaseAgreement>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease
      contextRef="cref_774196967"
      decimals="0"
      id="ixv-12126"
      unitRef="uref_921481251">-2777842</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
      contextRef="cref_1119474399"
      decimals="0"
      id="ixv-12127"
      unitRef="uref_921481251">3028401</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="cref_883848846" id="ixv-8030">

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Upon public listing and as of December 31, 2025,
the warrant liability value for the warrant issued to investor under the Share Purchase Agreement (Note 7) was determined using a Monte
Carlo simulation. Inputs used in the Monte Carlo simulation are as below:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tbody&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;As at &lt;br/&gt; October
        8,&lt;br/&gt; 2025&lt;/td&gt;
    &lt;td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;As at &lt;br/&gt; December
        31,&lt;br/&gt; 2025&lt;/td&gt;
    &lt;td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Risk-free interest rate&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;3.63&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;3.54&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Dividend yield&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1161587692"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_904101031"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Term (years)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;3.00&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;2.77&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Annual Volatility&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;87.1&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;94.4&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Closing stock price&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;7.00&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;3.94&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/tbody&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Put contract derivative liability as of public
listing date was not material. As of December 31, 2025, the put contract derivative liability was remeasured using a Black-Scholes option
valuation model, followed by a series of contractual adjustments. Inputs used in Black-Scholes model for valuation as of December 31,
2025 were as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tbody&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;
        &lt;p style="margin-top: 0; margin-bottom: 0"&gt;As at&lt;/p&gt;
        &lt;p style="margin-top: 0; margin-bottom: 0"&gt;December 31, &lt;br/&gt; 2025&lt;/p&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;Risk-free interest rate&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;3.61&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Dividend yield&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1920536609"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Term (years)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;2.77&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Annual Volatility&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;87.70&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Closing stock price&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;3.94&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/tbody&gt;
  &lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="cref_79394648"
      decimals="4"
      id="ixv-12128"
      unitRef="uref_1280488936">0.0363</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="cref_692088655"
      decimals="4"
      id="ixv-12129"
      unitRef="uref_1280488936">0.0354</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="cref_1255060193"
      decimals="2"
      id="ixv-12130"
      unitRef="uref_1280488936">3</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="cref_959056149"
      decimals="2"
      id="ixv-12131"
      unitRef="uref_1280488936">2.77</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="cref_1815012910"
      decimals="3"
      id="ixv-12132"
      unitRef="uref_1280488936">0.871</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="cref_1802705679"
      decimals="3"
      id="ixv-12133"
      unitRef="uref_1280488936">0.944</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="cref_1672670786"
      decimals="2"
      id="ixv-12134"
      unitRef="uref_1280488936">7</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="cref_1950547996"
      decimals="2"
      id="ixv-12135"
      unitRef="uref_1280488936">3.94</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="cref_375937522"
      decimals="4"
      id="ixv-12136"
      unitRef="uref_1280488936">0.0361</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="cref_290393463"
      decimals="2"
      id="ixv-12137"
      unitRef="uref_1280488936">2.77</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="cref_1984457882"
      decimals="4"
      id="ixv-12138"
      unitRef="uref_1280488936">0.877</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="cref_325524734"
      decimals="2"
      id="ixv-12139"
      unitRef="uref_1280488936">3.94</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="cref_883848846" id="ixv-8161">

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;
  &lt;tbody&gt;
  &lt;tr style="vertical-align: top; text-align: justify"&gt;
    &lt;td style="width: 0in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;4.&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;INTANGIBLE ASSETS&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-indent: 0in"&gt;&lt;span style="font-weight: normal; text-transform: none"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-indent: 0in"&gt;&lt;span style="font-weight: normal; text-transform: none"&gt;The
following table summarizes our intangible assets, net:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tbody&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;As at December 31, 2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;As at December 31, 2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Gross&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Gross&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Carrying&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Accumulated&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Net Carrying&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Carrying&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Accumulated&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Net Carrying&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Amount&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Amortization&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Amount&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Amount&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Amortization&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Amount&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;Finite-lived assets:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; width: 28%; text-align: left; padding-bottom: 1.5pt"&gt;Intangible asset - Patents&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;1,146,743&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;(257,530&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;889,213&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;993,758&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;(204,785&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;788,973&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.25in; text-align: left"&gt;Total finite-lived assets&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;1,146,743&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(257,530&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;889,213&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;993,758&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(204,785&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;788,973&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Indefinite-lived assets - Trademarks&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;32,958&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1448152013"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;32,958&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;32,958&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1685252194"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;32,958&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.25in; text-align: left; padding-bottom: 2.5pt"&gt;Total intangible assets&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,179,701&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(257,530&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;922,171&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,026,716&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(204,785&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;821,931&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/tbody&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Amortization
Expense&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt; Aggregate amortization expense related to finite-lived
intangible assets was approximately $53
thousand and $47
thousand for the years ended December 31, 2025 and 2024, respectively, primarily included in general and administrative expenses on our
consolidated statements of operations. &lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The following table summarizes the estimated future
amortization expense associated with our finite-lived intangible assets as of December 31, 2025:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tbody&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-top: 0pt; text-align: left; padding-right: 0pt; padding-left: 0pt; text-indent: 0pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Amount&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-top: 0pt; width: 88%; text-align: left; padding-left: 0pt; padding-right: 0pt; text-indent: 0pt"&gt;2026&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;57,337&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-top: 0pt; text-align: left; padding-left: 0pt; padding-right: 0pt; text-indent: 0pt"&gt;2027&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;57,337&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-top: 0pt; text-align: left; padding-left: 0pt; padding-right: 0pt; text-indent: 0pt"&gt;2028&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;57,337&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-top: 0pt; text-align: left; padding-left: 0pt; padding-right: 0pt; text-indent: 0pt"&gt;2029&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;57,337&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-top: 0pt; text-align: left; padding-left: 0pt; padding-right: 0pt; text-indent: 0pt"&gt;2030&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;57,337&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 1.5pt; text-align: left; text-indent: 0pt"&gt;Thereafter&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;602,528&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 4pt 0.125in; text-align: left; text-indent: 0pt"&gt;Total&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;889,213&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/tbody&gt;
  &lt;/table&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="cref_883848846" id="ixv-8170">

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-indent: 0in"&gt;&lt;span style="font-weight: normal; text-transform: none"&gt;The
following table summarizes our intangible assets, net:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tbody&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;As at December 31, 2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;As at December 31, 2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Gross&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Gross&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Carrying&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Accumulated&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Net Carrying&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Carrying&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Accumulated&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Net Carrying&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Amount&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Amortization&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Amount&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Amount&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Amortization&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Amount&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;Finite-lived assets:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; width: 28%; text-align: left; padding-bottom: 1.5pt"&gt;Intangible asset - Patents&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;1,146,743&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;(257,530&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;889,213&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;993,758&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;(204,785&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;788,973&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.25in; text-align: left"&gt;Total finite-lived assets&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;1,146,743&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(257,530&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;889,213&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;993,758&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(204,785&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;788,973&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Indefinite-lived assets - Trademarks&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;32,958&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1448152013"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;32,958&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;32,958&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1685252194"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;32,958&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.25in; text-align: left; padding-bottom: 2.5pt"&gt;Total intangible assets&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,179,701&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(257,530&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;922,171&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,026,716&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(204,785&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;821,931&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/tbody&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="cref_1380797291"
      decimals="0"
      id="ixv-12140"
      unitRef="uref_921481251">1146743</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="cref_1380797291"
      decimals="0"
      id="ixv-12141"
      unitRef="uref_921481251">-257530</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="cref_1380797291"
      decimals="0"
      id="ixv-12142"
      unitRef="uref_921481251">889213</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="cref_56268728"
      decimals="0"
      id="ixv-12143"
      unitRef="uref_921481251">993758</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="cref_56268728"
      decimals="0"
      id="ixv-12144"
      unitRef="uref_921481251">-204785</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="cref_56268728"
      decimals="0"
      id="ixv-12145"
      unitRef="uref_921481251">788973</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="cref_1973613927"
      decimals="0"
      id="ixv-12146"
      unitRef="uref_921481251">1146743</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="cref_1973613927"
      decimals="0"
      id="ixv-12147"
      unitRef="uref_921481251">-257530</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="cref_1973613927"
      decimals="0"
      id="ixv-12148"
      unitRef="uref_921481251">889213</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="cref_924705981"
      decimals="0"
      id="ixv-12149"
      unitRef="uref_921481251">993758</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="cref_924705981"
      decimals="0"
      id="ixv-12150"
      unitRef="uref_921481251">-204785</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="cref_924705981"
      decimals="0"
      id="ixv-12151"
      unitRef="uref_921481251">788973</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="cref_2089094047"
      decimals="0"
      id="ixv-12152"
      unitRef="uref_921481251">32958</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="cref_2089094047"
      decimals="0"
      id="ixv-12153"
      unitRef="uref_921481251">32958</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="cref_1254118259"
      decimals="0"
      id="ixv-12154"
      unitRef="uref_921481251">32958</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="cref_1254118259"
      decimals="0"
      id="ixv-12155"
      unitRef="uref_921481251">32958</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="cref_1736530910"
      decimals="0"
      id="ixv-12156"
      unitRef="uref_921481251">1179701</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="cref_1736530910"
      decimals="0"
      id="ixv-12157"
      unitRef="uref_921481251">-257530</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="cref_1736530910"
      decimals="0"
      id="ixv-12158"
      unitRef="uref_921481251">922171</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="cref_550689438"
      decimals="0"
      id="ixv-12159"
      unitRef="uref_921481251">1026716</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="cref_550689438"
      decimals="0"
      id="ixv-12160"
      unitRef="uref_921481251">-204785</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="cref_550689438"
      decimals="0"
      id="ixv-12161"
      unitRef="uref_921481251">821931</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="cref_883848846"
      decimals="-3"
      id="ixv-12162"
      unitRef="uref_921481251">53000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="cref_1258711090"
      decimals="-3"
      id="ixv-12163"
      unitRef="uref_921481251">47000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="cref_883848846" id="ixv-8397">

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The following table summarizes the estimated future
amortization expense associated with our finite-lived intangible assets as of December 31, 2025:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tbody&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-top: 0pt; text-align: left; padding-right: 0pt; padding-left: 0pt; text-indent: 0pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Amount&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-top: 0pt; width: 88%; text-align: left; padding-left: 0pt; padding-right: 0pt; text-indent: 0pt"&gt;2026&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;57,337&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-top: 0pt; text-align: left; padding-left: 0pt; padding-right: 0pt; text-indent: 0pt"&gt;2027&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;57,337&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-top: 0pt; text-align: left; padding-left: 0pt; padding-right: 0pt; text-indent: 0pt"&gt;2028&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;57,337&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-top: 0pt; text-align: left; padding-left: 0pt; padding-right: 0pt; text-indent: 0pt"&gt;2029&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;57,337&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-top: 0pt; text-align: left; padding-left: 0pt; padding-right: 0pt; text-indent: 0pt"&gt;2030&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;57,337&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 1.5pt; text-align: left; text-indent: 0pt"&gt;Thereafter&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;602,528&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 4pt 0.125in; text-align: left; text-indent: 0pt"&gt;Total&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;889,213&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/tbody&gt;
  &lt;/table&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="cref_1736530910"
      decimals="0"
      id="ixv-12164"
      unitRef="uref_921481251">57337</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="cref_1736530910"
      decimals="0"
      id="ixv-12165"
      unitRef="uref_921481251">57337</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="cref_1736530910"
      decimals="0"
      id="ixv-12166"
      unitRef="uref_921481251">57337</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="cref_1736530910"
      decimals="0"
      id="ixv-12167"
      unitRef="uref_921481251">57337</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="cref_1736530910"
      decimals="0"
      id="ixv-12168"
      unitRef="uref_921481251">57337</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
      contextRef="cref_1736530910"
      decimals="0"
      id="ixv-12169"
      unitRef="uref_921481251">602528</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="cref_1736530910"
      decimals="0"
      id="ixv-12170"
      unitRef="uref_921481251">889213</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="cref_883848846" id="ixv-8451">

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;
  &lt;tbody&gt;
  &lt;tr style="vertical-align: top; text-align: justify"&gt;
    &lt;td style="width: 0in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;5.&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;LEASES&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Operating
Lease&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt; We have a single lease for our headquarters,
which includes office space in Westlake Village, California. The lease commenced in September 2021 and was set to expire in August 2024.
In August 2024, we signed an amendment to the lease agreement for the same office space with a new expiration set to be in August 2027.
Monthly payments under the amended lease range from $4.11
thousand to $4.40
thousand. &lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The aggregate minimum annual lease payments under
the operating leases in effect as of December 31, 2025 were:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tbody&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-right: 0pt; text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Amount&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-right: 0pt; width: 88%; text-align: left; text-indent: 0pt; padding-left: 0.125in; padding-bottom: 0pt"&gt;2026&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;51,669&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-right: 0pt; text-align: left; text-indent: 0pt; padding-left: 0.125in; padding-bottom: 0pt"&gt;2027&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;35,240&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-right: 0pt; text-align: left; padding-bottom: 0pt; text-indent: 0pt; padding-left: 0.125in"&gt;Thereafter&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1677803623"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-right: 0pt; text-align: left; padding-left: 0pt; padding-bottom: 0pt; text-indent: 0pt"&gt;Total minimum lease payments&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;86,909&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-right: 0pt; text-align: left; padding-bottom: 0pt; padding-left: 0pt; text-indent: 0pt"&gt;Less: Present value discount&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(6,533&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-right: 0pt; text-align: left; padding-left: 0pt; padding-bottom: 0pt; text-indent: 0pt"&gt;Present value of operating lease
        liabilities&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;80,376&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-right: 0pt; text-align: left; padding-bottom: 0pt; padding-left: 0pt; text-indent: 0pt"&gt;Less: Current portion of operating
        lease liability&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(46,295&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-right: 0pt; text-align: left; padding-bottom: 0pt; padding-left: 0pt; text-indent: 0pt"&gt;Operating lease liability, net
        of current portion&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;34,081&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/tbody&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt; The lease had a remaining term of 1.7
years and 2.7
years as of December 31, 2025 and 2024, respectively. The lease liability was calculated based on a weighted-average discount rate of
9%
as of December 31, 2025 and 2024. During the years ended December 31, 2025 and 2024, we made cash payments for amounts included in the
measurement of lease liabilities of $49.92
thousand and $42.19
thousand, respectively. &lt;/p&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:OperatingLeaseExpense
      contextRef="cref_1880216289"
      decimals="-1"
      id="ixv-12171"
      unitRef="uref_921481251">4110</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="cref_1756333194"
      decimals="-1"
      id="ixv-12172"
      unitRef="uref_921481251">4400</us-gaap:OperatingLeaseExpense>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="cref_883848846" id="ixv-8469">

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The aggregate minimum annual lease payments under
the operating leases in effect as of December 31, 2025 were:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tbody&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-right: 0pt; text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Amount&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-right: 0pt; width: 88%; text-align: left; text-indent: 0pt; padding-left: 0.125in; padding-bottom: 0pt"&gt;2026&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;51,669&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-right: 0pt; text-align: left; text-indent: 0pt; padding-left: 0.125in; padding-bottom: 0pt"&gt;2027&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;35,240&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-right: 0pt; text-align: left; padding-bottom: 0pt; text-indent: 0pt; padding-left: 0.125in"&gt;Thereafter&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1677803623"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-right: 0pt; text-align: left; padding-left: 0pt; padding-bottom: 0pt; text-indent: 0pt"&gt;Total minimum lease payments&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;86,909&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-right: 0pt; text-align: left; padding-bottom: 0pt; padding-left: 0pt; text-indent: 0pt"&gt;Less: Present value discount&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(6,533&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-right: 0pt; text-align: left; padding-left: 0pt; padding-bottom: 0pt; text-indent: 0pt"&gt;Present value of operating lease
        liabilities&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;80,376&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-right: 0pt; text-align: left; padding-bottom: 0pt; padding-left: 0pt; text-indent: 0pt"&gt;Less: Current portion of operating
        lease liability&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(46,295&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-right: 0pt; text-align: left; padding-bottom: 0pt; padding-left: 0pt; text-indent: 0pt"&gt;Operating lease liability, net
        of current portion&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;34,081&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/tbody&gt;
  &lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="cref_1736530910"
      decimals="0"
      id="ixv-12173"
      unitRef="uref_921481251">51669</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="cref_1736530910"
      decimals="0"
      id="ixv-12174"
      unitRef="uref_921481251">35240</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="cref_1736530910"
      decimals="0"
      id="ixv-12175"
      unitRef="uref_921481251">86909</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="cref_1736530910"
      decimals="0"
      id="ixv-12176"
      unitRef="uref_921481251">6533</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="cref_1736530910"
      decimals="0"
      id="ixv-12177"
      unitRef="uref_921481251">80376</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="cref_1736530910"
      decimals="0"
      id="ixv-12178"
      unitRef="uref_921481251">46295</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="cref_1736530910"
      decimals="0"
      id="ixv-12179"
      unitRef="uref_921481251">34081</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="cref_1736530910" id="ixv-12180">P1Y8M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="cref_550689438" id="ixv-12181">P2Y8M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="cref_1736530910"
      decimals="2"
      id="ixv-12182"
      unitRef="uref_1280488936">0.09</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="cref_550689438"
      decimals="2"
      id="ixv-12183"
      unitRef="uref_1280488936">0.09</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeasePayments
      contextRef="cref_883848846"
      decimals="-1"
      id="ixv-12184"
      unitRef="uref_921481251">49920</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="cref_1258711090"
      decimals="-1"
      id="ixv-12185"
      unitRef="uref_921481251">42190</us-gaap:OperatingLeasePayments>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="cref_883848846" id="ixv-8532">

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;
  &lt;tbody&gt;
  &lt;tr style="vertical-align: top; text-align: justify"&gt;
    &lt;td style="width: 0in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;6.&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;CAPITALIZATION AND EQUITY TRANSACTIONS&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;Common Stock&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt; Our amended and restated certificate of incorporation
authorizes the issuance of up to 500,000,000
shares of common stock with a par value of $0.0001
per share. As of December 31, 2025 and 2024, 29,445,183
and 26,845,690
shares of our common stock were issued and outstanding, respectively. &lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;Preferred Stock&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt; Our amended and restated certificate of incorporation
authorizes the issuance of up to 100,000,000
shares of preferred stock with par value of $0.0001
per share. As of December 31, 2025 and 2024, &lt;span style="-sec-ix-hidden:fc_1731589186"&gt;&lt;span style="-sec-ix-hidden:fc_1921957413"&gt;&lt;span style="-sec-ix-hidden:fc_693613376"&gt;&lt;span style="-sec-ix-hidden:fc_458262351"&gt;no&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;
shares of our preferred stock were issued and outstanding. &lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;2024 Crowdfunding
Offering&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt; In May&#160;2024, we launched a crowdfunding
campaign pursuant to Regulation&#160;Crowdfunding with StartEngine as our registered platform. We were offering common stock to accredited
and non-accredited investors with an offering price of $4.59.
The offering closed on March&#160;15, 2025. During the years ended December 31, 2025 and 2024, we sold 215,972
and 351,208
shares of common stock, respectively. Net proceeds from the offering during the years ended December 31, 2025 and 2024 were approximately
$0.78
million and $1.15
million, respectively. &lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;2025 Regulation
A+ Offering&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt; On March 31, 2025, the SEC qualified our Regulation
A+ offering with StartEngine as our registered platform. We were offering common stock to accredited and non-accredited investors with
an offering price of $5.63.
The offering closed on June 27, 2025, and we sold 83,610
shares of our common stock with par value of $0.0001
and received net proceeds of $0.3
million, net of offering costs and platform fees. &lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;2025 Regulation
D Offering&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt; In March 2025, our Board authorized a private
offering pursuant to Regulation D. We were offering common stock to accredited investors with a minimum investment of $100,000,
an offering price of $4.59
per share and certain warrants with an exercise price of $0.005.
The offering closed on June 27, 2025, and we issued 596,478
shares of our common stock and received gross proceeds of approximately $2.7
million. All the investors in this offering simultaneously exercised the warrants, and we issued 178,990
shares of our common stock upon exercise of warrants for cash proceeds of approximately $900.
&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt; On October 23, 2025, we issued 25,252
shares of common stock, in aggregate, to a director and an officer at the closing market price of $4.95
per share on October 23, 2025. The gross proceeds from the issuance of shares were approximately $0.1
million. &lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Shares Issued
in Exchange for Advisory Services&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt; In March 2025, we engaged Clear Street LLC (&#x201c;Clear
Street&#x201d;) as an exclusive financial advisor for certain services, including advisory services, with respect to listing of our common
stock on a registered stock exchange. As part of the engagement, we issued 54,466
shares of our common stock to Clear Street for advisory services amounting to approximately $0.25
million. The related expense was recorded as period cost in general and administrative expenses. &lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Warrant Grants,
Exercises, Expirations and Modifications&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt; In 2017, we issued warrants to a certain investor
to purchase 47,620
our common stock at an exercise price of $0.005.
Upon conversion to a Corporation in 2018, the warrants were amended to purchase 47,620
shares of common stock with all other terms and conditions being unchanged. In 2025, the warrants were exercised and converted into 47,620
shares of our common stock. &lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt; In 2022, we issued warrants to a certain party,
as success fee for issuance and conversion of convertible notes, to purchase 40,124
shares of our common stock at an exercise price of $3.25.
&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The fair value of the warrants issued in 2017
and 2022 was estimated on the grant date using the Black-Scholes option pricing model, and the related expense was recognized on the grant
date as the warrants did not have a vesting period.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We evaluated the terms of the warrants issued
in 2017 and 2022 and determined that they should be classified as equity instruments within additional paid-in capital.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt; Upon Direct Listing, we issued warrants to certain
investor under the Share Purchase Agreement (Note 7) to purchase 1,192,207
shares of our common stock at an exercise price of $5.03.
&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of December 31, 2025, the following common
stock warrants were outstanding:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tbody&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Number of Common Shares&lt;/td&gt;
    &lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Exercise price&lt;/td&gt;
    &lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;Expiration&lt;/td&gt;
    &lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;underlying warrants&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;per share&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;date&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 32%; text-align: center"&gt;40,124&lt;/td&gt;
    &lt;td style="width: 1%; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: center"&gt;$&lt;/td&gt;
    &lt;td style="width: 33%; text-align: center"&gt;3.25&lt;/td&gt;
    &lt;td style="width: 1%; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 30%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden:fc_1822897190"&gt;July
        29, 2029&lt;/span&gt; &lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: center"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;1,192,207&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;$&lt;/td&gt;
    &lt;td style="text-align: center"&gt;5.03&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden:fc_89359823"&gt;October
        8, 2028&lt;/span&gt; &lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/tbody&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt; The weighted-average exercise price of all outstanding
warrants as of December 31, 2025 is $4.97.
All outstanding warrants are exercisable by the holder by payment in cash of the stated exercise price per share or through cashless exercise.
&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Reserved Shares&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We had the following shares of common stock reserved
for future issuance:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tbody&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;As at December 31,&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 0.125in; width: 76%; text-align: justify; text-indent: -0.125in"&gt;Subject to outstanding options under the
        Amended and Restated 2018 Stock Option Plan, 2024 Stock Option Plan and 2025 Omnibus Incentive Plan&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;1,942,184&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;1,679,054&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 0.125in; text-align: left; text-indent: -0.125in"&gt;Subject to outstanding RSUs under the 2025 Omnibus Incentive
        Plan&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;40,000&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_2030495464"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 0.125in; text-align: left; text-indent: -0.125in"&gt;Subject to exercise of outstanding warrants&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;1,232,331&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;87,744&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 0.125in; text-align: left; text-indent: -0.125in"&gt;Available for future grants under the Amended and Restated
        2018 Stock Option Plan&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_2103163862"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1648087271"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 0.125in; text-align: left; text-indent: -0.125in"&gt;Available for future grants under the 2024 Stock Option
        Plan&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;697,816&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;720,946&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 0.125in; text-align: left; text-indent: -0.125in"&gt;Available for future grants under the 2025 Omnibus Incentive
        Plan&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,720,000&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_2099920207"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;6,632,331&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,487,744&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/tbody&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt; As of December 31, 2025, we have 463,922,486
authorized shares of our common stock not subject to reserves and available for future issuance. &lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="cref_1736530910"
      decimals="0"
      id="ixv-12186"
      unitRef="uref_1683791803">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="cref_1736530910"
      decimals="4"
      id="ixv-12187"
      unitRef="uref_923572658">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="cref_1736530910"
      decimals="0"
      id="ixv-12188"
      unitRef="uref_1683791803">29445183</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="cref_1736530910"
      decimals="0"
      id="ixv-12189"
      unitRef="uref_1683791803">29445183</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="cref_550689438"
      decimals="0"
      id="ixv-12190"
      unitRef="uref_1683791803">26845690</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="cref_550689438"
      decimals="0"
      id="ixv-12191"
      unitRef="uref_1683791803">26845690</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="cref_1736530910"
      decimals="0"
      id="ixv-12192"
      unitRef="uref_1683791803">100000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="cref_1736530910"
      decimals="4"
      id="ixv-12193"
      unitRef="uref_923572658">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="cref_272530156"
      decimals="2"
      id="ixv-12194"
      unitRef="uref_923572658">4.59</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="cref_1612569306"
      decimals="0"
      id="ixv-12195"
      unitRef="uref_1683791803">215972</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="cref_1999913520"
      decimals="0"
      id="ixv-12196"
      unitRef="uref_1683791803">351208</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="cref_1612569306"
      decimals="-4"
      id="ixv-12197"
      unitRef="uref_921481251">780000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="cref_1999913520"
      decimals="-4"
      id="ixv-12198"
      unitRef="uref_921481251">1150000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="cref_726349098"
      decimals="2"
      id="ixv-12199"
      unitRef="uref_923572658">5.63</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="cref_1838285380"
      decimals="0"
      id="ixv-12200"
      unitRef="uref_1683791803">83610</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="cref_726349098"
      decimals="4"
      id="ixv-12201"
      unitRef="uref_923572658">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="cref_1838285380"
      decimals="-5"
      id="ixv-12202"
      unitRef="uref_921481251">300000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <ttrx:MinimumInvestmentForAccreditedInvestors
      contextRef="cref_1777302032"
      decimals="0"
      id="ixv-12203"
      unitRef="uref_921481251">100000</ttrx:MinimumInvestmentForAccreditedInvestors>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="cref_1542701830"
      decimals="2"
      id="ixv-12204"
      unitRef="uref_923572658">4.59</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="cref_1542701830"
      decimals="3"
      id="ixv-12205"
      unitRef="uref_923572658">0.005</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="cref_1948620180"
      decimals="0"
      id="ixv-12206"
      unitRef="uref_1683791803">596478</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="cref_1948620180"
      decimals="-5"
      id="ixv-12207"
      unitRef="uref_921481251">2700000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <ttrx:StockIssuedDuringPeriodExercisedOfWarrant
      contextRef="cref_1542701830"
      decimals="0"
      id="ixv-12208"
      unitRef="uref_1683791803">178990</ttrx:StockIssuedDuringPeriodExercisedOfWarrant>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="cref_1948620180"
      decimals="0"
      id="ixv-12209"
      unitRef="uref_921481251">900</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="cref_1703771666"
      decimals="0"
      id="ixv-12210"
      unitRef="uref_1683791803">25252</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="cref_667980030"
      decimals="2"
      id="fc_667980030"
      unitRef="uref_923572658">4.95</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="cref_1420823530"
      decimals="-5"
      id="ixv-12212"
      unitRef="uref_921481251">100000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="cref_858939083"
      decimals="0"
      id="ixv-12213"
      unitRef="uref_1683791803">54466</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="cref_883848846"
      decimals="-4"
      id="ixv-12214"
      unitRef="uref_921481251">250000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <ttrx:NumberOfWarrantsIssuedToCertainInvestors
      contextRef="cref_39095262"
      decimals="0"
      id="ixv-12215"
      unitRef="uref_1683791803">47620</ttrx:NumberOfWarrantsIssuedToCertainInvestors>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="cref_39095262"
      decimals="3"
      id="ixv-12216"
      unitRef="uref_923572658">0.005</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ttrx:NumberOfWarrantsAmendedForPurchase
      contextRef="cref_552847412"
      decimals="0"
      id="ixv-12217"
      unitRef="uref_1683791803">47620</ttrx:NumberOfWarrantsAmendedForPurchase>
    <ttrx:StockIssuedDuringPeriodExercisedOfWarrant
      contextRef="cref_1420194174"
      decimals="0"
      id="ixv-12218"
      unitRef="uref_1683791803">47620</ttrx:StockIssuedDuringPeriodExercisedOfWarrant>
    <ttrx:NumberOfWarrantsIssuedToCertainInvestors
      contextRef="cref_1722875840"
      decimals="0"
      id="ixv-12219"
      unitRef="uref_1683791803">40124</ttrx:NumberOfWarrantsIssuedToCertainInvestors>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="cref_1722875840"
      decimals="2"
      id="ixv-12220"
      unitRef="uref_923572658">3.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="cref_972788662"
      decimals="0"
      id="ixv-12221"
      unitRef="uref_1683791803">1192207</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="cref_972788662"
      decimals="2"
      id="ixv-12222"
      unitRef="uref_923572658">5.03</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ttrx:ScheduleOfCommonStockWarrantsWereOutstandingTableTextBlock contextRef="cref_883848846" id="ixv-8636">

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of December 31, 2025, the following common
stock warrants were outstanding:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tbody&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Number of Common Shares&lt;/td&gt;
    &lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Exercise price&lt;/td&gt;
    &lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;Expiration&lt;/td&gt;
    &lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;underlying warrants&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;per share&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;date&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 32%; text-align: center"&gt;40,124&lt;/td&gt;
    &lt;td style="width: 1%; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: center"&gt;$&lt;/td&gt;
    &lt;td style="width: 33%; text-align: center"&gt;3.25&lt;/td&gt;
    &lt;td style="width: 1%; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 30%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden:fc_1822897190"&gt;July
        29, 2029&lt;/span&gt; &lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: center"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;1,192,207&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;$&lt;/td&gt;
    &lt;td style="text-align: center"&gt;5.03&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden:fc_89359823"&gt;October
        8, 2028&lt;/span&gt; &lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/tbody&gt;
  &lt;/table&gt;</ttrx:ScheduleOfCommonStockWarrantsWereOutstandingTableTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="cref_1088714907"
      decimals="0"
      id="ixv-12223"
      unitRef="uref_1683791803">40124</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="cref_1088714907"
      decimals="2"
      id="fc_1088714907"
      unitRef="uref_923572658">3.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="cref_1736530910"
      decimals="0"
      id="ixv-12225"
      unitRef="uref_1683791803">1192207</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="cref_1736530910"
      decimals="2"
      id="ixv-12226"
      unitRef="uref_923572658">5.03</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ttrx:WeightedAverageExercisePriceOfWarrant
      contextRef="cref_1420194174"
      decimals="2"
      id="ixv-12227"
      unitRef="uref_923572658">4.97</ttrx:WeightedAverageExercisePriceOfWarrant>
    <ttrx:ScheduleOfCommonStockReservedTableTextBlock contextRef="cref_883848846" id="ixv-8688">

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We had the following shares of common stock reserved
for future issuance:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tbody&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;As at December 31,&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 0.125in; width: 76%; text-align: justify; text-indent: -0.125in"&gt;Subject to outstanding options under the
        Amended and Restated 2018 Stock Option Plan, 2024 Stock Option Plan and 2025 Omnibus Incentive Plan&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;1,942,184&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;1,679,054&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 0.125in; text-align: left; text-indent: -0.125in"&gt;Subject to outstanding RSUs under the 2025 Omnibus Incentive
        Plan&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;40,000&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_2030495464"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 0.125in; text-align: left; text-indent: -0.125in"&gt;Subject to exercise of outstanding warrants&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;1,232,331&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;87,744&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 0.125in; text-align: left; text-indent: -0.125in"&gt;Available for future grants under the Amended and Restated
        2018 Stock Option Plan&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_2103163862"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1648087271"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 0.125in; text-align: left; text-indent: -0.125in"&gt;Available for future grants under the 2024 Stock Option
        Plan&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;697,816&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;720,946&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 0.125in; text-align: left; text-indent: -0.125in"&gt;Available for future grants under the 2025 Omnibus Incentive
        Plan&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,720,000&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_2099920207"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;6,632,331&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,487,744&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/tbody&gt;
  &lt;/table&gt;</ttrx:ScheduleOfCommonStockReservedTableTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="cref_1898829802"
      decimals="0"
      id="ixv-12228"
      unitRef="uref_1683791803">1942184</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="cref_1804545600"
      decimals="0"
      id="ixv-12229"
      unitRef="uref_1683791803">1679054</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="cref_768225102"
      decimals="0"
      id="ixv-12230"
      unitRef="uref_1683791803">40000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="cref_1420194174"
      decimals="0"
      id="fc_1420194174"
      unitRef="uref_1683791803">1232331</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="cref_2075620970"
      decimals="0"
      id="ixv-12232"
      unitRef="uref_1683791803">87744</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="cref_191593545"
      decimals="0"
      id="fc_870431956"
      unitRef="uref_1683791803">697816</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="cref_241059500"
      decimals="0"
      id="ixv-12234"
      unitRef="uref_1683791803">720946</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="cref_1073580153"
      decimals="0"
      id="fc_1310032407"
      unitRef="uref_1683791803">2720000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="cref_1736530910"
      decimals="0"
      id="fc_1634427052"
      unitRef="uref_1683791803">6632331</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="cref_550689438"
      decimals="0"
      id="ixv-12237"
      unitRef="uref_1683791803">2487744</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="cref_1736530910"
      decimals="0"
      id="ixv-12238"
      unitRef="uref_1683791803">463922486</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <ttrx:SharePurchaseAgreementTextBlock contextRef="cref_883848846" id="ixv-8786">

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;
  &lt;tbody&gt;
  &lt;tr style="vertical-align: top; text-align: justify"&gt;
    &lt;td style="width: 0in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;7.&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;SHARE PURCHASE AGREEMENT&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt; In December 2024, we entered into a share purchase
agreement with a certain investor for the sale of our common stock of up to $75.0
million (the &#x201c;Aggregate Limit&#x201d;) contingent upon us achieving a public listing of its common stock. The agreement allows us
to issue common stock to the investor, within three (3) years from public listing, at 90%
of the average daily closing price during the draw-down pricing period and the draw-down amount not exceeding 300%
of the average trading volume of 15
days immediately preceding the draw-down exercise date. The agreement allows us to put restrictions on stock sales volume by investor,
prohibitions on short selling by investor and us being able to set a threshold &#x2018;floor&#x2019; price during draw-down periods. &lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt; In April 2025, the Share Purchase Agreement was
amended to increase the Aggregate Limit from $75.0
million to $85.0
million with the additional $10.0
million available only via a day-one draw-down (the &#x201c;Initial Draw-Down&#x201d;). Moreover, the draw-down pricing period for Initial
Draw-Down was reduced to 10
trading days with the investor having an option to shorten with six (6) hours&#x2019; notice to us. The Initial Draw-Down amount with reduced
draw-down pricing period was capped at $10.0
million. &lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In August 2025, the Share Purchase Agreement was
further amended to make changes to the registration rights of the investor and the timing of such registrations. This amendment did not
materially change any key terms including the Aggregate Limit, the commitment fee, underlying warrants issuable under the agreement and
the draw-down pricing and timing including the initial draw-down.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt; On the public listing date, we issued a warrant
to the investor granting the right to purchase 1,192,207
shares of our common stock representing 4%
of the total equity interest at an exercise price of $5.03.
The warrant was recognized at fair value on the issuance date as a derivative liability using a Monte Carlo valuation method with offsetting
debit deferred offering cost asset recorded on the consolidated balance sheets. The fair-value of the warrant was remeasured as of December
31, 2025 using the same valuation methodology, and the resulting gain was recognized in consolidated statement of operations. The deferred
offering cost is being amortized on straight-line basis over the term of the agreement with related expense being recorded in consolidated
statement of operations. During the year ended December 31, 2025, approximately $0.5
million was recognized as amortization of deferred offering cost. Future amortization expense in 2026, 2027 and 2028 will be approximately
$1.87
million, $1.87
million and $1.40
million, respectively. &lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt; The investor was also entitled to a 1%
commitment fee of the Aggregate Limit, either in cash or common stock, which was settled through issuance of 161,905
shares of our common stock. The commitment fee was initially recorded on the consolidated balance sheet as a deferred offering cost which
shall be amortized subsequently as we draw-down amounts under the share purchase agreement. During the year ended December 31, 2025, approximately
$0.03
million was recognized as amortization of deferred offering cost. We expect the future amortization expense in 2026, 2027 and 2028 to
be $100
thousand, $320
thousand and $400
thousand, respectively. &lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt; On October 31, 2025, we issued the Initial Draw-Down
Notice for 1,235,200
shares of common stock to investor and the draw-down period for the initial draw-down was extended from 10
trading days to 30
trading days by mutual agreement between us and the investor. The investor advanced us $3.0
million. On closing date of the initial draw-down notice, i.e., December 15, 2025, the investor accepted 1,235,200
shares at a closing price of approximately $3.29
per share resulting in gross proceeds of $4.07
million, of which $1.1
million is recorded as subscription receivable as of December 31, 2025 and $3.0
million was received as advance on October 31, 2025. &lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt; Upon issuance of Initial Draw-Down Notice on
October 31, 2025, we recorded $0.47
million fair value of forward contract liability. The fair value of the forward contract was remeasured to a $0.4
million asset at December 15, 2025, the closing date of Initial Draw-Down Notice and the forward contract liability was eliminated. &lt;/p&gt;</ttrx:SharePurchaseAgreementTextBlock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="cref_1348601230"
      decimals="-5"
      id="ixv-12239"
      unitRef="uref_921481251">75000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <ttrx:PercentageOfAverageDailyClosingPrice
      contextRef="cref_1493865715"
      decimals="2"
      id="ixv-12240"
      unitRef="uref_1280488936">0.90</ttrx:PercentageOfAverageDailyClosingPrice>
    <ttrx:PercentageOfAverageDailyClosingPrice
      contextRef="cref_1940919373"
      decimals="2"
      id="ixv-12241"
      unitRef="uref_1280488936">3</ttrx:PercentageOfAverageDailyClosingPrice>
    <ttrx:AverageTradingDaysPrecedingDrawDownExerciseDate contextRef="cref_1813648080" id="ixv-12242">P15D</ttrx:AverageTradingDaysPrecedingDrawDownExerciseDate>
    <ttrx:AmendedAggregateLimit
      contextRef="cref_473866816"
      decimals="-5"
      id="ixv-12243"
      unitRef="uref_921481251">75000000</ttrx:AmendedAggregateLimit>
    <ttrx:AmendedAggregateLimit
      contextRef="cref_274473387"
      decimals="-5"
      id="ixv-12244"
      unitRef="uref_921481251">85000000</ttrx:AmendedAggregateLimit>
    <ttrx:IncreaseInAmendedAggregateLimit
      contextRef="cref_1386699006"
      decimals="-5"
      id="ixv-12245"
      unitRef="uref_921481251">10000000</ttrx:IncreaseInAmendedAggregateLimit>
    <ttrx:ExtensionOfInitialDrawDownTradingDays contextRef="cref_883848846" id="fc_1960769162">P10Y</ttrx:ExtensionOfInitialDrawDownTradingDays>
    <ttrx:IncreaseInAmendedAggregateLimit
      contextRef="cref_1386699006"
      decimals="-5"
      id="ixv-12247"
      unitRef="uref_921481251">10000000</ttrx:IncreaseInAmendedAggregateLimit>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="cref_1736530910"
      decimals="0"
      id="ixv-12248"
      unitRef="uref_1683791803">1192207</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <ttrx:EquityInterestOfIssuanceOfWarrantToInvestor
      contextRef="cref_883848846"
      decimals="2"
      id="fc_1630320388"
      unitRef="uref_1280488936">0.04</ttrx:EquityInterestOfIssuanceOfWarrantToInvestor>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="cref_1736530910"
      decimals="2"
      id="ixv-12250"
      unitRef="uref_923572658">5.03</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:AmortizationOfDeferredCharges
      contextRef="cref_883848846"
      decimals="-5"
      id="ixv-12251"
      unitRef="uref_921481251">500000</us-gaap:AmortizationOfDeferredCharges>
    <ttrx:FutureAmortizationExpense
      contextRef="cref_1173190570"
      decimals="-4"
      id="ixv-12252"
      unitRef="uref_921481251">1870000</ttrx:FutureAmortizationExpense>
    <ttrx:FutureAmortizationExpense
      contextRef="cref_132470439"
      decimals="-4"
      id="ixv-12253"
      unitRef="uref_921481251">1870000</ttrx:FutureAmortizationExpense>
    <ttrx:FutureAmortizationExpense
      contextRef="cref_810996763"
      decimals="-4"
      id="ixv-12254"
      unitRef="uref_921481251">1400000</ttrx:FutureAmortizationExpense>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="cref_883848846"
      decimals="2"
      id="ixv-12255"
      unitRef="uref_1280488936">0.01</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <ttrx:StockIssuedDuringPeriodShareCommonStockForDeferredOfferingCost
      contextRef="cref_883848846"
      decimals="0"
      id="ixv-12256"
      unitRef="uref_1683791803">161905</ttrx:StockIssuedDuringPeriodShareCommonStockForDeferredOfferingCost>
    <us-gaap:AmortizationOfDeferredCharges
      contextRef="cref_1317970188"
      decimals="-4"
      id="ixv-12257"
      unitRef="uref_921481251">30000.00</us-gaap:AmortizationOfDeferredCharges>
    <ttrx:FutureAmortizationExpense
      contextRef="cref_1107119832"
      decimals="-3"
      id="ixv-12258"
      unitRef="uref_921481251">100000</ttrx:FutureAmortizationExpense>
    <ttrx:FutureAmortizationExpense
      contextRef="cref_1659816710"
      decimals="-3"
      id="ixv-12259"
      unitRef="uref_921481251">320000</ttrx:FutureAmortizationExpense>
    <ttrx:FutureAmortizationExpense
      contextRef="cref_1532961810"
      decimals="-3"
      id="ixv-12260"
      unitRef="uref_921481251">400000</ttrx:FutureAmortizationExpense>
    <ttrx:StockIssuedDuringPeriodSharesIssuanceOfCommonStockForDrawDownNotice
      contextRef="cref_463525103"
      decimals="0"
      id="ixv-12261"
      unitRef="uref_1683791803">1235200</ttrx:StockIssuedDuringPeriodSharesIssuanceOfCommonStockForDrawDownNotice>
    <ttrx:ExtensionOfInitialDrawDownTradingDays contextRef="cref_1880216289" id="fc_1880216289">P10Y</ttrx:ExtensionOfInitialDrawDownTradingDays>
    <ttrx:ExtensionOfInitialDrawDownTradingDays contextRef="cref_1756333194" id="fc_1756333194">P30Y</ttrx:ExtensionOfInitialDrawDownTradingDays>
    <us-gaap:ProceedsFromCollectionOfAdvanceToAffiliate
      contextRef="cref_463525103"
      decimals="-5"
      id="ixv-12264"
      unitRef="uref_921481251">3000000</us-gaap:ProceedsFromCollectionOfAdvanceToAffiliate>
    <ttrx:StockIssuedDuringPeriodSharesIssuanceOfCommonStockForDrawDownNotice
      contextRef="cref_463525103"
      decimals="0"
      id="ixv-12265"
      unitRef="uref_1683791803">1235200</ttrx:StockIssuedDuringPeriodSharesIssuanceOfCommonStockForDrawDownNotice>
    <ttrx:ClosingPricePerShare
      contextRef="cref_883848846"
      decimals="2"
      id="ixv-12266"
      unitRef="uref_923572658">3.29</ttrx:ClosingPricePerShare>
    <us-gaap:ProceedsFromContributedCapital
      contextRef="cref_883848846"
      decimals="-4"
      id="ixv-12267"
      unitRef="uref_921481251">4070000.00</us-gaap:ProceedsFromContributedCapital>
    <ttrx:SubscriptionReceivable
      contextRef="cref_1736530910"
      decimals="-5"
      id="ixv-12268"
      unitRef="uref_921481251">1100000</ttrx:SubscriptionReceivable>
    <us-gaap:ProceedsFromCollectionOfAdvanceToAffiliate
      contextRef="cref_463525103"
      decimals="-5"
      id="ixv-12269"
      unitRef="uref_921481251">3000000</us-gaap:ProceedsFromCollectionOfAdvanceToAffiliate>
    <ttrx:FairValueOfForwardContractLiability
      contextRef="cref_1079578947"
      decimals="2"
      id="ixv-12270"
      unitRef="uref_921481251">0.47</ttrx:FairValueOfForwardContractLiability>
    <ttrx:FairValueOfForwardContractLiability
      contextRef="cref_887761315"
      decimals="1"
      id="ixv-12271"
      unitRef="uref_921481251">0.4</ttrx:FairValueOfForwardContractLiability>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="cref_883848846" id="ixv-8827">

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;
  &lt;tbody&gt;
  &lt;tr style="vertical-align: top; text-align: justify"&gt;
    &lt;td style="width: 0in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;8.&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;STOCK-BASED COMPENSATION&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Stock Option
Plans&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;2018 Stock Option Plan&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt; In 2018, the Board authorized the Stock Option
Plan (which may be referred to as the &#x201c;2018 Plan&#x201d;). 2,000,000
shares of our common stock were originally reserved to be issued under the Plan and in July 2024, the Board amended the 2018 Plan to decrease
the shares reserved to 1,508,934.
As of December 31, 2025, no options were available for grant under the 2018 Plan and 1,508,934
shares of our common stock were outstanding under the 2018 Plan subject to option exercise by the holders. &lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;2024 Stock Option Plan&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt; In 2024, the Board authorized a new Stock Option
Plan (which may be referred to as the &#x201c;2024 Plan&#x201d;). 891,066
shares of our common stock were reserved to be issued under the 2024 Plan, which provides for the grant of shares of stock options to
employees, non-employee directors, and non-employee consultants. As of December 31, 2025, 697,816
options to purchase shares of our common stock were available for grant and 193,250
shares of our common stock were outstanding under the 2024 Plan subject to option exercise by the holders and vesting restrictions. &lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;2025 Omnibus Incentive Plan&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt; In September 2025, the Board authorized 2025
Omnibus Plan (which may be referred to as the &#x201c;2025 Plan&#x201d;). 3,000,000
shares of our common stock were reserved to be issued under the 2025 Plan, which provides for the grant of shares of stock options, restricted
stock units and other equity-based instruments to employees, directors, non-employee directors and consultants among others. As of December
31, 2025, 2,720,000
shares of our common stock were available for grant and 240,000
shares of our common stock were outstanding under the 2025 Plan subject to option exercise by the holders and vesting restrictions. &lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The following table summarizes option activity
for the years ended December 31, 2025 and 2024:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tbody&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Options&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted-Average Exercise Price per Share
        (USD)&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted-Average Remaining Contractual Term
        (Years)&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Aggregate Intrinsic Value (USD)&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-indent: -0.125in; padding-left: 0.125in"&gt;Outstanding at January 1, 2024&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;1,763,402&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;2.86&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;5.58&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;2,000,000&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in"&gt;Granted&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;220,150&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;4.59&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in"&gt;Exercised&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1757654135"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1905163605"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in"&gt;Cancelled/expired&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(304,498&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;7.32&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-indent: -0.125in; padding-left: 0.125in"&gt;Outstanding at December 31, 2024&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;1,679,054&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;2.28&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;4.60&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;3,876,925&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-indent: -0.125in; padding-left: 0.125in"&gt;Exercisable at December 31, 2024&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;1,576,952&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;2.43&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;4.60&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;3,876,925&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in"&gt;Granted&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;303,160&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;8.87&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in"&gt;Exercised&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1687452012"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1991277332"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in"&gt;Cancelled/expired&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(40,030&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4.59&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-indent: -0.125in; padding-left: 0.125in"&gt;Outstanding at December 31, 2025&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;1,942,184&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;3.26&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;4.42&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;8,075,661&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-indent: -0.125in; padding-left: 0.125in"&gt;Exercisable at December 31, 2025&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;1,619,969&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;3.91&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;4.42&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;8,075,661&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/tbody&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Stock-Based
Compensation Expense&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We use the Black-Scholes option pricing model
with the following assumptions to estimate the stock-based compensation expense:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tbody&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;As at December 31&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: 0pt; padding-left: 0pt"&gt;Risk-free interest rate&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.82%
        - 4.43%&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;4.25&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt"&gt;Dividend yield&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1828132396"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1068764795"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt"&gt;Expected holding period (years)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;5.69&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;5.45&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt"&gt;Weighted-average volatility&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;90.52&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;79.46&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt"&gt;Estimated forfeiture rates for options granted&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_797993294"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1132659108"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/tbody&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The risk-free interest rate assumption for options
granted is based upon observed interest rates on the United States government securities appropriate for the expected term of our employee
stock options.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The dividend yield assumption for options granted
is based on our history and expectation of dividend payouts. We have never declared or paid any cash dividends on our common stock, and
we do not anticipate paying any cash dividends in the foreseeable future.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Due to lack of historical exercise data, the expected
holding period for employee stock options is calculated using the simplified method which takes into consideration the contractual life
and vesting terms of the options.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We determined the expected volatility assumption for
options granted using the historical volatility of comparable public companies&#x2019; stock. We will continue to monitor peer companies
and other relevant factors used to measure expected volatility for future stock option grants, until such time that our common stock has
enough market history to use historical volatility. Forfeitures are recognized as incurred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt; Stock option expense for the years ended December
31, 2025 and 2024, was approximately $0.32
million and $0.35
million, respectively. The stock-based compensation expense is recognized as period cost in general and administrative expenses. As of
December 31, 2025, the unrecognized stock-based compensation expense was $1.4
million, which is expected to be recognized over a period of approximately 3.42
years. &lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Restricted
Stock Units&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;RSUs granted to directors under the plans generally
vest over one year. The number of shares issued on the date the RSUs vest is net of the minimum statutory tax withholdings, which are
paid in cash to the appropriate taxing authorities. We recognize the stock-based compensation expense over the requisite service period
of the individual grantees, which generally equals the vesting period.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The following table summarizes RSU activity during
the years ended December 31, 2025 and 2024:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tbody&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Number of Shares&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted-Average&lt;br/&gt;
        Grant-Date&lt;br/&gt; Fair Value&lt;br/&gt; Per Share&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in"&gt;Unvested restricted stock units as of January 1, 2024&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_900855687"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_925291853"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in"&gt;Granted&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_831707518"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_390540446"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in"&gt;Vested&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_115080714"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1703437644"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in"&gt;Forfeited&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_134391249"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_2140821549"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in"&gt;Unvested restricted stock units as of December 31, 2024&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_462562138"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_616701571"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 76%; text-indent: -0.125in; padding-left: 0.125in"&gt;Granted&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;40,000&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;10.00&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in"&gt;Vested&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1008009244"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1916845139"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in"&gt;Forfeited&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1201657668"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1979471054"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-indent: -0.125in; padding-left: 0.125in"&gt;Unvested restricted stock units as of December 31, 2025&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;40,000&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;10.00&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/tbody&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt; As of December 31, 2025 and 2024, unrecognized
stock-based compensation expense related to RSUs was $0.3
million and $0,
respectively. The unrecognized stock-based compensation expense is estimated to be recognized over a period of 0.75
years as of December 31, 2025. &lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt; Stock-based compensation expense for the years
ended December 31, 2025 and 2024, was $0.1
million and $0,
respectively. The stock-based compensation expense is recognized as period costs in general and administrative expenses. &lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt; &lt;span style="-sec-ix-hidden:fc_1254595273"&gt;&lt;span style="-sec-ix-hidden:fc_1555861181"&gt;No&lt;/span&gt;&lt;/span&gt;
RSUs vested during the years ended December 31, 2025 and 2024. &lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="cref_2096142304"
      decimals="0"
      id="ixv-12272"
      unitRef="uref_1683791803">2000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="cref_809785702"
      decimals="0"
      id="ixv-12273"
      unitRef="uref_1683791803">1508934</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="cref_809785702"
      decimals="0"
      id="ixv-12274"
      unitRef="uref_1683791803">1508934</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="cref_241059500"
      decimals="0"
      id="ixv-12275"
      unitRef="uref_1683791803">891066</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="cref_191593545"
      decimals="0"
      id="ixv-12276"
      unitRef="uref_1683791803">697816</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:CommonStockOtherSharesOutstanding
      contextRef="cref_191593545"
      decimals="0"
      id="ixv-12277"
      unitRef="uref_1683791803">193250</us-gaap:CommonStockOtherSharesOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="cref_1952615956"
      decimals="0"
      id="ixv-12278"
      unitRef="uref_1683791803">3000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="cref_1073580153"
      decimals="0"
      id="ixv-12279"
      unitRef="uref_1683791803">2720000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:CommonStockOtherSharesOutstanding
      contextRef="cref_1073580153"
      decimals="0"
      id="ixv-12280"
      unitRef="uref_1683791803">240000</us-gaap:CommonStockOtherSharesOutstanding>
    <us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock contextRef="cref_883848846" id="ixv-8876">

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The following table summarizes option activity
for the years ended December 31, 2025 and 2024:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tbody&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Options&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted-Average Exercise Price per Share
        (USD)&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted-Average Remaining Contractual Term
        (Years)&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Aggregate Intrinsic Value (USD)&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-indent: -0.125in; padding-left: 0.125in"&gt;Outstanding at January 1, 2024&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;1,763,402&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;2.86&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;5.58&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;2,000,000&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in"&gt;Granted&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;220,150&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;4.59&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in"&gt;Exercised&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1757654135"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1905163605"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in"&gt;Cancelled/expired&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(304,498&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;7.32&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-indent: -0.125in; padding-left: 0.125in"&gt;Outstanding at December 31, 2024&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;1,679,054&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;2.28&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;4.60&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;3,876,925&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-indent: -0.125in; padding-left: 0.125in"&gt;Exercisable at December 31, 2024&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;1,576,952&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;2.43&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;4.60&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;3,876,925&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in"&gt;Granted&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;303,160&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;8.87&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in"&gt;Exercised&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1687452012"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1991277332"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in"&gt;Cancelled/expired&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(40,030&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4.59&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-indent: -0.125in; padding-left: 0.125in"&gt;Outstanding at December 31, 2025&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;1,942,184&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;3.26&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;4.42&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;8,075,661&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-indent: -0.125in; padding-left: 0.125in"&gt;Exercisable at December 31, 2025&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;1,619,969&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;3.91&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;4.42&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;8,075,661&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/tbody&gt;
  &lt;/table&gt;</us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="cref_1676632137"
      decimals="0"
      id="ixv-12281"
      unitRef="uref_1683791803">1763402</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="cref_1676632137"
      decimals="2"
      id="ixv-12282"
      unitRef="uref_923572658">2.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="cref_89276483" id="fc_89276483">P5Y6M29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="cref_1676632137"
      decimals="0"
      id="ixv-12284"
      unitRef="uref_921481251">2000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="cref_1258711090"
      decimals="0"
      id="ixv-12285"
      unitRef="uref_1683791803">220150</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="cref_1258711090"
      decimals="2"
      id="ixv-12286"
      unitRef="uref_923572658">4.59</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="cref_1258711090"
      decimals="0"
      id="ixv-12287"
      unitRef="uref_1683791803">304498</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="cref_1258711090"
      decimals="2"
      id="ixv-12288"
      unitRef="uref_923572658">7.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="cref_550689438"
      decimals="0"
      id="ixv-12289"
      unitRef="uref_1683791803">1679054</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="cref_550689438"
      decimals="2"
      id="ixv-12290"
      unitRef="uref_923572658">2.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="cref_1258711090" id="fc_256754991">P4Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="cref_550689438"
      decimals="0"
      id="fc_1101702885"
      unitRef="uref_921481251">3876925</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="cref_550689438"
      decimals="0"
      id="ixv-12293"
      unitRef="uref_1683791803">1576952</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="cref_550689438"
      decimals="2"
      id="ixv-12294"
      unitRef="uref_923572658">2.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="cref_1258711090" id="ixv-12295">P4Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="cref_550689438"
      decimals="0"
      id="ixv-12296"
      unitRef="uref_921481251">3876925</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="cref_883848846"
      decimals="0"
      id="ixv-12297"
      unitRef="uref_1683791803">303160</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="cref_883848846"
      decimals="2"
      id="ixv-12298"
      unitRef="uref_923572658">8.87</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="cref_883848846"
      decimals="0"
      id="ixv-12299"
      unitRef="uref_1683791803">40030</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="cref_883848846"
      decimals="2"
      id="ixv-12300"
      unitRef="uref_923572658">4.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="cref_1736530910"
      decimals="0"
      id="fc_927685820"
      unitRef="uref_1683791803">1942184</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="cref_1736530910"
      decimals="2"
      id="ixv-12302"
      unitRef="uref_923572658">3.26</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="cref_883848846" id="fc_165534645">P4Y5M1D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="cref_1736530910"
      decimals="0"
      id="ixv-12304"
      unitRef="uref_921481251">8075661</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="cref_1736530910"
      decimals="0"
      id="ixv-12305"
      unitRef="uref_1683791803">1619969</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="cref_1736530910"
      decimals="2"
      id="ixv-12306"
      unitRef="uref_923572658">3.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="cref_883848846" id="ixv-12307">P4Y5M1D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="cref_1736530910"
      decimals="0"
      id="ixv-12308"
      unitRef="uref_921481251">8075661</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock contextRef="cref_883848846" id="ixv-9104">

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We use the Black-Scholes option pricing model
with the following assumptions to estimate the stock-based compensation expense:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tbody&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;As at December 31&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: 0pt; padding-left: 0pt"&gt;Risk-free interest rate&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.82%
        - 4.43%&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;4.25&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt"&gt;Dividend yield&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1828132396"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1068764795"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt"&gt;Expected holding period (years)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;5.69&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;5.45&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt"&gt;Weighted-average volatility&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;90.52&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;79.46&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt"&gt;Estimated forfeiture rates for options granted&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_797993294"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1132659108"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/tbody&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="cref_1455255571"
      decimals="4"
      id="ixv-12309"
      unitRef="uref_1280488936">0.0382</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="cref_343391046"
      decimals="4"
      id="ixv-12310"
      unitRef="uref_1280488936">0.0443</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="cref_1600168694"
      decimals="4"
      id="ixv-12311"
      unitRef="uref_1280488936">0.0425</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="cref_2046516106" id="ixv-12312">P5Y8M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="cref_1600168694" id="ixv-12313">P5Y5M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="cref_2046516106"
      decimals="4"
      id="ixv-12314"
      unitRef="uref_1280488936">0.9052</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="cref_1600168694"
      decimals="4"
      id="ixv-12315"
      unitRef="uref_1280488936">0.7946</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="cref_883848846"
      decimals="-4"
      id="ixv-12316"
      unitRef="uref_921481251">320000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="cref_1258711090"
      decimals="-4"
      id="ixv-12317"
      unitRef="uref_921481251">350000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="cref_1736530910"
      decimals="-5"
      id="ixv-12318"
      unitRef="uref_921481251">1400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="cref_883848846" id="ixv-12319">P3Y5M1D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock contextRef="cref_883848846" id="ixv-9213">

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The following table summarizes RSU activity during
the years ended December 31, 2025 and 2024:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tbody&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Number of Shares&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted-Average&lt;br/&gt;
        Grant-Date&lt;br/&gt; Fair Value&lt;br/&gt; Per Share&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in"&gt;Unvested restricted stock units as of January 1, 2024&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_900855687"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_925291853"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in"&gt;Granted&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_831707518"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_390540446"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in"&gt;Vested&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_115080714"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1703437644"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in"&gt;Forfeited&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_134391249"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_2140821549"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in"&gt;Unvested restricted stock units as of December 31, 2024&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_462562138"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_616701571"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 76%; text-indent: -0.125in; padding-left: 0.125in"&gt;Granted&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;40,000&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;10.00&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in"&gt;Vested&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1008009244"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1916845139"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in"&gt;Forfeited&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1201657668"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1979471054"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-indent: -0.125in; padding-left: 0.125in"&gt;Unvested restricted stock units as of December 31, 2025&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;40,000&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;10.00&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/tbody&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="cref_1482179895"
      decimals="0"
      id="ixv-12320"
      unitRef="uref_1683791803">40000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="cref_1482179895"
      decimals="2"
      id="ixv-12321"
      unitRef="uref_923572658">10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="cref_1095715565"
      decimals="0"
      id="ixv-12322"
      unitRef="uref_1683791803">40000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="cref_1095715565"
      decimals="2"
      id="ixv-12323"
      unitRef="uref_923572658">10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="cref_1095715565"
      decimals="-5"
      id="ixv-12324"
      unitRef="uref_921481251">300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="cref_1952870394"
      decimals="0"
      id="ixv-12325"
      unitRef="uref_921481251">0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="cref_1482179895" id="ixv-12326">P0Y9M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="cref_1482179895"
      decimals="-2"
      id="ixv-12327"
      unitRef="uref_921481251">100</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="cref_109726865"
      decimals="-3"
      id="ixv-12328"
      unitRef="uref_921481251">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="cref_883848846" id="ixv-9343">

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;
  &lt;tbody&gt;
  &lt;tr style="vertical-align: top; text-align: justify"&gt;
    &lt;td style="width: 0in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;9.&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;INCOME TAXES&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We had no current or deferred federal and state
income tax expense or benefit for the years ended December 31, 2025 and 2024, because we generated net operating losses, and currently
we do not believe it is more likely than not that the net operating losses will be realized.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The provision for income tax expense (benefit)
for the years ended December 31, 2025 and 2024 was comprised of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tbody&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-top: 0pt; padding-right: 0pt; padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;As at December 31,&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-top: 0pt; padding-right: 0pt; padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-top: 0pt; font-weight: bold; padding-right: 0pt; padding-left: 0.125in; text-indent: -0.125in"&gt;Current provision for income
        taxes:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-top: 0pt; text-align: left; padding-right: 0pt; padding-left: 0.25in; text-indent: -0.125in"&gt;Federal&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_2018375862"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1363859510"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 1.5pt 0.25in; text-indent: -0.125in"&gt;State&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_376116076"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1587337319"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 1.5pt 0.375in; text-indent: -0.125in"&gt;Total&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_74677262"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_969593374"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-top: 0pt; padding-left: 0.125in; padding-right: 0pt; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-top: 0pt; font-weight: bold; text-align: left; padding-left: 0.125in; padding-right: 0pt; text-indent: -0.125in"&gt;Deferred
        provision for income taxes:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-top: 0pt; width: 76%; text-indent: -0.125in; padding-left: 0.25in; padding-right: 0pt"&gt;Federal&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;(1,288,823&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;(305,212&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 1.5pt 0.25in; text-indent: -0.125in"&gt;State&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_554446855"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;709&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-top: 0pt; text-indent: -0.125in; padding-left: 0.375in; padding-right: 0pt"&gt;Total&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(1,288,823&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(304,503&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 1.5pt 0.125in; text-align: left; text-indent: -0.125in"&gt;Increase in valuation allowance for income taxes (federal
        only)&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,288,823&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;304,503&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 4pt 0.5in; text-align: left; text-indent: -0.125in"&gt;Total provision for income taxes&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1329091867"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_858113959"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/tbody&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt; Deferred income taxes reflect the net tax effect
of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used
for income tax purposes. Significant
components of our net deferred tax asset are as follows: &lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tbody&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-right: 0pt; padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;As at December 31,&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-right: 0pt; padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-right: 0pt; font-weight: bold; padding-left: 0.125in; text-indent: -0.125in"&gt;Deferred tax assets:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-right: 0pt; width: 76%; text-align: left; text-indent: -0.125in; padding-left: 0.25in"&gt;Net operating loss carryovers&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;3,544,688&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;2,311,077&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-right: 0pt; text-align: left; text-indent: -0.125in; padding-left: 0.25in"&gt;Research and development credit carryforwards&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;34,927&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;21,027&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-right: 0pt; text-align: left; text-indent: -0.125in; padding-left: 0.25in"&gt;Stock-based compensation&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;159,995&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;60,455&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-right: 0pt; text-align: left; text-indent: -0.125in; padding-left: 0.25in"&gt;Deferred revenue&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;301,983&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;301,983&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-right: 0pt; text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.25in"&gt;Operating lease liability&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;16,879&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;25,418&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-right: 0pt; text-align: left; text-indent: -0.125in; padding-left: 0.375in"&gt;Total deferred tax assets&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;4,058,472&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;2,719,960&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-right: 0pt; text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.25in"&gt;Valuation allowance&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(3,938,483&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(2,651,663&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-right: 0pt; text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.375in"&gt;Total deferred tax assets
        net of valuation allowance&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;119,989&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;68,297&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-right: 0pt; font-weight: bold; text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;Deferred tax liabilities:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-right: 0pt; text-align: left; text-indent: -0.125in; padding-left: 0.25in"&gt;Basis differences in property and equipment
        and intangibles&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(103,478&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(43,002&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-right: 0pt; text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.25in"&gt;Operating Right-of-use
        asset&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(16,511&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(25,295&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-right: 0pt; text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.375in"&gt;Total deferred tax liabilities&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(119,989&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(68,297&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-right: 0pt; text-align: left; padding-bottom: 2.5pt; text-indent: -0.125in; padding-left: 0.5in"&gt;Net deferred tax asset&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1371966609"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1737986731"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/tbody&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Income tax expense differed from the amounts computed
by applying the statutory federal income tax rate of 21% to pretax income (loss) as a result of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tbody&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Years Ended December 31,&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: 0pt; padding-left: 0pt"&gt;Computed expected tax benefit&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;-21.00&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;-21.00&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt"&gt;Research and development credit&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;-0.23&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;0.00&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt"&gt;Domestic state and local income taxes, net of federal effect (A.)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;-0.03&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;0.00&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt"&gt;Increase in state NOL carryovers (A.)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;0.03&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;0.00&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt"&gt;Tax effect of other non-deductible items&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;0.00&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;0.77&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt"&gt;Change in valuation allowance (federal only)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;21.34&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;20.03&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt"&gt;Provision to return adjustment&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;-0.23&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;0.00&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt"&gt;Other&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;0.12&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;0.20&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; text-indent: 0pt; padding-left: 0pt"&gt;Income tax expense&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;0.00&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;0.00&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;/tbody&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt; &lt;i&gt;(A.)
    State taxes in Georgia made up the majority (greater than 50 percent) of the tax effect in these categories.&lt;/i&gt;
                    &lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt; Realization of deferred tax assets is dependent upon future earnings,
                    if any, the timing and amount of which are uncertain. Accordingly, the deferred tax assets have been fully offset by a valuation allowance.
                    The valuation allowance increased by approximately $1.3
                    million and $0.3
                    million during the fiscal years ended December 31, 2025 and 2024, respectively. &lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt; As of December 31, 2025, we had U.S. federal net operating loss carryforwards
                    of approximately $14.5
                    million and state net operating loss carryforwards of approximately $7.3
                    million. Federal net operating loss carryforwards of approximately $14.5
                    million generated since fiscal years beginning after December 31, 2017 will carry forward indefinitely, but are subject to an 80%
                    taxable income limitation. We also have federal and state research and development tax credit carryforwards of approximately $0.03
                    million. The federal and state tax credits will expire at various dates beginning with our fiscal year ending December 31, 2042, unless
                    utilized. &lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We recognize the financial statement effects of tax positions when
                    it is more likely than not, based on the technical merits, that the position will be sustained upon examination. Tax positions that do
                    not meet the recognition threshold are recorded as unrecognized tax benefits. As of December 31, 2025 and 2024, we have not recorded any
                    unrecognized tax benefits.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We file income tax returns in the U.S. federal, and various U.S. state
                    jurisdictions. We are subject to U.S. federal and state income tax examinations by tax authorities for tax years 2018 through 2025 due
                    to net operating losses that are being carried forward for tax purposes, but we are not currently under examination by tax authorities
                    in any jurisdiction.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Our policy is to recognize interest and penalties related to income
                    taxes as components of interest expense and other expense, respectively. We incurred no material interest or penalties related to unrecognized
                    tax benefits in the years ended December 31, 2025 or 2024. We do not anticipate any significant changes in our uncertain tax positions
                    within 12 months of this reporting date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As a result of the One Big Beautiful Bill Act, we are permitted to
                    immediately deduct domestic R&amp;amp;D expenditures incurred in 2025 and future years, rather than capitalizing and amortizing such costs.
                    This change reduces the amount of deductible temporary differences related to unamortized research and development expenditures and, accordingly,
                    reduces the related deferred tax assets. In accordance with ASC 740, we remeasured our deferred tax assets and liabilities as of December
                    31, 2025, to reflect the impact of the new law. The effect of the remeasurement was immaterial.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="cref_883848846" id="ixv-9353">

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The provision for income tax expense (benefit)
for the years ended December 31, 2025 and 2024 was comprised of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tbody&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-top: 0pt; padding-right: 0pt; padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;As at December 31,&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-top: 0pt; padding-right: 0pt; padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-top: 0pt; font-weight: bold; padding-right: 0pt; padding-left: 0.125in; text-indent: -0.125in"&gt;Current provision for income
        taxes:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-top: 0pt; text-align: left; padding-right: 0pt; padding-left: 0.25in; text-indent: -0.125in"&gt;Federal&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_2018375862"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1363859510"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 1.5pt 0.25in; text-indent: -0.125in"&gt;State&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_376116076"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1587337319"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 1.5pt 0.375in; text-indent: -0.125in"&gt;Total&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_74677262"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_969593374"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-top: 0pt; padding-left: 0.125in; padding-right: 0pt; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-top: 0pt; font-weight: bold; text-align: left; padding-left: 0.125in; padding-right: 0pt; text-indent: -0.125in"&gt;Deferred
        provision for income taxes:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-top: 0pt; width: 76%; text-indent: -0.125in; padding-left: 0.25in; padding-right: 0pt"&gt;Federal&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;(1,288,823&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;(305,212&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 1.5pt 0.25in; text-indent: -0.125in"&gt;State&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_554446855"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;709&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-top: 0pt; text-indent: -0.125in; padding-left: 0.375in; padding-right: 0pt"&gt;Total&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(1,288,823&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(304,503&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 1.5pt 0.125in; text-align: left; text-indent: -0.125in"&gt;Increase in valuation allowance for income taxes (federal
        only)&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,288,823&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;304,503&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 4pt 0.5in; text-align: left; text-indent: -0.125in"&gt;Total provision for income taxes&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1329091867"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_858113959"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/tbody&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="cref_883848846"
      decimals="0"
      id="ixv-12329"
      unitRef="uref_921481251">-1288823</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="cref_1258711090"
      decimals="0"
      id="ixv-12330"
      unitRef="uref_921481251">-305212</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="cref_1258711090"
      decimals="0"
      id="ixv-12331"
      unitRef="uref_921481251">709</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit
      contextRef="cref_883848846"
      decimals="0"
      id="ixv-12332"
      unitRef="uref_921481251">-1288823</us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit>
    <us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit
      contextRef="cref_1258711090"
      decimals="0"
      id="ixv-12333"
      unitRef="uref_921481251">-304503</us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit>
    <us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations
      contextRef="cref_883848846"
      decimals="0"
      id="ixv-12334"
      unitRef="uref_921481251">1288823</us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations
      contextRef="cref_1258711090"
      decimals="0"
      id="ixv-12335"
      unitRef="uref_921481251">304503</us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="cref_883848846" id="ixv-12336">Significant
components of our net deferred tax asset are as follows:

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tbody&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-right: 0pt; padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;As at December 31,&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-right: 0pt; padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-right: 0pt; font-weight: bold; padding-left: 0.125in; text-indent: -0.125in"&gt;Deferred tax assets:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-right: 0pt; width: 76%; text-align: left; text-indent: -0.125in; padding-left: 0.25in"&gt;Net operating loss carryovers&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;3,544,688&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;2,311,077&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-right: 0pt; text-align: left; text-indent: -0.125in; padding-left: 0.25in"&gt;Research and development credit carryforwards&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;34,927&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;21,027&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-right: 0pt; text-align: left; text-indent: -0.125in; padding-left: 0.25in"&gt;Stock-based compensation&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;159,995&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;60,455&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-right: 0pt; text-align: left; text-indent: -0.125in; padding-left: 0.25in"&gt;Deferred revenue&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;301,983&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;301,983&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-right: 0pt; text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.25in"&gt;Operating lease liability&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;16,879&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;25,418&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-right: 0pt; text-align: left; text-indent: -0.125in; padding-left: 0.375in"&gt;Total deferred tax assets&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;4,058,472&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;2,719,960&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-right: 0pt; text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.25in"&gt;Valuation allowance&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(3,938,483&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(2,651,663&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-right: 0pt; text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.375in"&gt;Total deferred tax assets
        net of valuation allowance&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;119,989&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;68,297&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-right: 0pt; font-weight: bold; text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;Deferred tax liabilities:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-right: 0pt; text-align: left; text-indent: -0.125in; padding-left: 0.25in"&gt;Basis differences in property and equipment
        and intangibles&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(103,478&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(43,002&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-right: 0pt; text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.25in"&gt;Operating Right-of-use
        asset&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(16,511&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(25,295&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-right: 0pt; text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.375in"&gt;Total deferred tax liabilities&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(119,989&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(68,297&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-right: 0pt; text-align: left; padding-bottom: 2.5pt; text-indent: -0.125in; padding-left: 0.5in"&gt;Net deferred tax asset&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1371966609"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1737986731"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/tbody&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="cref_1736530910"
      decimals="0"
      id="ixv-12337"
      unitRef="uref_921481251">3544688</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="cref_550689438"
      decimals="0"
      id="ixv-12338"
      unitRef="uref_921481251">2311077</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="cref_1736530910"
      decimals="0"
      id="ixv-12339"
      unitRef="uref_921481251">34927</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="cref_550689438"
      decimals="0"
      id="ixv-12340"
      unitRef="uref_921481251">21027</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="cref_1736530910"
      decimals="0"
      id="ixv-12341"
      unitRef="uref_921481251">159995</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="cref_550689438"
      decimals="0"
      id="ixv-12342"
      unitRef="uref_921481251">60455</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="cref_1736530910"
      decimals="0"
      id="ixv-12343"
      unitRef="uref_921481251">301983</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="cref_550689438"
      decimals="0"
      id="ixv-12344"
      unitRef="uref_921481251">301983</us-gaap:DeferredTaxAssetsDeferredIncome>
    <ttrx:DeferredTaxAssetsOperatingLeaseLIability
      contextRef="cref_1736530910"
      decimals="0"
      id="ixv-12345"
      unitRef="uref_921481251">16879</ttrx:DeferredTaxAssetsOperatingLeaseLIability>
    <ttrx:DeferredTaxAssetsOperatingLeaseLIability
      contextRef="cref_550689438"
      decimals="0"
      id="ixv-12346"
      unitRef="uref_921481251">25418</ttrx:DeferredTaxAssetsOperatingLeaseLIability>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="cref_1736530910"
      decimals="0"
      id="ixv-12347"
      unitRef="uref_921481251">4058472</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="cref_550689438"
      decimals="0"
      id="ixv-12348"
      unitRef="uref_921481251">2719960</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="cref_1736530910"
      decimals="0"
      id="ixv-12349"
      unitRef="uref_921481251">3938483</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="cref_550689438"
      decimals="0"
      id="ixv-12350"
      unitRef="uref_921481251">2651663</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="cref_1736530910"
      decimals="0"
      id="ixv-12351"
      unitRef="uref_921481251">119989</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="cref_550689438"
      decimals="0"
      id="ixv-12352"
      unitRef="uref_921481251">68297</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="cref_1736530910"
      decimals="0"
      id="ixv-12353"
      unitRef="uref_921481251">103478</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="cref_550689438"
      decimals="0"
      id="ixv-12354"
      unitRef="uref_921481251">43002</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <ttrx:DeferredTaxLiabilitiesOperatingRightOfUseAssets
      contextRef="cref_1736530910"
      decimals="0"
      id="ixv-12355"
      unitRef="uref_921481251">16511</ttrx:DeferredTaxLiabilitiesOperatingRightOfUseAssets>
    <ttrx:DeferredTaxLiabilitiesOperatingRightOfUseAssets
      contextRef="cref_550689438"
      decimals="0"
      id="ixv-12356"
      unitRef="uref_921481251">25295</ttrx:DeferredTaxLiabilitiesOperatingRightOfUseAssets>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="cref_1736530910"
      decimals="0"
      id="ixv-12357"
      unitRef="uref_921481251">119989</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="cref_550689438"
      decimals="0"
      id="ixv-12358"
      unitRef="uref_921481251">68297</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="cref_883848846" id="ixv-9665">

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Income tax expense differed from the amounts computed
by applying the statutory federal income tax rate of 21% to pretax income (loss) as a result of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tbody&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Years Ended December 31,&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: 0pt; padding-left: 0pt"&gt;Computed expected tax benefit&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;-21.00&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;-21.00&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt"&gt;Research and development credit&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;-0.23&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;0.00&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt"&gt;Domestic state and local income taxes, net of federal effect (A.)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;-0.03&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;0.00&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt"&gt;Increase in state NOL carryovers (A.)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;0.03&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;0.00&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt"&gt;Tax effect of other non-deductible items&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;0.00&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;0.77&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt"&gt;Change in valuation allowance (federal only)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;21.34&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;20.03&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt"&gt;Provision to return adjustment&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;-0.23&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;0.00&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt"&gt;Other&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;0.12&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;0.20&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; text-indent: 0pt; padding-left: 0pt"&gt;Income tax expense&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;0.00&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;0.00&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;/tbody&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="cref_883848846"
      decimals="4"
      id="ixv-12359"
      unitRef="uref_1280488936">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="cref_1258711090"
      decimals="4"
      id="ixv-12360"
      unitRef="uref_1280488936">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="cref_883848846"
      decimals="4"
      id="ixv-12361"
      unitRef="uref_1280488936">-0.0023</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="cref_1258711090"
      decimals="4"
      id="ixv-12362"
      unitRef="uref_1280488936">0</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="cref_883848846"
      decimals="4"
      id="fc_1970036997"
      unitRef="uref_1280488936">-0.0003</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="cref_1258711090"
      decimals="4"
      id="fc_405687047"
      unitRef="uref_1280488936">0</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <ttrx:EffectiveTaxReconciliationIncreaseInStateNOLCarryovers
      contextRef="cref_883848846"
      decimals="4"
      id="fc_1516429433"
      unitRef="uref_1280488936">0.0003</ttrx:EffectiveTaxReconciliationIncreaseInStateNOLCarryovers>
    <ttrx:EffectiveTaxReconciliationIncreaseInStateNOLCarryovers
      contextRef="cref_1258711090"
      decimals="4"
      id="fc_1955399735"
      unitRef="uref_1280488936">0</ttrx:EffectiveTaxReconciliationIncreaseInStateNOLCarryovers>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="cref_883848846"
      decimals="4"
      id="ixv-12367"
      unitRef="uref_1280488936">-0</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="cref_1258711090"
      decimals="4"
      id="ixv-12368"
      unitRef="uref_1280488936">-0.0077</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="cref_883848846"
      decimals="4"
      id="ixv-12369"
      unitRef="uref_1280488936">-0.2134</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="cref_1258711090"
      decimals="4"
      id="ixv-12370"
      unitRef="uref_1280488936">-0.2003</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="cref_883848846"
      decimals="4"
      id="ixv-12371"
      unitRef="uref_1280488936">0.0023</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="cref_1258711090"
      decimals="4"
      id="ixv-12372"
      unitRef="uref_1280488936">-0</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="cref_883848846"
      decimals="4"
      id="ixv-12373"
      unitRef="uref_1280488936">-0.0012</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="cref_1258711090"
      decimals="4"
      id="ixv-12374"
      unitRef="uref_1280488936">-0.002</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="cref_883848846"
      decimals="4"
      id="ixv-12375"
      unitRef="uref_1280488936">-0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="cref_1258711090"
      decimals="4"
      id="ixv-12376"
      unitRef="uref_1280488936">-0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="cref_883848846"
      decimals="-5"
      id="ixv-12378"
      unitRef="uref_921481251">1300000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="cref_1258711090"
      decimals="-5"
      id="ixv-12379"
      unitRef="uref_921481251">300000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic
      contextRef="cref_1345747743"
      decimals="-5"
      id="ixv-12380"
      unitRef="uref_921481251">14500000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="cref_1736530910"
      decimals="-5"
      id="ixv-12381"
      unitRef="uref_921481251">7300000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic
      contextRef="cref_1736530910"
      decimals="-5"
      id="ixv-12382"
      unitRef="uref_921481251">14500000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <ttrx:IncomeTaxCarryForwardTaxableIncomeLimitation
      contextRef="cref_883848846"
      decimals="2"
      id="fc_114768330"
      unitRef="uref_1280488936">0.80</ttrx:IncomeTaxCarryForwardTaxableIncomeLimitation>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="cref_1736530910"
      decimals="-4"
      id="ixv-12384"
      unitRef="uref_921481251">30000.00</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <ttrx:LicensingAgreementsTextBlock contextRef="cref_883848846" id="ixv-9807">

                    &lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;
  &lt;tbody&gt;
  &lt;tr style="vertical-align: top; text-align: justify"&gt;
    &lt;td style="width: 0in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;10.&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;LICENSING AGREEMENTS&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The following table presents changes in the balances
of contract liabilities related to strategic collaboration agreements during the year ended December 31, 2025:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tbody&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;As at&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;As at&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December 31, 2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Additions&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Deductions&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December 31, 2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left; text-indent: 0pt; padding-left: 0pt"&gt;Contract liabilities:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left; padding-bottom: 2.5pt; text-indent: 0pt; padding-left: 0pt"&gt;Deferred revenue&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;1,438,013&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden:fc_857573411"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden:fc_1530781833"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;1,438,013&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/tbody&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;MiMedx Agreement&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In 2022, we entered into a licensing and distribution
agreement with MiMedx Group Inc. (NASDAQ: MDXG, hereinafter referred to as &#x201c;MiMedx&#x201d;) wherein we granted MiMedx rights and
licenses to our IP, technologies and biomaterials related to FleX product and other additional products (&#x201c;additional products&#x201d;)
to be developed using the same IP, technologies and biomaterials in the field of wound care, burn care and surgical care.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Under the MiMedx Agreement, we granted MiMedx
an exclusive license to develop and commercialize FleX in United States, Australia, Canada, Japan, Kuwait, New Zealand, Saudi Arabia,
Singapore, South Korea, Taiwan and UAE (collectively called the &#x201c;Territory&#x201d;) and certain non-exclusive rights to trademarks
in the Territory. We retain exclusive development and commercialization rights for FleX outside the Territory with MiMedx having the right-of-first
refusal.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt; We have received $1.00
million milestone payment which was due upon signing of the license agreement and approximately $0.5
million as part of the &#x201c;Letter of Intent&#x201d;. The $0.5
million received is to be adjusted from the next milestone payment due upon latest of (i) marketing approval from the FDA, (ii) MiMedx
entering into a supply agreement, or (iii) our completion of the regulatory and quality activities. We have concluded that our primary
obligation under the contract has not been satisfied, and therefore, the amounts received have been recorded as deferred revenue in the
consolidated balance sheets presented. &lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt; We are responsible for overseeing, monitoring
and coordinating all regulatory actions, communications and filings with, and submissions to the FDA with respect to initial marketing
approval. Additionally, upon successful development and commercialization of FleX in the Territory, we are eligible to receive milestone
payments of up to $69.6
million and $1.0
million for each additional product developed and commercialized. Furthermore, we are eligible to receive royalty payments on a country-by-country
basis based on net sales for the later of ten years or the expiration of patent or regulatory exclusivity in the jurisdiction. &lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We have determined that we have one combined performance
obligation under the agreement which primarily includes knowledge and biomaterials transfer to MiMedx, assisting and coordinating the
regulatory approvals with the FDA and ongoing access and upkeep of intellectual property during the term of the agreement and related
development and regulatory services. Development and commercialization milestones were not considered probable at inception and, therefore,
were excluded from the initial transaction price. The royalties were excluded from the initial transaction price because they relate to
a license of intellectual property and are subject to the royalty constraint.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt; We recognize revenue as the combined performance
obligation is satisfied over time using an output method. Significant management judgment is required to determine the level of effort
attributable to the performance obligation included in the MiMedx Agreement and the period over which we expect to complete our performance
obligation under the arrangement. The performance period or measure of progress was estimated at the inception of the arrangement and
is re-evaluated in subsequent reporting periods. This re-evaluation may shorten or lengthen the period over which we recognize revenue.
Due to unpredictable outcomes and timelines of the FDA approval process which cannot be reasonably estimated, we have deferred all revenues
under the MiMedx Agreement and no revenue has been recognized during the periods presented and the aggregate amount of the transaction
price allocated to the remaining performance obligation (deferred revenue) is $1,438,013
which will be recognized as revenue as our performance obligation is satisfied. &lt;/p&gt;</ttrx:LicensingAgreementsTextBlock>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock contextRef="cref_883848846" id="ixv-9815">

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The following table presents changes in the balances
of contract liabilities related to strategic collaboration agreements during the year ended December 31, 2025:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tbody&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;As at&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;As at&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December 31, 2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Additions&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Deductions&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December 31, 2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left; text-indent: 0pt; padding-left: 0pt"&gt;Contract liabilities:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left; padding-bottom: 2.5pt; text-indent: 0pt; padding-left: 0pt"&gt;Deferred revenue&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;1,438,013&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden:fc_857573411"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden:fc_1530781833"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;1,438,013&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/tbody&gt;
  &lt;/table&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:ContractWithCustomerLiability
      contextRef="cref_550689438"
      decimals="0"
      id="fc_550689438"
      unitRef="uref_921481251">1438013</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="cref_1736530910"
      decimals="0"
      id="fc_465120299"
      unitRef="uref_921481251">1438013</us-gaap:ContractWithCustomerLiability>
    <ttrx:RevenueRecognitionMilestoneMethod
      contextRef="cref_422807255"
      decimals="-4"
      id="ixv-12387"
      unitRef="uref_921481251">1000000</ttrx:RevenueRecognitionMilestoneMethod>
    <ttrx:RevenueRecognitionMilestoneMethod
      contextRef="cref_1872303994"
      decimals="-5"
      id="ixv-12388"
      unitRef="uref_921481251">500000</ttrx:RevenueRecognitionMilestoneMethod>
    <ttrx:RevenueRecognitionMilestoneMethod
      contextRef="cref_883848846"
      decimals="-5"
      id="ixv-12389"
      unitRef="uref_921481251">500000</ttrx:RevenueRecognitionMilestoneMethod>
    <ttrx:RevenueRecognitionMilestoneMethod
      contextRef="cref_1368018852"
      decimals="-5"
      id="ixv-12390"
      unitRef="uref_921481251">69600000</ttrx:RevenueRecognitionMilestoneMethod>
    <ttrx:RevenueRecognitionMilestoneMethod
      contextRef="cref_1473726351"
      decimals="-5"
      id="ixv-12391"
      unitRef="uref_921481251">1000000</ttrx:RevenueRecognitionMilestoneMethod>
    <us-gaap:ContractWithCustomerLiability
      contextRef="cref_1736530910"
      decimals="0"
      id="ixv-12392"
      unitRef="uref_921481251">1438013</us-gaap:ContractWithCustomerLiability>
    <us-gaap:EarningsPerShareTextBlock contextRef="cref_883848846" id="ixv-9921">

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;
  &lt;tbody&gt;
  &lt;tr style="vertical-align: top; text-align: justify"&gt;
    &lt;td style="width: 0in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;11.&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Basic and diluted net loss per share was calculated
as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tbody&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Years Ended December 31,&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;Numerator:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; width: 76%; text-align: left"&gt;Net loss attributable to common stockholders&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;(3,194,080&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;(1,768,415&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; font-weight: bold"&gt;Denominator:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"&gt;Weighted-average common shares outstanding, basic and diluted&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;27,716,045&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;26,643,432&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Net loss per share attributable to common stockholders, basic and diluted&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(0.12&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(0.07&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;/tbody&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Our potentially dilutive securities, which include
or have included outstanding stock options and certain warrants, have been excluded from the computation of diluted net loss per share
as the effect would be to reduce the net loss per share. Therefore, the weighted-average number of common shares outstanding used to calculate
both basic and diluted net loss per share attributable to common stockholders is the same.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We excluded the following from the computation
of diluted net loss per share attributable to common stockholders because including them would have had an anti-dilutive effect:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tbody&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;As at December 31,&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 0.125in; width: 76%; text-align: left; text-indent: -0.125in"&gt;Outstanding options under the Amended and Restated
        2018 Stock Option Plan, 2024 Stock Option Plan and 2025 Omnibus Incentive Plan&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;1,942,184&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;1,679,054&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 0.125in; text-align: left; text-indent: -0.125in"&gt;Outstanding RSUs under the 2025 Omnibus Incentive Plan&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;40,000&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_909308480"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 0.125in; text-align: left; text-indent: -0.125in"&gt;Outstanding warrants&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,232,331&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;40,124&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,214,515&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,719,178&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/tbody&gt;
  &lt;/table&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="cref_883848846" id="ixv-9929">

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Basic and diluted net loss per share was calculated
as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tbody&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Years Ended December 31,&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;Numerator:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; width: 76%; text-align: left"&gt;Net loss attributable to common stockholders&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;(3,194,080&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;(1,768,415&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; font-weight: bold"&gt;Denominator:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"&gt;Weighted-average common shares outstanding, basic and diluted&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;27,716,045&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;26,643,432&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Net loss per share attributable to common stockholders, basic and diluted&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(0.12&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(0.07&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;/tbody&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="cref_883848846"
      decimals="0"
      id="ixv-12393"
      unitRef="uref_921481251">-3194080</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="cref_1258711090"
      decimals="0"
      id="ixv-12394"
      unitRef="uref_921481251">-1768415</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="cref_883848846"
      decimals="0"
      id="ixv-12395"
      unitRef="uref_1683791803">27716045</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="cref_883848846"
      decimals="0"
      id="ixv-12396"
      unitRef="uref_1683791803">27716045</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="cref_1258711090"
      decimals="0"
      id="ixv-12397"
      unitRef="uref_1683791803">26643432</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="cref_1258711090"
      decimals="0"
      id="ixv-12398"
      unitRef="uref_1683791803">26643432</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="cref_883848846"
      decimals="2"
      id="ixv-12399"
      unitRef="uref_923572658">-0.12</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="cref_883848846"
      decimals="2"
      id="ixv-12400"
      unitRef="uref_923572658">-0.12</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="cref_1258711090"
      decimals="2"
      id="ixv-12401"
      unitRef="uref_923572658">-0.07</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="cref_1258711090"
      decimals="2"
      id="ixv-12402"
      unitRef="uref_923572658">-0.07</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="cref_883848846" id="ixv-10015">

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We excluded the following from the computation
of diluted net loss per share attributable to common stockholders because including them would have had an anti-dilutive effect:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tbody&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;As at December 31,&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 0.125in; width: 76%; text-align: left; text-indent: -0.125in"&gt;Outstanding options under the Amended and Restated
        2018 Stock Option Plan, 2024 Stock Option Plan and 2025 Omnibus Incentive Plan&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;1,942,184&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;1,679,054&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 0.125in; text-align: left; text-indent: -0.125in"&gt;Outstanding RSUs under the 2025 Omnibus Incentive Plan&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;40,000&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_909308480"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 0.125in; text-align: left; text-indent: -0.125in"&gt;Outstanding warrants&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,232,331&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;40,124&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,214,515&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,719,178&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/tbody&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="cref_1952831379"
      decimals="0"
      id="ixv-12403"
      unitRef="uref_1683791803">1942184</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="cref_860008128"
      decimals="0"
      id="ixv-12404"
      unitRef="uref_1683791803">1679054</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="cref_67270298"
      decimals="0"
      id="ixv-12405"
      unitRef="uref_1683791803">40000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="cref_132432864"
      decimals="0"
      id="ixv-12406"
      unitRef="uref_1683791803">1232331</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="cref_1550899278"
      decimals="0"
      id="ixv-12407"
      unitRef="uref_1683791803">40124</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="cref_883848846"
      decimals="0"
      id="ixv-12408"
      unitRef="uref_1683791803">3214515</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="cref_1258711090"
      decimals="0"
      id="ixv-12409"
      unitRef="uref_1683791803">1719178</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="cref_883848846" id="ixv-10076">

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;
  &lt;tbody&gt;
  &lt;tr style="vertical-align: top; text-align: justify"&gt;
    &lt;td style="width: 0in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;12.&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;COMMITMENTS, CONTINGENCIES, GUARANTEES AND INDEMNIFICATIONS&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Contractual
Commitments&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We enter into contracts in the normal course of
business with contract research organizations (&#x201c;CROs&#x201d;), contract manufacturing organizations (&#x201c;CMOs&#x201d;), academic
institutions and other third parties for preclinical and clinical research studies, testing and manufacturing services. These contracts
generally do not contain minimum purchase commitments and are cancellable by us upon prior written notice, although purchase orders for
preclinical materials are generally non-cancellable or have cancellation penalties. Payments due upon cancellation consist primarily of
payments for services provided or expenses incurred, including non-cancellable obligations from our service providers, up to the date
of cancellation or upon the completion of a manufacturing run.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Litigation
and Claims&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;From time to time, we may be party to litigation,
arbitration, claims or other legal proceedings in the course of our business. The outcome of any such legal proceedings, regardless of
the merits, is inherently uncertain. In addition, litigation and related matters are costly and may divert the attention of our management
and other resources that would otherwise be engaged in other activities. If we were unable to prevail in any such legal proceedings, our
business, results of operations, liquidity, and financial condition could be adversely affected.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Indemnifications
Obligations&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We entered into indemnification agreements with our
officers and directors that require us to indemnify such individuals for certain events or occurrences while each such officer or director
is, or was, serving at our request in such capacity. The maximum potential future payments we could be required to make is, in many cases,
unlimited. We have directors&#x2019; and officers&#x2019; liability insurance coverage that limits its exposure and enables us to recover
a portion of any future amounts to be paid.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="cref_883848846" id="ixv-10109">

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;
  &lt;tbody&gt;
  &lt;tr style="vertical-align: top; text-align: justify"&gt;
    &lt;td style="width: 0in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;13.&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;SEGMENT REPORTING&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt; Our CODM is our &lt;span style="-sec-ix-hidden:fc_1205013097"&gt;Chief
Executive Officer&lt;/span&gt;. The
CODM uses net loss, as reported on our consolidated statements of operations, in evaluating performance and determining how to allocate
resources. The CODM does not review assets in evaluating the results and therefore, such information is not presented.
&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The following table provides the segment expenses
and income (loss):&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tbody&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Years Ended December 31,&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;Operating Expenses&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: 0pt; padding-left: 0.125in"&gt;Personnel-related expenses&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;(1,340,138&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;(866,984&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: 0pt; padding-left: 0.125in"&gt;Research and development expenses&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(265,570&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(245,956&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: 0pt; padding-left: 0.125in"&gt;Legal, professional and consulting expenses&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(3,324,378&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(364,008&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: 0pt; padding-left: 0.125in"&gt;Corporate expenses&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(928,562&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(320,176&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; text-indent: 0pt; padding-left: 0pt"&gt;Other Income&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0.125in"&gt;Other segment income&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,664,568&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;28,709&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; text-indent: 0pt; padding-left: 0.25in"&gt;Segment net loss&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(3,194,080&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(1,768,415&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;/tbody&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Other segment income (expense) includes total
other income (expense), net on the consolidated statements of operations.&lt;/p&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:SegmentReportingCodmProfitLossMeasureHowUsedDescription contextRef="cref_883848846" id="ixv-12410">The
CODM uses net loss, as reported on our consolidated statements of operations, in evaluating performance and determining how to allocate
resources.</us-gaap:SegmentReportingCodmProfitLossMeasureHowUsedDescription>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="cref_883848846" id="ixv-10137">

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The following table provides the segment expenses
and income (loss):&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tbody&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Years Ended December 31,&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;Operating Expenses&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: 0pt; padding-left: 0.125in"&gt;Personnel-related expenses&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;(1,340,138&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;(866,984&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: 0pt; padding-left: 0.125in"&gt;Research and development expenses&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(265,570&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(245,956&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: 0pt; padding-left: 0.125in"&gt;Legal, professional and consulting expenses&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(3,324,378&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(364,008&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: 0pt; padding-left: 0.125in"&gt;Corporate expenses&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(928,562&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(320,176&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; text-indent: 0pt; padding-left: 0pt"&gt;Other Income&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0.125in"&gt;Other segment income&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,664,568&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;28,709&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; text-indent: 0pt; padding-left: 0.25in"&gt;Segment net loss&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(3,194,080&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(1,768,415&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;/tbody&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:OtherExpenses
      contextRef="cref_883848846"
      decimals="0"
      id="ixv-12411"
      unitRef="uref_921481251">1340138</us-gaap:OtherExpenses>
    <us-gaap:OtherExpenses
      contextRef="cref_1258711090"
      decimals="0"
      id="ixv-12412"
      unitRef="uref_921481251">866984</us-gaap:OtherExpenses>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="cref_883848846"
      decimals="0"
      id="ixv-12413"
      unitRef="uref_921481251">265570</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="cref_1258711090"
      decimals="0"
      id="ixv-12414"
      unitRef="uref_921481251">245956</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ProfessionalFees
      contextRef="cref_883848846"
      decimals="0"
      id="ixv-12415"
      unitRef="uref_921481251">3324378</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees
      contextRef="cref_1258711090"
      decimals="0"
      id="ixv-12416"
      unitRef="uref_921481251">364008</us-gaap:ProfessionalFees>
    <ttrx:CorporateExpenses
      contextRef="cref_883848846"
      decimals="0"
      id="ixv-12417"
      unitRef="uref_921481251">928562</ttrx:CorporateExpenses>
    <ttrx:CorporateExpenses
      contextRef="cref_1258711090"
      decimals="0"
      id="ixv-12418"
      unitRef="uref_921481251">320176</ttrx:CorporateExpenses>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="cref_883848846"
      decimals="0"
      id="ixv-12419"
      unitRef="uref_921481251">2664568</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="cref_1258711090"
      decimals="0"
      id="ixv-12420"
      unitRef="uref_921481251">28709</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="cref_883848846"
      decimals="0"
      id="ixv-12421"
      unitRef="uref_921481251">-3194080</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="cref_1258711090"
      decimals="0"
      id="ixv-12422"
      unitRef="uref_921481251">-1768415</us-gaap:NetIncomeLoss>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="cref_883848846" id="ixv-10237">

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;
  &lt;tbody&gt;
  &lt;tr style="vertical-align: top; text-align: justify"&gt;
    &lt;td style="width: 0in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;14.&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;RELATED PARTY TRANSACTIONS&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt; In March 2025, we engaged Davis Polk &amp;amp; Wardwell
LLP (&#x201c;Davis Polk&#x201d;) for legal advisory services for the public listing of our common stock on a registered stock exchange.
On September 30, 2025, Mr. Arthur Golden joined our Board. Mr. Golden is a senior counsel at Davis Polk. During the years ended December
31, 2025 and 2024, legal expenses charged by Davis Polk were $1.5
million and $0,
respectively. As of December 31, 2025 and 2024, we have outstanding legal costs of approximately $1.5
million and $0,
respectively, payable to Davis Polk. &lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:LegalFees
      contextRef="cref_680374124"
      decimals="-5"
      id="ixv-12423"
      unitRef="uref_921481251">1500000</us-gaap:LegalFees>
    <us-gaap:LegalFees
      contextRef="cref_86219827"
      decimals="0"
      id="ixv-12424"
      unitRef="uref_921481251">0</us-gaap:LegalFees>
    <us-gaap:PaymentsForLegalSettlements
      contextRef="cref_680374124"
      decimals="-5"
      id="ixv-12425"
      unitRef="uref_921481251">1500000</us-gaap:PaymentsForLegalSettlements>
    <us-gaap:PaymentsForLegalSettlements
      contextRef="cref_86219827"
      decimals="0"
      id="ixv-12426"
      unitRef="uref_921481251">0</us-gaap:PaymentsForLegalSettlements>
    <us-gaap:SubsequentEventsTextBlock contextRef="cref_883848846" id="fc_883848846">

&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;
  &lt;tbody&gt;
  &lt;tr style="vertical-align: top; text-align: justify"&gt;
    &lt;td style="width: 0in"&gt;&lt;/td&gt;
    &lt;td style="width: 0.25in; text-align: left"&gt;15.&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;SUBSEQUENT EVENT&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;Loan Agreement
with Avenue Capital&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On March 23, 2026 (the &#x201c;Closing Date&#x201d;),
we entered into a Loan and Security Agreement (the &#x201c;Loan and Security Agreement&#x201d;) and a Supplement to the Loan and Security
Agreement (together with the Loan and Security Agreement, the &#x201c;Loan Agreement&#x201d;), with Avenue Venture Opportunities Fund II,
L.P., as administrative agent and collateral agent (the &#x201c;Agent&#x201d;) and Avenue Venture Opportunities Fund II, L.P., as lender
(the &#x201c;Lender&#x201d;, together with Agent, &#x201c;Avenue Capital&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt; The Loan Agreement makes available to us term loans
in an aggregate principal amount of up to $25.0
million with (i) $7.0
million funded on March 24, 2026 (&#x201c;Tranche 1&#x201d;), (ii) up to $8.0
million to be made available to us between September 1, 2026 and March 31, 2027, subject to, (i) dosing of first patients in a phase 3
trial of Onychomycosis, (ii) raising $10.0
million via equity financing and (iii) positive data in our ongoing phase 2 clinical study of GX-03 for moderate-severe atopic dermatitis
(&#x201c;Tranche 2&#x201d;). The Lender may make additional term loans of up to an additional $10.0
million (the &#x201c;Discretionary Tranche 3&#x201d; and collectively with Tranche 1, and Tranche 2, the &#x201c;Loans&#x201d;), to be funded
between January 1, 2027 and June 30, 2028, subject to, among other things, (i) our achievement of a certain clinical milestone and (ii)
the mutual written agreement between us and the Lender (upon the Lender&#x2019;s investment committee approval). &lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt; The Loans bear interest at an annual rate equal
to the greater of (x) the sum of 5.50%
plus the prime rate as reported in The Wall Street Journal and (y) 12.25%.
The Loans are secured by a lien upon and security interest in all of our assets, including intellectual property, subject to agreed exceptions.
The loan matures on 42 month anniversary from the Closing Date (the &#x201c;Maturity Date&#x201d;). The Loan Agreement does not contain
any minimum cash requirement or other financial covenants. &lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We will make interest-only payments on the Loans
until the 15-month anniversary of the Closing Date, subject to (i) a 9-month extension, so long as Tranche 2 has been funded and (ii)
an additional 6-month extension if we achieve the Discretionary Tranche 3 milestone. The Loan principal is repayable in equal monthly
installments from the end of interest-only period to the Maturity Date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt; We may, at our option at any time, prepay the Loans
in their entirety by paying the then-outstanding principal balance and all accrued and unpaid interest on the Loans, subject to a prepayment
fee equal to (i) 3.0%
of the principal amount outstanding if the prepayment occurs on or prior to the first anniversary following the Closing Date, (ii) 2.0%
of the principal amount outstanding if the prepayment occurs after the first anniversary following the Closing Date, but on or prior to
the second anniversary following the Closing Date, and (iii) 1.0%
of the principal amount outstanding if the prepayment occurs after the second anniversary following the Closing Date. We will pay a final
payment of 3.75%
of the amount funded and outstanding on the earlier of (x) the Maturity Date and (y) the date that we prepay all of the outstanding principal
amount of the Loans in full. &lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt; On the Closing Date, we paid the Lender a commitment
fee of $0.15
million. On the Closing Date, we also issued 342,857
shares of our common stock at no cost to the lender which represent 8.00%
of the Tranche 1 and Tranche 2 amounts. The price per share was determined using the 5 days volume weighted-average price calculated on
the day prior to closing date. If we draw the Discretionary Tranche 3, we will issue further shares to the lender at no cost which shall
equal to 8.00%
of the $10.0
million (amount of the Discretionary Tranche 3) at 5 days volume weighted-average price calculated on the day prior to funding of Discretionary
Tranche 3. &lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Loan Agreement contains customary representations,
warranties and covenants, including covenants by us limiting, among other things, additional indebtedness, liens, guaranties, mergers
and consolidations, substantial asset sales, investments and loans, certain corporate changes, transactions with affiliates and fundamental
changes. The Loan Agreement provides for events of default customary for term loans of this type, including but not limited to non-payment,
breaches or defaults in the performance of covenants, insolvency, bankruptcy and the occurrence of a material adverse effect on the Company.
After the occurrence of an event of default, the Agent may (i) accelerate payment of all obligations, impose an increased rate of interest,
and terminate the Lender&#x2019;s commitments under the Loan Agreement and (ii) exercise any other right or remedy provided by contract
or applicable law including a foreclosure on our assets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt; Pursuant to the Loan Agreement, the Lender will
have the right to convert initially up to $2.0
million of the outstanding principal of the Loans (the &#x201c;Conversion Option&#x201d;) at a price per share equal to 80%
of the trading price on the date of conversion, subject to certain terms and conditions, including beneficial ownership limitations. Upon
draw-down of Tranche 2, the Conversion Option will be increased by $1.0
million. &lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt; In addition, subject to applicable law, the Lender
may participate in certain equity financing transactions in an aggregate amount of up to $1.0
million on the same terms, conditions and pricing offered by us to other investors participating in such financing transaction (such right,
the &#x201c;Participation Right&#x201d;). The Participation Right terminates upon the earlier of the Maturity Date and the repayment in
full of all of the obligations under the Loan Agreement. &lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="cref_248263701"
      decimals="-5"
      id="ixv-12427"
      unitRef="uref_921481251">25000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="cref_614510382"
      decimals="-5"
      id="ixv-12428"
      unitRef="uref_921481251">7000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="cref_100235816"
      decimals="-5"
      id="ixv-12429"
      unitRef="uref_921481251">8000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="cref_1452955949"
      decimals="-5"
      id="ixv-12430"
      unitRef="uref_921481251">10000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="cref_1149805041"
      decimals="-5"
      id="ixv-12431"
      unitRef="uref_921481251">10000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LongTermDebtPercentageBearingFixedInterestRate
      contextRef="cref_16953884"
      decimals="4"
      id="ixv-12432"
      unitRef="uref_1280488936">0.055</us-gaap:LongTermDebtPercentageBearingFixedInterestRate>
    <us-gaap:LongTermDebtPercentageBearingFixedInterestRate
      contextRef="cref_222881735"
      decimals="4"
      id="ixv-12433"
      unitRef="uref_1280488936">0.1225</us-gaap:LongTermDebtPercentageBearingFixedInterestRate>
    <ttrx:PercentageOfPrincipalPrepaymentPriorToFirstAnniversary
      contextRef="cref_599627115"
      decimals="3"
      id="ixv-12434"
      unitRef="uref_1280488936">0.03</ttrx:PercentageOfPrincipalPrepaymentPriorToFirstAnniversary>
    <ttrx:PercentageOfPrincipalPrepaymentPriorToSecondAnniversary
      contextRef="cref_1280488936"
      decimals="3"
      id="ixv-12435"
      unitRef="uref_1280488936">0.02</ttrx:PercentageOfPrincipalPrepaymentPriorToSecondAnniversary>
    <ttrx:PercentageOfPrincipalPrepaymentOccursAfterSecondAnniversary
      contextRef="cref_1587420057"
      decimals="3"
      id="ixv-12436"
      unitRef="uref_1280488936">0.01</ttrx:PercentageOfPrincipalPrepaymentOccursAfterSecondAnniversary>
    <ttrx:FinalPrincipleAmountRate
      contextRef="cref_1280488936"
      decimals="4"
      id="ixv-12437"
      unitRef="uref_1280488936">0.0375</ttrx:FinalPrincipleAmountRate>
    <us-gaap:LineOfCreditFacilityCommitmentFeeAmount
      contextRef="cref_2003872429"
      decimals="-4"
      id="ixv-12438"
      unitRef="uref_921481251">150000</us-gaap:LineOfCreditFacilityCommitmentFeeAmount>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="cref_1280488936"
      decimals="0"
      id="ixv-12439"
      unitRef="uref_1683791803">342857</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="cref_1280488936"
      decimals="4"
      id="ixv-12440"
      unitRef="uref_1280488936">0.08</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="cref_1479140274"
      decimals="4"
      id="ixv-12441"
      unitRef="uref_1280488936">0.08</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="cref_1770926710"
      decimals="-5"
      id="ixv-12442"
      unitRef="uref_921481251">10000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="cref_1280488936"
      decimals="-5"
      id="ixv-12443"
      unitRef="uref_921481251">2000000</us-gaap:DebtConversionOriginalDebtAmount1>
    <us-gaap:DebtConversionOriginalDebtInterestRateOfDebt
      contextRef="cref_1280488936"
      decimals="2"
      id="ixv-12444"
      unitRef="uref_1280488936">0.80</us-gaap:DebtConversionOriginalDebtInterestRateOfDebt>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="cref_722814996"
      decimals="-5"
      id="ixv-12445"
      unitRef="uref_921481251">1000000</us-gaap:DebtConversionOriginalDebtAmount1>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="cref_921481251"
      decimals="-5"
      id="ixv-12446"
      unitRef="uref_921481251">1000000</us-gaap:DebtConversionOriginalDebtAmount1>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#fc_234313724"
          xlink:label="fc_234313724"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1727071466"
          xlink:label="fc_1727071466"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_326726658"
          xlink:label="fc_326726658"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_630707599"
          xlink:label="fc_630707599"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_850771456"
          xlink:label="fc_850771456"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_2125858781"
          xlink:label="fc_2125858781"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1618157086"
          xlink:label="fc_1618157086"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1159091871"
          xlink:label="fc_1159091871"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1558260796"
          xlink:label="fc_1558260796"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1975586323"
          xlink:label="fc_1975586323"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1428237468"
          xlink:label="fc_1428237468"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_141944097"
          xlink:label="fc_141944097"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_2051066427"
          xlink:label="fc_2051066427"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1567774098"
          xlink:label="fc_1567774098"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_358054683"
          xlink:label="fc_358054683"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_362564499"
          xlink:label="fc_362564499"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1235019873"
          xlink:label="fc_1235019873"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1608902388"
          xlink:label="fc_1608902388"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_149733321"
          xlink:label="fc_149733321"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1888374326"
          xlink:label="fc_1888374326"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1245061297"
          xlink:label="fc_1245061297"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1196160309"
          xlink:label="fc_1196160309"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1134039189"
          xlink:label="fc_1134039189"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1914277625"
          xlink:label="fc_1914277625"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1776654961"
          xlink:label="fc_1776654961"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_949861460"
          xlink:label="fc_949861460"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_997512259"
          xlink:label="fc_997512259"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_2076402872"
          xlink:label="fc_2076402872"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1261566747"
          xlink:label="fc_1261566747"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1883966516"
          xlink:label="fc_1883966516"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1839485908"
          xlink:label="fc_1839485908"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1664853907"
          xlink:label="fc_1664853907"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_802189528"
          xlink:label="fc_802189528"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_153310236"
          xlink:label="fc_153310236"
          xlink:type="locator"/>
        <link:footnote id="fref_1493245574" xlink:label="fref_1493245574" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Retroactively adjusted for 2-for-1 forward stock split.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_234313724"
          xlink:to="fref_1493245574"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1727071466"
          xlink:to="fref_1493245574"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_326726658"
          xlink:to="fref_1493245574"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_630707599"
          xlink:to="fref_1493245574"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_850771456"
          xlink:to="fref_1493245574"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_2125858781"
          xlink:to="fref_1493245574"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1618157086"
          xlink:to="fref_1493245574"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1159091871"
          xlink:to="fref_1493245574"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1558260796"
          xlink:to="fref_1493245574"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1975586323"
          xlink:to="fref_1493245574"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1428237468"
          xlink:to="fref_1493245574"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_141944097"
          xlink:to="fref_1493245574"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_2051066427"
          xlink:to="fref_1493245574"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1567774098"
          xlink:to="fref_1493245574"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_358054683"
          xlink:to="fref_1493245574"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_362564499"
          xlink:to="fref_1493245574"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1235019873"
          xlink:to="fref_1493245574"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1608902388"
          xlink:to="fref_1493245574"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_149733321"
          xlink:to="fref_1493245574"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1888374326"
          xlink:to="fref_1493245574"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1245061297"
          xlink:to="fref_1493245574"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1196160309"
          xlink:to="fref_1493245574"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1134039189"
          xlink:to="fref_1493245574"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1914277625"
          xlink:to="fref_1493245574"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1776654961"
          xlink:to="fref_1493245574"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_949861460"
          xlink:to="fref_1493245574"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_997512259"
          xlink:to="fref_1493245574"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_2076402872"
          xlink:to="fref_1493245574"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1261566747"
          xlink:to="fref_1493245574"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1883966516"
          xlink:to="fref_1493245574"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1839485908"
          xlink:to="fref_1493245574"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1664853907"
          xlink:to="fref_1493245574"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_802189528"
          xlink:to="fref_1493245574"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_153310236"
          xlink:to="fref_1493245574"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#fc_1516429433"
          xlink:label="fc_1516429433"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1955399735"
          xlink:label="fc_1955399735"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1970036997"
          xlink:label="fc_1970036997"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_405687047"
          xlink:label="fc_405687047"
          xlink:type="locator"/>
        <link:footnote id="fref_1847929445" xlink:label="fref_1847929445" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">State taxes in Georgia made up the majority (greater than 50 percent) of the tax effect in these categories.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1516429433"
          xlink:to="fref_1847929445"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1955399735"
          xlink:to="fref_1847929445"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1970036997"
          xlink:to="fref_1847929445"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_405687047"
          xlink:to="fref_1847929445"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
